<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="1d7b4793-3f52-4731-8c78-78e258645157"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use IMBRUVICA safely and effectively. See full prescribing information for IMBRUVICA.</content>
      <br/>
      <content styleCode="bold"> </content>
      <br/>
      <content styleCode="bold">IMBRUVICA</content>
      <content styleCode="bold">
         <sup>®</sup>
      </content>
      <content styleCode="bold"> (ibrutinib) capsules, for oral use</content>
      <br/>
      <content styleCode="bold">IMBRUVICA</content>
      <content styleCode="bold">
         <sup>®</sup>
      </content>
      <content styleCode="bold"> (ibrutinib) tablets, for oral use</content>
      <br/>
      <content styleCode="bold">IMBRUVICA</content>
      <content styleCode="bold">
         <sup>®</sup>
      </content>
      <content styleCode="bold"> (ibrutinib) oral suspension</content>
      <br/>
      <content styleCode="bold">Initial U.S. Approval: 2013 </content>
      <br/>
   </title>
   <effectiveTime value="20241220"/>
   <setId root="0dfd0279-ff17-4ea9-89be-9803c71bab44"/>
   <versionNumber value="60"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="079857498" root="1.3.6.1.4.1.519.1"/>
            <name>Pharmacyclics LLC</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="5c4ea349-c596-4ac4-a3ed-d999db699c05"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20250306"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="57962-070" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Imbruvica</name>
                        <formCode code="C25158" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Ibrutinib</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="70"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="1X70OSD4VX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>IBRUTINIB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="1X70OSD4VX" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>IBRUTINIB</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="28"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="57962-070-28" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" displayName="BOTTLE, PLASTIC" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20171220"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA205552" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20171220"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" displayName="yellow" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">ibr;70;mg</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="18" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="57962-140" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Imbruvica</name>
                        <formCode code="C25158" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Ibrutinib</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="140"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="1X70OSD4VX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>IBRUTINIB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="1X70OSD4VX" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>IBRUTINIB</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="90"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="57962-140-09" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" displayName="BOTTLE, PLASTIC" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20131113"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="120"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="57962-140-12" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" displayName="BOTTLE, PLASTIC" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20131113"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA205552" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20131113"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="white" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">ibr;140;mg</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="22" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="57962-014" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Imbruvica</name>
                        <formCode code="C42931" displayName="TABLET, FILM COATED" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Ibrutinib</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="140"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="1X70OSD4VX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>IBRUTINIB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="1X70OSD4VX" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>IBRUTINIB</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="28"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" displayName="BLISTER PACK" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="57962-014-28" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20180216"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA210563" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20180216"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48329" displayName="green" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>Yellow-green to green</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">ibr;140</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48348" displayName="ROUND" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="9" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="57962-280" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Imbruvica</name>
                        <formCode code="C42931" displayName="TABLET, FILM COATED" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Ibrutinib</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="280"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="1X70OSD4VX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>IBRUTINIB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="1X70OSD4VX" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>IBRUTINIB</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="28"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" displayName="BLISTER PACK" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="57962-280-28" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20180216"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA210563" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20180216"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48327" displayName="purple" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">ibr;280</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" displayName="OVAL" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>Oblong</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="15" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="57962-420" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Imbruvica</name>
                        <formCode code="C42931" displayName="TABLET, FILM COATED" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Ibrutinib</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="420"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="1X70OSD4VX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>IBRUTINIB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="1X70OSD4VX" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>IBRUTINIB</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="28"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" displayName="BLISTER PACK" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="57962-420-28" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20180216"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="28"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" displayName="BLISTER PACK" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="57962-420-71" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="completed"/>
                                       <effectiveTime>
                                          <low value="20190206"/>
                                          <high value="20201231"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA210563" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20180216"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48329" displayName="green" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>Yellow-green to green</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">ibr;420</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" displayName="OVAL" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>Oblong</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="18" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="57962-007" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Imbruvica</name>
                        <formCode code="C42994" displayName="SUSPENSION" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Ibrutinib</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="70"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="1X70OSD4VX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>IBRUTINIB</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="1X70OSD4VX" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>IBRUTINIB</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="LKG8494WBH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZYL ALCOHOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2968PHW8QP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CITRIC ACID MONOHYDRATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="22ADO53M6F" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM PHOSPHATE, DIBASIC, ANHYDROUS</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3NXW29V3WO" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="96K6UQ3ZD4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCRALOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="108"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43172" displayName="BOTTLE, GLASS" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="57962-007-12" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" displayName="CARTON" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20220824"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA217003" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" displayName="NDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20220824"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="white" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>white to off-white</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section>
               <id root="4bc4bc59-076a-4bea-8b06-c66e45d5b54f"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43683-2" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20241220"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table>
                           <col width="403"/>
                           <col width="235"/>
                           <tbody>
                              <tr>
                                 <td>Warnings and Precautions, Hepatotoxicity, <br/>Including Drug-Induced Liver Injury (<linkHtml href="#_5_7_Hepatotoxicity__Including">5.7</linkHtml>)</td>
                                 <td align="right">     5/2024</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section>
               <id root="a04dc09c-afb8-4116-ad0c-46a3e0af4f96"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34067-9" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>
                  <content styleCode="bold">1</content>
		     
	<content styleCode="bold">INDICATIONS AND USAGE</content>
               </title>
               <effectiveTime value="20241220"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>IMBRUVICA is a kinase inhibitor indicated for the treatment of:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) (<linkHtml href="#_1_1_Chronic_Lymphocytic">1.1</linkHtml>).<br/>
                           </item>
                           <item>Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion (<linkHtml href="#_1_3_Chronic_Lymphocytic">1.2</linkHtml>).<br/>
                           </item>
                           <item>Adult patients with Waldenström’s macroglobulinemia (WM) (<linkHtml href="#_1_3_Waldenström_s_Macroglobulinemia">1.3</linkHtml>). <br/>
                           </item>
                           <item>Adult and pediatric patients age 1 year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy (<linkHtml href="#_1_4_Chronic_Graft">1.4</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_1_1_Chronic_Lymphocytic">
                     <id root="650aa832-9ede-40de-8090-8ce923fc56dc"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">1.1</content>
		     
	<content styleCode="bold">Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</content>
                     </title>
                     <text>
                        <paragraph>IMBRUVICA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="_1_3_Chronic_Lymphocytic">
                     <id root="87a37877-187f-4ccc-ae89-22856ecc6250"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">1.</content>
                        <content styleCode="bold">2</content>
                        <content styleCode="bold">
		     
	Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma with 17p deletion</content>
                     </title>
                     <text>
                        <paragraph>IMBRUVICA is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) with 17p deletion.</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="_1_3_Waldenström_s_Macroglobulinemia">
                     <id root="15ef1c8c-aa76-46ed-be50-72ef0ee45dd2"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">1.</content>
                        <content styleCode="bold">3</content>
                        <content styleCode="bold">
		     
	Waldenström’s Macroglobulinemia</content>
                     </title>
                     <text>
                        <paragraph>IMBRUVICA is indicated for the treatment of adult patients with Waldenström’s macroglobulinemia (WM).</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="_1_4_Chronic_Graft">
                     <id root="adfb33de-511b-4660-b6e8-3c6ad767bb38"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">1.</content>
                        <content styleCode="bold">4</content>
                        <content styleCode="bold">
		     
	Chronic Graft versus Host Disease</content>
                     </title>
                     <text>
                        <paragraph>IMBRUVICA is indicated for the treatment of adult and pediatric patients age 1 year and older with chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy.</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="c6408a61-94a0-4fdb-9297-a7b5e2cb8587"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34068-7" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>
                  <content styleCode="bold">2</content>
		     
	<content styleCode="bold">DOSAGE AND ADMINISTRATION</content>
               </title>
               <effectiveTime value="20241220"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">CLL/SLL and WM</content>: 420 mg taken orally once daily (<linkHtml href="#_2_1_Recommended_Dosage">2.1</linkHtml>).<br/>
                           </item>
                           <item>
                              <content styleCode="underline">cGVHD</content>: <br/>◦ Patients 12 years and older: 420 mg taken orally once daily (<linkHtml href="#_2_1_Recommended_Dosage">2.1</linkHtml>).<br/>◦ Patients 1 to less than 12 years of age: 240 mg/m<sup>2</sup> taken orally once daily (up to a dose of 420 mg) (<linkHtml href="#_2_1_Recommended_Dosage">2.1</linkHtml>).</item>
                        </list>
                        <paragraph>Tablets or capsules should be taken orally with a glass of water. Do not open, break, or chew the capsules. Do not cut, crush, or chew the tablets. See full prescribing information for oral suspension administration instructions (<linkHtml href="#_2_1_Recommended_Dosage">2.1</linkHtml>).</paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_2_1_Recommended_Dosage">
                     <id root="59754b84-dcd9-436b-a58a-c8a04a7ebcb5"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.1</content>
                        <content styleCode="bold">
		     
	Recommended Dosage</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Waldenström’s Macroglobulinemia</content>
                        </paragraph>
                        <paragraph>The recommended dosage of IMBRUVICA for CLL/SLL and WM is 420 mg orally once daily until disease progression or unacceptable toxicity. </paragraph>
                        <paragraph>For CLL/SLL, IMBRUVICA can be administered as a single agent, in combination with rituximab or obinutuzumab, or in combination with bendamustine and rituximab (BR). </paragraph>
                        <paragraph>For WM, IMBRUVICA can be administered as a single agent or in combination with rituximab.</paragraph>
                        <paragraph>When administering IMBRUVICA in combination with rituximab or obinutuzumab, consider administering IMBRUVICA prior to rituximab or obinutuzumab when given on the same day.<br/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Chronic Graft versus Host Disease</content>
                        </paragraph>
                        <paragraph>The recommended dosage of IMBRUVICA for patients age 12 years and older with cGVHD is 420 mg orally once daily, and for patients 1 to less than 12 years of age with cGVHD is 240 mg/m<sup>2</sup> orally once daily (up to a dose of 420 mg), until cGVHD progression, recurrence of an underlying malignancy, or unacceptable toxicity. When a patient no longer requires therapy for the treatment of cGVHD, IMBRUVICA should be discontinued considering the medical assessment of the individual patient.</paragraph>
                        <table>
                           <caption>Table 1: Recommended dosage based on body surface area (BSA) for patients 1 to less than 12 years of age using either IMBRUVICA capsules/tablets or oral suspension </caption>
                           <col width="120"/>
                           <col width="240"/>
                           <col width="258"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">
                                    <content styleCode="bold">Recommended dose to achieve 240 mg/m</content>
                                    <content styleCode="bold">
                                       <sup>2</sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">BSA* (m</content>
                                    <content styleCode="bold">
                                       <sup>2</sup>
                                    </content>
                                    <content styleCode="bold">) Range </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Dose (mg) of IMBRUVICA Capsules/Tablets to Administer </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Volume (mL) of IMBRUVICA Oral Suspension (70 mg/mL) to Administer </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&gt; 0.3 to 0.4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1.2 mL</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&gt; 0.4 to 0.5</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1.5 mL</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&gt; 0.5 to 0.6</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1.9 mL</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&gt; 0.6 to 0.7</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2.2 mL</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&gt; 0.7 to 0.8</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">210 mg</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2.6 mL</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&gt; 0.8 to 0.9</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">210 mg</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2.9 mL</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&gt; 0.9 to 1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">210 mg</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3.3 mL</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&gt; 1 to 1.1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">280 mg</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3.6 mL</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&gt; 1.1 to 1.2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">280 mg</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4 mL</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&gt; 1.2 to 1.3</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">280 mg</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4.3 mL</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&gt; 1.3 to 1.4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">350 mg</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4.6 mL</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&gt; 1.4 to 1.5</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">350 mg </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">5 mL</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&gt; 1.5 to 1.6</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">350 mg</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">5.3 mL</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&gt; 1.6</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">420 mg</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">6 mL</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>    *BSA = body surface area.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Administration</content>
                        </paragraph>
                        <paragraph>Administer IMBRUVICA at approximately the same time each day. </paragraph>
                        <paragraph>Swallow tablets or capsules whole with a glass of water. Do not open, break, or chew the capsules. Do not cut, crush, or chew the tablets.</paragraph>
                        <paragraph>Follow Instructions for Use for further administration details of IMBRUVICA oral suspension.</paragraph>
                        <paragraph>If a dose of IMBRUVICA is not taken at the scheduled time, it can be taken as soon as possible on the same day with a return to the normal schedule the following day. Do not take extra doses of IMBRUVICA to make up for the missed dose.</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="_2_2_Dosage_Modifications">
                     <id root="70446f6e-c908-4a6e-b77d-9219f1451718"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.2</content>
                        <content styleCode="bold">
		     
	Dosage Modifications for Adverse Reactions</content>
                     </title>
                     <text>
                        <paragraph>For adverse reactions listed in Table <linkHtml href="#Table2">2</linkHtml>, interrupt IMBRUVICA therapy. Once the adverse reaction has improved to Grade 1 or baseline (recovery), follow the recommended dosage modifications (see Table <linkHtml href="#Table2">2</linkHtml>).</paragraph>
                        <table ID="Table2">
                           <caption>Table 2: Recommended Dosage Modifications for Adverse Reactions</caption>
                           <col width="208"/>
                           <col width="93"/>
                           <col width="186"/>
                           <col width="186"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Adverse Reaction</content>
                                    <content styleCode="bold">
                                       <sup>a,b</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Occurrence</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Dose Modification for CLL/SLL, WM, and</content>
                                    <br/>
                                    <content styleCode="bold">Patients  12 Years or older</content>
                                    <br/>
                                    <content styleCode="bold">with cGVHD After</content>
                                    <br/>
                                    <content styleCode="bold">Recovery</content>
                                    <br/>
                                    <content styleCode="bold">Starting Dose = 420 mg</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Dose Modification for</content>
                                    <br/>
                                    <content styleCode="bold">Patients 1 Year to less than</content>
                                    <br/>
                                    <content styleCode="bold">12 Years with cGVHD</content>
                                    <br/>
                                    <content styleCode="bold">After Recovery</content>
                                    <br/>
                                    <content styleCode="bold">Starting Dose = 240 mg/m</content>
                                    <content styleCode="bold">
                                       <sup>2</sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Grade 2 cardiac failure</td>
                                 <td styleCode="Toprule Lrule Rrule ">First</td>
                                 <td styleCode="Toprule Lrule Rrule ">Restart at 280 mg daily<sup>c</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">Restart at 160 mg/m<sup>2</sup> daily<sup>c</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule ">Second</td>
                                 <td styleCode="Toprule Lrule Rrule ">Restart at 140 mg daily<sup>c</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">Restart at 80 mg/m<sup>2 </sup>daily<sup>c</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule ">Third</td>
                                 <td styleCode="Toprule Lrule Rrule ">Discontinue IMBRUVICA</td>
                                 <td styleCode="Toprule Lrule Rrule ">Discontinue IMBRUVICA</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Grade 3 cardiac arrhythmias</td>
                                 <td styleCode="Toprule Lrule Rrule ">First</td>
                                 <td styleCode="Toprule Lrule Rrule ">Restart at 280 mg daily<sup>c</sup> </td>
                                 <td styleCode="Toprule Lrule Rrule ">Restart at 160 mg/m<sup>2</sup> daily<sup>c</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule ">Second</td>
                                 <td styleCode="Toprule Lrule Rrule ">Discontinue IMBRUVICA</td>
                                 <td styleCode="Toprule Lrule Rrule ">Discontinue IMBRUVICA</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Grade 3 or 4 cardiac failure <br/>Grade 4 cardiac arrhythmias </td>
                                 <td styleCode="Toprule Lrule Rrule ">First</td>
                                 <td styleCode="Toprule Lrule Rrule ">Discontinue IMBRUVICA</td>
                                 <td styleCode="Toprule Lrule Rrule ">Discontinue IMBRUVICA</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Other Grade 3 or 4<sup> </sup>non-hematological toxicities<sup>d</sup>
                                    <br/>Grade 3 or 4 neutropenia<br/>with infection or fever<br/>Grade 4 hematological<br/>toxicities</td>
                                 <td styleCode="Toprule Lrule Rrule ">First</td>
                                 <td styleCode="Toprule Lrule Rrule ">Restart at 280 mg daily</td>
                                 <td styleCode="Toprule Lrule Rrule ">Restart at 160 mg/m<sup>2</sup> daily<sup>c</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule ">Second</td>
                                 <td styleCode="Toprule Lrule Rrule ">Restart at 140 mg daily</td>
                                 <td styleCode="Toprule Lrule Rrule ">Restart at 80 mg/m<sup>2 </sup>daily<sup>c</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule ">Third</td>
                                 <td styleCode="Toprule Lrule Rrule ">Discontinue IMBRUVICA</td>
                                 <td styleCode="Toprule Lrule Rrule ">Discontinue IMBRUVICA</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>a</sup>
                           <sup> </sup>
                           <content styleCode="italics">[see </content>
                           <content styleCode="italics">Warnings and Precautions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_5_WARNINGS_AND">5</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>
                           <content styleCode="italics">]</content>
                           <content styleCode="italics">.</content>
                           <sup> </sup>
                        </paragraph>
                        <paragraph>
                           <sup>b </sup>Grading based on National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) criteria, or International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria for hematologic toxicities in CLL/SLL.</paragraph>
                        <paragraph>
                           <sup>c </sup>Evaluate the benefit-risk before resuming treatment.</paragraph>
                        <paragraph>
                           <sup>d </sup>For Grade 4 non-hematologic toxicities, evaluate the benefit-risk before resuming treatment.</paragraph>
                        <table>
                           <caption>Table 3: Recommended dosage modifications based on BSA using either IMBRUVICA capsules/tablets or oral suspension</caption>
                           <col width="90"/>
                           <col width="144"/>
                           <col width="144"/>
                           <col width="144"/>
                           <col width="144"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">
                                    <content styleCode="bold">Recommended dose to achieve 160 mg/m</content>
                                    <content styleCode="bold">
                                       <sup>2</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">
                                    <content styleCode="bold">Recommended dose to achieve 80 mg/m</content>
                                    <content styleCode="bold">
                                       <sup>2</sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">BSA* (m</content>
                                    <content styleCode="bold">
                                       <sup>2</sup>
                                    </content>
                                    <content styleCode="bold">) Range </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Dose (mg) of IMBRUVICA Capsules/Tablets to Administer </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Volume (mL) of IMBRUVICA Oral Suspension (70 mg/mL) to Administer </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Dose (mg) of IMBRUVICA Capsules/Tablets to Administer </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Volume (mL) of IMBRUVICA Oral Suspension (70 mg/mL) to Administer </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&gt; 0.3 to 0.4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0.8 mL</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0.4 mL</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&gt; 0.4 to 0.5</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1 mL</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0.5 mL</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&gt; 0.5 to 0.6</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1.3 mL</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0.6 mL</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&gt; 0.6 to 0.7</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1.5 mL</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0.7 mL</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&gt; 0.7 to 0.8</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">140 mg</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1.7 mL</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">70 mg</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0.9 mL</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&gt; 0.8 to 0.9</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">140 mg</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1.9 mL</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">70 mg</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1 mL</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&gt; 0.9 to 1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">140 mg</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2.2 mL</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">70 mg</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1.1 mL</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&gt; 1 to 1.1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">140 mg</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2.4 mL</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">70 mg</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1.2 mL</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&gt; 1.1 to 1.2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">210 mg</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2.6 mL</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1.3 mL</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&gt; 1.2 to 1.3</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">210 mg</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2.9 mL</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1.4 mL</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&gt; 1.3 to 1.4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">210 mg</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3.1 mL</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">-</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1.5 mL</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&gt; 1.4 to 1.5</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">210 mg</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3.3 mL</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">140 mg</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1.7 mL</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&gt; 1.5 to 1.6</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">280 mg</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3.5 mL</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">140 mg</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1.8 mL</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&gt; 1.6</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">280 mg</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4 mL</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">140 mg</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2 mL</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>*BSA = body surface area.</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="_2_3_Dosage_Modifications">
                     <id root="0b29f6d5-18e5-490a-9936-2525804fe684"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.3</content>
                        <content styleCode="bold">
		     
	Dosage Modifications for Use with CYP3A Inhibitors</content>
                     </title>
                     <text>
                        <paragraph>Recommended dosage modifications are described below <content styleCode="italics">[see Drug Interactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_7_1_Effect_of">7.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>:</paragraph>
                        <table>
                           <caption>Table 4:  Recommended Dosage Modifications for Use with CYP3A Inhibitors</caption>
                           <col width="138"/>
                           <col width="258"/>
                           <col width="250"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Patient Population</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Coadministered Drug</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Recommended IMBRUVICA Dosage</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">B-cell Malignancies</td>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Moderate CYP3A inhibitor</item>
                                    </list>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">280 mg once daily<br/>
                                    <br/>Modify dose as recommended <content styleCode="italics">[see Dosage and Administration (</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#_2_2_Dosage_Modifications">2.2</linkHtml>
                                    </content>
                                    <content styleCode="italics">)].</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Voriconazole 200 mg twice daily<br/>
                                       </item>
                                       <item>Posaconazole suspension 100 mg once daily, 100 mg twice daily, or 200 mg twice daily</item>
                                    </list>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">140 mg once daily<br/>
                                    <br/>Modify dose as recommended <content styleCode="italics">[see Dosage and Administration (</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#_2_2_Dosage_Modifications">2.2</linkHtml>
                                    </content>
                                    <content styleCode="italics">)].</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Posaconazole suspension 200 mg three times daily or 400 mg twice daily<br/>
                                       </item>
                                       <item>Posaconazole intravenously 300 mg once daily<br/>
                                       </item>
                                       <item>Posaconazole delayed-release tablets 300 mg once daily</item>
                                    </list>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">70 mg once daily<br/>
                                    <br/>Interrupt dose as recommended <content styleCode="italics">[see Dosage and Administration (</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#_2_2_Dosage_Modifications">2.2</linkHtml>
                                    </content>
                                    <content styleCode="italics">)].</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Other strong CYP3A inhibitors</item>
                                    </list>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">Avoid concomitant use.  <br/>
                                    <br/>If these inhibitors will be used short-term (such as anti-infectives for seven days or less), interrupt IMBRUVICA.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Patients 12 years and older with cGVHD</td>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Moderate CYP3A inhibitor</item>
                                    </list>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">420 mg once daily<br/>
                                    <br/>Modify dose as recommended<content styleCode="italics"> [see Dosage and Administration (</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#_2_2_Dosage_Modifications">2.2</linkHtml>
                                    </content>
                                    <content styleCode="italics">)].</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Voriconazole 200 mg twice daily<br/>
                                       </item>
                                       <item>Posaconazole suspension 100 mg once daily, 100 mg twice daily, or 200 mg twice daily</item>
                                    </list>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">280 mg once daily<br/>
                                    <br/>Modify dose as recommended <content styleCode="italics">[see Dosage and Administration (</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#_2_2_Dosage_Modifications">2.2</linkHtml>
                                    </content>
                                    <content styleCode="italics">)].</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Posaconazole suspension 200 mg three times daily or 400 mg twice daily<br/>
                                       </item>
                                       <item>Posaconazole intravenously 300 mg once daily<br/>
                                       </item>
                                       <item>Posaconazole delayed-release tablets 300 mg once daily</item>
                                    </list>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">140 mg once daily<br/>
                                    <br/>Interrupt dose as recommended <content styleCode="italics">[see Dosage and Administration (</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#_2_2_Dosage_Modifications">2.2</linkHtml>
                                    </content>
                                    <content styleCode="italics">)].</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Other strong CYP3A inhibitors</item>
                                    </list>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">Avoid concomitant use.  <br/>
                                    <br/>If these inhibitors will be used short-term (such as anti-infectives for seven days or less), interrupt IMBRUVICA.</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Patients 1 year to less than 12 years of age with cGVHD</td>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Moderate CYP3A inhibitors</item>
                                    </list>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">240 mg/m<sup>2</sup> once daily<br/>
                                    <br/>Modify dose as recommended<content styleCode="italics"> [see Dosage and Administration (</content>
                                    <content styleCode="italics">
                                       <linkHtml href="#_2_2_Dosage_Modifications">2.2</linkHtml>
                                    </content>
                                    <content styleCode="italics">)].</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Voriconazole for suspension 9 mg/kg (maximum dose: 350 mg) twice daily </item>
                                    </list>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">160 mg/m<sup>2</sup> once daily</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Posaconazole at any dosage</item>
                                    </list>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">80 mg/m<sup>2</sup> once daily </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <list listType="unordered" styleCode="Disc">
                                       <item>Other strong CYP3A inhibitors</item>
                                    </list>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">Avoid concomitant use.  <br/>
                                    <br/>If these inhibitors will be used short-term (such as anti-infectives for seven days or less), interrupt IMBRUVICA.</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>After discontinuation of a CYP3A inhibitor, resume previous dose of IMBRUVICA <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_1_Recommended_Dosage">2.1</linkHtml>
                           </content>
                           <content styleCode="italics">), Drug Interactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_7_1_Effect_of">7.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.  </paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="_2_4_Dosage_Modifications">
                     <id root="3d3b5a2d-1705-48cb-8972-5a7da7179866"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">2.4</content>
                        <content styleCode="bold">
		     
	Dosage Modifications for Use in Hepatic Impairment</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Adult Patients with B-cell Malignancies</content>
                        </paragraph>
                        <paragraph>The recommended dosage is 140 mg daily for patients with mild hepatic impairment (Child-Pugh class A).</paragraph>
                        <paragraph>The recommended dosage is 70 mg daily for patients with moderate hepatic impairment (Child-Pugh class B).</paragraph>
                        <paragraph>Avoid the use of IMBRUVICA in patients with severe hepatic impairment (Child-Pugh class C) <content styleCode="italics">[see Use in Specific Populations (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_8_6_Hepatic_Impairment">8.6</linkHtml>
                           </content>
                           <content styleCode="italics">), Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_12_3_Pharmacokinetics">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Patients with cGVHD</content>
                        </paragraph>
                        <paragraph>The recommended dosage is 140 mg daily for patients 12 years of age and older with total bilirubin level &gt;1.5 to 3 x upper limit of normal (ULN) (unless of non-hepatic origin or due to Gilbert’s syndrome).</paragraph>
                        <paragraph>The recommended dosage is 80 mg/m<sup>2</sup> daily for patients 1 to less than 12 years of age with total bilirubin level &gt;1.5 to 3 x ULN (unless of non-hepatic origin or due to Gilbert’s syndrome).</paragraph>
                        <paragraph>Avoid the use of IMBRUVICA in these patients with total bilirubin level &gt; 3 x ULN (unless of non-hepatic origin or due to Gilbert’s syndrome)<content styleCode="italics"> [see Use in Specific Populations (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_8_6_Hepatic_Impairment">8.6</linkHtml>
                           </content>
                           <content styleCode="italics">), Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_12_3_Pharmacokinetics">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_3_DOSAGE_FORMS">
               <id root="baafd71e-84c6-457c-a6ae-47f4d0a56528"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43678-2" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>
                  <content styleCode="bold">3</content>
		     
	<content styleCode="bold">DOSAGE FORMS AND STRENGTHS</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Capsules:</content>
                  </paragraph>
                  <paragraph>Each 70 mg capsule is a yellow, opaque capsule marked with “ibr 70 mg” in black ink.</paragraph>
                  <paragraph>Each 140 mg capsule is a white, opaque capsule marked with “ibr 140 mg” in black ink.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Tablets:</content>
                  </paragraph>
                  <paragraph>Each 140 mg tablet is a yellow green to green round tablet debossed with “ibr” on one side and “140” on the other side.</paragraph>
                  <paragraph>Each 280 mg tablet is a purple oblong tablet debossed with “ibr” on one side and “280” on the other side.</paragraph>
                  <paragraph>Each 420 mg tablet is a yellow green to green oblong tablet debossed with “ibr” on one side and “420” on the other side. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Oral Suspension:</content>
                  </paragraph>
                  <paragraph>70 mg/mL, white to off-white suspension.</paragraph>
               </text>
               <effectiveTime value="20241220"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Capsules: 70 mg and 140 mg (<linkHtml href="#_3_DOSAGE_FORMS">3</linkHtml>)</paragraph>
                        <paragraph>Tablets:  140 mg, 280 mg, and 420 mg (<linkHtml href="#_3_DOSAGE_FORMS">3</linkHtml>)</paragraph>
                        <paragraph>Oral suspension: 70 mg/mL (<linkHtml href="#_3_DOSAGE_FORMS">3</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_4_CONTRAINDICATIONS">
               <id root="a9d632ba-5f80-4e86-a641-203b3f90f6a0"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34070-3" displayName="CONTRAINDICATIONS SECTION"/>
               <title>
                  <content styleCode="bold">4</content>
		     
	<content styleCode="bold">CONTRAINDICATIONS</content>
               </title>
               <text>
                  <paragraph>None</paragraph>
               </text>
               <effectiveTime value="20241220"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None (<linkHtml href="#_4_CONTRAINDICATIONS">4</linkHtml>)</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="_5_WARNINGS_AND">
               <id root="af498ea0-4592-4e7f-a7bb-382e5f1124d9"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43685-7" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>
                  <content styleCode="bold">5</content>
		     
	<content styleCode="bold">WARNINGS AND PRECAUTIONS</content>
               </title>
               <effectiveTime value="20241220"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Hemorrhage</content>: Monitor for bleeding and manage (<linkHtml href="#_5_1_Hemorrhage">5.1</linkHtml>).<br/>
                           </item>
                           <item>
                              <content styleCode="underline">Infections</content>: Monitor patients for fever and infections, evaluate promptly, and treat (<linkHtml href="#_5_2_Infections">5.2</linkHtml>).<br/>
                           </item>
                           <item>
                              <content styleCode="underline">Cardiac Arrhythmias</content>
                              <content styleCode="underline">,</content>
                              <content styleCode="underline"> Cardiac Failure</content>
                              <content styleCode="underline">, and Sudden Death</content>: Monitor for symptoms of arrhythmias and cardiac failure and manage (<linkHtml href="#_5_3_Cardiac_Arrhythmias_">5.3</linkHtml>). <br/>
                           </item>
                           <item>
                              <content styleCode="underline">Hypertension</content>: Monitor blood pressure and treat (<linkHtml href="#_5_4_Hypertension">5.4</linkHtml>).<br/>
                           </item>
                           <item>
                              <content styleCode="underline">Cytopenias</content>: Check complete blood counts monthly (<linkHtml href="#_5_5_Cytopenias">5.5</linkHtml>).<br/>
                           </item>
                           <item>
                              <content styleCode="underline">Second Primary Malignancies</content>: Other malignancies have occurred in patients, including skin cancers, and other carcinomas (<linkHtml href="#_5_6_Second_Primary">5.6</linkHtml>).<br/>
                           </item>
                           <item>
                              <content styleCode="underline">Hepatotoxicity, Including Drug-</content>
                              <content styleCode="underline">Induced Liver Injury</content>:  Monitor hepatic function throughout treatment (<linkHtml href="#_5_7_Hepatotoxicity__Including">5.7</linkHtml>).<br/>
                           </item>
                           <item>
                              <content styleCode="underline">Tumor Lysis Syndrome (TLS)</content>: Assess baseline risk and take precautions. Monitor and treat for TLS (<linkHtml href="#_5_7_Tumor_Lysis">5.8</linkHtml>).<br/>
                           </item>
                           <item>
                              <content styleCode="underline">Embryo-Fetal Toxicity</content>: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective contraception (<linkHtml href="#_5_8_Embryo_Fetal_Toxicity">5.9</linkHtml>, <linkHtml href="#_8_1_Pregnancy">8.1</linkHtml>, <linkHtml href="#_8_3_Females_and">8.3</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_5_1_Hemorrhage">
                     <id root="5bf159f6-4268-41de-8d37-4f28539774f8"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.1</content>
                        <content styleCode="bold">
		     
	Hemorrhage</content>
                     </title>
                     <text>
                        <paragraph>Fatal bleeding events have occurred in patients who received IMBRUVICA. Major hemorrhage (≥ Grade 3, serious, or any central nervous system events; e.g., intracranial hemorrhage [including subdural hematoma], gastrointestinal bleeding, hematuria, and post procedural hemorrhage) occurred in 4.2% of patients, with fatalities occurring in 0.4% of 2,838 patients who received IMBRUVICA in 27 clinical trials. Bleeding events of any grade including bruising and petechiae occurred in 39%, and excluding bruising and petechiae occurred in 23% of patients who received IMBRUVICA, respectively <content styleCode="italics">[see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_6_1_Clinical_Trials">6.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                        <paragraph>The mechanism for the bleeding events is not well understood.</paragraph>
                        <paragraph>Use of either anticoagulant or antiplatelet agents concomitantly with IMBRUVICA increases the risk of major hemorrhage. Across clinical trials, 3.1% of 2,838 patients who received IMBRUVICA without antiplatelet or anticoagulant therapy experienced major hemorrhage.  The addition of antiplatelet therapy with or without anticoagulant therapy increased this percentage to 4.4%, and the addition of anticoagulant therapy with or without antiplatelet therapy increased this percentage to 6.1%.  Consider the risks and benefits of anticoagulant or antiplatelet therapy when co-administered with IMBRUVICA. Monitor for signs and symptoms of bleeding. </paragraph>
                        <paragraph>Consider the benefit-risk of withholding IMBRUVICA for at least 3 to 7 days pre- and post-surgery depending upon the type of surgery and the risk of bleeding <content styleCode="italics">[see</content> <content styleCode="italics">Clinical Studies (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_14_CLINICAL_STUDIES">14</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_2_Infections">
                     <id root="9f1d0dda-58c1-42ee-a62a-241a451cdf32"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.2</content>
                        <content styleCode="bold">
		     
	Infections</content>
                     </title>
                     <text>
                        <paragraph>Fatal and non-fatal infections (including bacterial, viral, or fungal) have occurred with IMBRUVICA therapy. Grade 3 or greater infections occurred in 21% of 1,476 patients with B-cell malignancies who received IMBRUVICA in clinical trials <content styleCode="italics">[see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_6_1_Clinical_Trials">6.1</linkHtml>
                           </content>
                           <content styleCode="italics">, </content>
                           <content styleCode="italics">
                              <linkHtml href="#_6_2_Postmarketing_Experience">6.2</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. Cases of progressive multifocal leukoencephalopathy (PML) and Pneumocystis jirovecii pneumonia (PJP) have occurred in patients treated with IMBRUVICA. Consider prophylaxis according to standard of care in patients who are at increased risk for opportunistic infections. Monitor and evaluate patients for fever and infections and treat appropriately.</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_3_Cardiac_Arrhythmias_">
                     <id root="55266659-96f0-43af-93a6-743a24685f98"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.3</content>
		     
	<content styleCode="bold">Cardiac Arrhythmias, Cardiac Failure, and Sudden Death</content>
                     </title>
                     <text>
                        <paragraph>Fatal and serious cardiac arrhythmias and cardiac failure have occurred with IMBRUVICA. Deaths due to cardiac causes or sudden deaths occurred in 1% of 4,896 patients who received IMBRUVICA in clinical trials, including in patients who received IMBRUVICA in unapproved monotherapy or combination regimens. These adverse reactions occurred in patients with and without preexisting hypertension or cardiac comorbidities. Patients with cardiac comorbidities may be at greater risk of these events.  </paragraph>
                        <paragraph>Grade 3 or greater ventricular tachyarrhythmias were reported in 0.2%, Grade 3 or greater atrial fibrillation and atrial flutter were reported in 3.7%, and Grade 3 or greater cardiac failure was reported in 1.3% of 4,896 patients who received IMBRUVICA in clinical trials, including in patients who received IMBRUVICA in unapproved monotherapy or combination regimens. These events have occurred particularly in patients with cardiac risk factors including hypertension and diabetes mellitus, a previous history of cardiac arrhythmias, and in patients with acute infections <content styleCode="italics">[see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_6_1_Clinical_Trials">6.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                        <paragraph>Evaluate cardiac history and function at baseline, and monitor patients for cardiac arrhythmias and cardiac function.  Obtain further evaluation (e.g., ECG, echocardiogram) as indicated for patients who develop symptoms of arrhythmia (e.g., palpitations, lightheadedness, syncope, chest pain), new onset dyspnea, or other cardiovascular concerns. Manage cardiac arrhythmias and cardiac failure appropriately, follow dose modification guidelines <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_2_Dosage_Modifications">2.2</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>, and consider the risks and benefits of continued IMBRUVICA treatment.</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_4_Hypertension">
                     <id root="130fa16b-17b2-437f-addb-715a4b691547"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.4</content>
		     
	<content styleCode="bold">Hypertension</content>
                     </title>
                     <text>
                        <paragraph>Hypertension occurred in 19% of 1,476 patients with B-cell malignancies who received IMBRUVICA in clinical trials.  Grade 3 or greater hypertension occurred in 8% of patients <content styleCode="italics">[see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_6_1_Clinical_Trials">6.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. Based on data from a subset of these patients (N=1,124), the median time to onset was 5.9 months (range, 0 to 24 months). In a long-term safety analysis over 5 years of 1,284 patients with B-cell malignancies treated for a median of 36 months (range, 0 to 98 months), the cumulative rate of hypertension increased over time. The prevalence for Grade 3 or greater hypertension was 4% (year 0-1), 7% (year 1-2), 9% (year 2-3), 9% (year 3-4), and 9% (year 4-5); the overall incidence for the 5-year period was 11%.   </paragraph>
                        <paragraph>Monitor blood pressure in patients treated with IMBRUVICA, initiate or adjust anti-hypertensive medication throughout treatment with IMBRUVICA as appropriate, and follow dosage modification guidelines for Grade 3 or higher hypertension <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_2_Dosage_Modifications">2.2</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_5_Cytopenias">
                     <id root="50c0231a-831d-4a1c-9670-53bc17b3138f"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.5</content>
		     
	<content styleCode="bold">Cytopenias</content>
                     </title>
                     <text>
                        <paragraph>In 645 patients with B-cell malignancies who received IMBRUVICA as a single agent, grade 3 or 4 neutropenia occurred in 23% of patients, grade 3 or 4 thrombocytopenia in 8% and grade 3 or 4 anemia in 2.8%, based on laboratory measurements <content styleCode="italics">[see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_6_1_Clinical_Trials">6.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                        <paragraph>Monitor complete blood counts monthly.</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_6_Second_Primary">
                     <id root="47d3d7a5-168b-4050-867b-5b04d420c6e6"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.6</content>
                        <content styleCode="bold">
		     
	Second Primary Malignancies</content>
                     </title>
                     <text>
                        <paragraph>Other malignancies (10%), including non-skin carcinomas (3.9%), occurred among the 1,476 patients with B-cell malignancies who received IMBRUVICA in clinical trials <content styleCode="italics">[see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_6_1_Clinical_Trials">6.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. The most frequent second primary malignancy was non-melanoma skin cancer (6%).</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_7_Hepatotoxicity__Including">
                     <id root="1da22a9f-da55-4b79-9a22-8a5d849885ec"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.7</content>
                        <content styleCode="bold">
		     
	Hepatotoxicity, Including Drug-Induced Liver Injury</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">Hepatotoxicity, including severe, life-threatening, and potentially fatal cases of drug-induced liver injury (DILI), has occurred in patients treated with Bruton tyrosine kinase inhibitors, including IMBRUVICA.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="xmChange">Evaluate bilirubin and transaminases at baseline and throughout treatment with IMBRUVICA. For patients who develop abnormal liver tests after IMBRUVICA, monitor more frequently for liver test abnormalities and clinical signs and symptoms of hepatic toxicity. If DILI is suspected, withhold IMBRUVICA. Upon confirmation of DILI, discontinue IMBRUVICA. </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_7_Tumor_Lysis">
                     <id root="43e40e84-82a4-4479-b94b-417cf897ec21"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.</content>
                        <content styleCode="bold">8</content>
                        <content styleCode="bold">
		     
	Tumor Lysis Syndrome</content>
                     </title>
                     <text>
                        <paragraph>Tumor lysis syndrome has been infrequently reported with IMBRUVICA <content styleCode="italics">[see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_6_2_Postmarketing_Experience">6.2</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.  Assess the baseline risk (e.g., high tumor burden) and take appropriate precautions. Monitor patients closely and treat as appropriate.</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="_5_8_Embryo_Fetal_Toxicity">
                     <id root="23a1e07d-c36d-4e97-91b3-90dc22afae1b"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">5.</content>
                        <content styleCode="bold">9</content>
                        <content styleCode="bold">
		     
	Embryo-Fetal Toxicity</content>
                     </title>
                     <text>
                        <paragraph>Based on findings in animals, IMBRUVICA can cause fetal harm when administered to a pregnant woman. Administration of ibrutinib to pregnant rats and rabbits during the period of organogenesis caused embryo-fetal toxicity including malformations at exposures that were 3-20 times higher than those reported in patients with hematologic malignancies. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with IMBRUVICA and for 1 month after the last dose. <content styleCode="italics">[see Use in Specific Populations (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_8_1_Pregnancy">8.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_6_ADVERSE_REACTIONS">
               <id root="217d088f-1bf5-441a-bb42-860ef265b12e"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34084-4" displayName="ADVERSE REACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">6</content>
		     
	<content styleCode="bold">ADVERSE REACTIONS</content>
               </title>
               <text>
                  <paragraph>The following clinically significant adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Hemorrhage <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#_5_1_Hemorrhage">5.1</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                        <br/>
                     </item>
                     <item>Infections <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#_5_2_Infections">5.2</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                        <br/>
                     </item>
                     <item>Cardiac Arrhythmias, Cardiac Failure, and Sudden Death <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#_5_3_Cardiac_Arrhythmias_">5.3</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                        <br/>
                     </item>
                     <item>Hypertension<content styleCode="italics"> [see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#_5_4_Hypertension">5.4</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                        <br/>
                     </item>
                     <item>Cytopenias <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#_5_5_Cytopenias">5.5</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                        <br/>
                     </item>
                     <item>Second Primary Malignancies <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#_5_6_Second_Primary">5.6</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                        <br/>
                     </item>
                     <item>Hepatotoxicity, including DILI <content styleCode="italics">[see Warning</content>
                        <content styleCode="italics">s</content>
                        <content styleCode="italics"> and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#_5_7_Hepatotoxicity__Including">5.7</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                        <br/>
                     </item>
                     <item>Tumor Lysis Syndrome <content styleCode="italics">[see Warnings and Precautions (</content>
                        <content styleCode="italics">
                           <linkHtml href="#_5_7_Tumor_Lysis">5.8</linkHtml>
                        </content>
                        <content styleCode="italics">)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20241220"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>The most common (≥30%) adverse reactions in patients with B-cell malignancies are thrombocytopenia, diarrhea, fatigue, musculoskeletal pain, neutropenia, rash, anemia, bruising, and nausea (<linkHtml href="#_6_ADVERSE_REACTIONS">6</linkHtml>).<br/>
                           </item>
                           <item>The most common (≥20%) adverse reactions in adult or pediatric patients with cGVHD are fatigue, anemia, bruising, diarrhea, thrombocytopenia, musculoskeletal pain, pyrexia, muscle spasms, stomatitis, hemorrhage, nausea, abdominal pain, pneumonia, and headache (<linkHtml href="#_6_ADVERSE_REACTIONS">6</linkHtml>).</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">
                              <br/>
                              <br/>To report SUSPECTED ADVERSE REACTIONS, contact Pharmacyclics at 1-877-877-3536 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_6_1_Clinical_Trials">
                     <id root="139ec171-3724-477a-843f-7cc98fbdb1c8"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="90374-0" displayName="CLINICAL TRIALS EXPERIENCE SECTION"/>
                     <title>
                        <content styleCode="bold">6.1</content>
                        <content styleCode="bold">
		     
	Clinical Trials Experience</content>
                     </title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely variable conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared with rates of clinical trials of another drug and may not reflect the rates observed in practice.<br/>
                        </paragraph>
                        <paragraph>Unless otherwise specified, the pooled safety population described in the WARNINGS AND PRECAUTIONS reflects exposure to IMBRUVICA in 6 trials. IMBRUVICA was  administered as a single agent at 420 mg orally once daily (475 patients), as a single agent at 560 mg orally once daily [1.3 times the recommended adult dosage (174 patients)], and in combination with other drugs at 420 mg orally once daily (827 patients) in patients with B-cell malignancies.  In this pooled safety population of 1,476 patients, 87% were exposed for 6 months or longer and 68% were exposed for greater than one year.  The most common adverse reactions (≥ 30%) were thrombocytopenia, diarrhea, fatigue, musculoskeletal pain, neutropenia, rash, anemia, bruising, and nausea.</paragraph>
                        <paragraph>Certain subsections in the WARNINGS AND PRECAUTIONS include patients who received IMBRUVICA in unapproved monotherapy or combination regimens.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</content>
                        </paragraph>
                        <paragraph>The data described below reflect exposure to IMBRUVICA in one single-arm, open-label clinical trial (Study 1102) and five randomized controlled clinical trials (RESONATE, RESONATE-2, HELIOS, iLLUMINATE, and E1912) in patients with CLL/SLL (n=2,016 total, including n=1,133 patients exposed to IMBRUVICA). In general, patients with creatinine clearance (CLcr) ≤ 30 mL/min, AST or ALT ≥ 2.5 x ULN, or total bilirubin ≥ 1.5 x ULN (unless of non-hepatic origin) were excluded from these trials. In Study E1912, patients with AST or ALT &gt; 3 x ULN or total bilirubin &gt; 2.5 x ULN were excluded. Study 1102 included 51 patients with previously treated CLL/SLL. RESONATE included 386 randomized patients with previously treated CLL or SLL who received single agent IMBRUVICA or ofatumumab. RESONATE-2 included 267 randomized patients with treatment naïve CLL or SLL who were 65 years or older and received single agent IMBRUVICA or chlorambucil. HELIOS included 574 randomized patients with previously treated CLL or SLL who received IMBRUVICA in combination with BR or placebo in combination with BR. iLLUMINATE included 228 randomized patients with treatment naïve CLL/SLL who were 65 years or older or with coexisting medical conditions and received IMBRUVICA in combination with obinutuzumab or chlorambucil in combination with obinutuzumab. E1912 included 510 patients with previously untreated CLL/SLL who were 70 years or younger and received IMBRUVICA in combination with rituximab or received fludarabine, cyclophosphamide, and rituximab (FCR). </paragraph>
                        <paragraph>The most common adverse reactions in patients with CLL/SLL receiving IMBRUVICA (≥ 30%) were thrombocytopenia, diarrhea, fatigue, musculoskeletal pain, neutropenia, rash, anemia, bruising, and nausea.</paragraph>
                        <paragraph>Four to 10 percent of patients with CLL/SLL receiving IMBRUVICA discontinued treatment due to adverse reactions. These included pneumonia, hemorrhage, atrial fibrillation, neutropenia, arthralgia, rash, and thrombocytopenia. Adverse reactions leading to dose reduction occurred in approximately 9% of patients.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Study 1102</content>
                        </paragraph>
                        <paragraph>Adverse reactions and laboratory abnormalities from Study 1102 (N=51) using single agent IMBRUVICA 420 mg daily in patients with previously treated CLL/SLL occurring at a rate of ≥ 10% with a median duration of treatment of 15.6 months are presented in Table <linkHtml href="#Table5new">5</linkHtml> and Table <linkHtml href="#Table6new">6</linkHtml>.</paragraph>
                        <table ID="Table5new">
                           <caption>Table 5:  Non-Hematologic Adverse Reactions in ≥ 10% of Patients with CLL/SLL (N=51) in Study 1102</caption>
                           <col width="199"/>
                           <col width="212"/>
                           <col width="109"/>
                           <col width="118"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">Body System</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">Adverse Reaction</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">All Grades (%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Grade 3 or Higher (%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Gastrointestinal disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">Diarrhea<br/>Constipation<br/>Nausea<br/>Stomatitis<br/>Vomiting<br/>Abdominal pain<br/>Dyspepsia </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">59<br/>22<br/>20<br/>20<br/>18<br/>14<br/>12</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4<br/>2<br/>2<br/>0<br/>2<br/>0<br/>0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Skin and subcutaneous tissue disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">Bruising <br/>Rash <br/>Petechiae</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">51<br/>25<br/>16</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2<br/>0<br/>0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Infections and infestations</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">Upper respiratory tract infection<br/>Sinusitis<br/>Skin infection<br/>Pneumonia<br/>Urinary tract infection</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">47<br/>22<br/>16<br/>12<br/>12</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2<br/>6<br/>6<br/>10<br/>2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">General disorders and administration site conditions</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">Fatigue<br/>Pyrexia <br/>Peripheral edema<br/>Asthenia<br/>Chills</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">33<br/>24<br/>22<br/>14<br/>12</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">6<br/>2<br/>0<br/>6<br/>0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Musculoskeletal and connective tissue disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">Musculoskeletal pain<br/>Arthralgia<br/>Muscle spasms</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">25<br/>24<br/>18</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">6<br/>0<br/>2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Respiratory, thoracic and mediastinal disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">Cough<br/>Oropharyngeal pain<br/>Dyspnea</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">22<br/>14<br/>12</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0<br/>0<br/>0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Nervous system disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">Dizziness<br/>Headache</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">20<br/>18</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0<br/>2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Vascular disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">Hypertension</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">16</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">8</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Metabolism and nutrition disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">Decreased appetite</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">16</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Neoplasms benign, malignant, unspecified</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule ">Second malignancies</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2<sup>†</sup>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>†</sup>One patient death due to histiocytic sarcoma.</paragraph>
                        <table ID="Table6new">
                           <caption>Table 6:  Treatment-Emergent* Hematologic Laboratory Abnormalities in Patients with CLL/SLL (N=51) in Study 1102</caption>
                           <col width="213"/>
                           <col width="213"/>
                           <col width="213"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">
                                    <content styleCode="bold">Percent of Patients (N=51)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">All Grades (%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Grade 3 or 4 (%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Platelets decreased</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">69</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">12</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Neutrophils decreased</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">53</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">26</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Hemoglobin decreased</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">43</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">0</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>* Based on laboratory measurements per IWCLL criteria and adverse reactions.</paragraph>
                        <paragraph>Treatment-emergent Grade 4 thrombocytopenia (8%) and neutropenia (12%) occurred in patients.</paragraph>
                        <paragraph>
                           <content styleCode="italics">RESONATE</content>
                        </paragraph>
                        <paragraph>Adverse reactions and laboratory abnormalities described below in Table <linkHtml href="#Table7new">7</linkHtml> and Table <linkHtml href="#Table8new">8</linkHtml> reflect exposure to IMBRUVICA with a median duration of 8.6 months and exposure to ofatumumab with a median of 5.3 months in RESONATE in patients with previously treated CLL/SLL.</paragraph>
                        <table ID="Table7new">
                           <caption>Table 7:  Adverse Reactions Reported in ≥ 10% of Patients in the IMBRUVICA Treated Arm in Patients with CLL/SLL in RESONATE</caption>
                           <col width="228"/>
                           <col width="102"/>
                           <col width="114"/>
                           <col width="108"/>
                           <col width="120"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule " align="center">
                                    <content styleCode="bold">Body System</content>
                                    <content styleCode="bold">
                                       <br/>Adverse Reaction</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">
                                    <content styleCode="bold">IMBRUVICA</content>
                                    <content styleCode="bold">
                                       <br/>(N=195)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">
                                    <content styleCode="bold">Ofatumumab</content>
                                    <content styleCode="bold">
                                       <br/>(N=191)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule "/>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">All Grades</content>
                                    <content styleCode="bold">
                                       <br/>(%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Grade 3 or </content>
                                    <br/>
                                    <content styleCode="bold">Higher (%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">All Grades</content>
                                    <content styleCode="bold">
                                       <br/>(%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Grade 3 or </content>
                                    <br/>
                                    <content styleCode="bold">Higher (%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Gastrointestinal disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule "/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Diarrhea</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">48</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">18</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Nausea</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">26</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">18</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Stomatitis*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">17</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">6</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Constipation</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">15</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">9</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Vomiting</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">14</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">6</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Musculoskeletal and connective tissue disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Musculoskeletal pain*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">28</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">18</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Arthralgia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">17</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">7</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Muscle spasms</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">13</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">8</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Skin and subcutaneous tissue disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Rash*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">24</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">13</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Petechiae</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">14</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Bruising*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">General disorders and administration site conditions</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Pyrexia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">24</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">15</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2<sup>†</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Respiratory, thoracic and mediastinal disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   Cough</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">19</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">23</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   Dyspnea</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Infections and infestations</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Upper respiratory tract infection</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">16</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2<sup>†</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Pneumonia*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">15</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12<sup>†</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">13</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10<sup>†</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Sinusitis*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">6</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Urinary tract infection</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">5</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Nervous system disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Headache</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">14</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">6</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Dizziness</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">5</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Injury, poisoning and procedural complications</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Contusion</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Eye disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Vision blurred</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule " colspan="5">The body system and individual ADR terms are sorted in descending frequency order in the IMBRUVICA arm.<br/>* Includes multiple ADR terms.<br/>
                                    <sup>†</sup> Includes 3 events of pneumonia with fatal outcome in each arm, and 1 event of pyrexia and upper respiratory tract infection with a fatal outcome in the ofatumumab arm.</td>
                              </tr>
                           </tbody>
                        </table>
                        <table ID="Table8new">
                           <caption>Table 8:  Treatment-Emergent Hematologic Laboratory Abnormalities in Patients with CLL/SLL in RESONATE</caption>
                           <col width="169"/>
                           <col width="117"/>
                           <col width="117"/>
                           <col width="117"/>
                           <col width="117"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">  </td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">
                                    <content styleCode="bold">  </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">
                                    <content styleCode="bold">  </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">
                                    <content styleCode="bold">IMBRUVICA</content>
                                    <content styleCode="bold">
                                       <br/>(N=195)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">
                                    <content styleCode="bold">Ofatumumab</content>
                                    <content styleCode="bold">
                                       <br/>(N=191)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">All Grades</content>
                                    <content styleCode="bold">
                                       <br/>(%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Grade 3 or 4</content>
                                    <content styleCode="bold">
                                       <br/>(%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">All Grades</content>
                                    <content styleCode="bold">
                                       <br/>(%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Grade 3 or 4</content>
                                    <content styleCode="bold">
                                       <br/>(%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Neutrophils decreased</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">51</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">23</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">57</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">26</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Platelets decreased</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">52</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">5</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">45</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Hemoglobin decreased</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">36</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">21</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Treatment-emergent Grade 4 thrombocytopenia (2% in the IMBRUVICA arm vs 3% in the ofatumumab arm) and neutropenia (8% in the IMBRUVICA arm vs 8% in the ofatumumab arm) occurred in patients.</paragraph>
                        <paragraph>
                           <content styleCode="italics">RESONATE-2</content>
                        </paragraph>
                        <paragraph>Adverse reactions and laboratory abnormalities described below in Table <linkHtml href="#Table9new">9</linkHtml> and Table <linkHtml href="#Table10new">10</linkHtml> reflect exposure to IMBRUVICA with a median duration of 17.4 months. The median exposure to chlorambucil was 7.1 months in RESONATE-2.</paragraph>
                        <table ID="Table9new">
                           <caption>Table 9:  Adverse Reactions Reported in ≥ 10% of Patients in the IMBRUVICA Treated Arm in Patients with CLL/SLL in RESONATE-2</caption>
                           <col width="198"/>
                           <col width="114"/>
                           <col width="108"/>
                           <col width="108"/>
                           <col width="102"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">Body System</content>
                                    <br/>
                                    <content styleCode="bold">Adverse Reaction</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">
                                    <content styleCode="bold">IMBRUVICA</content>
                                    <content styleCode="bold">
                                       <br/>(N=135)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">
                                    <content styleCode="bold">Chlorambucil</content>
                                    <content styleCode="bold">
                                       <br/>(N=132)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule " valign="bottom" align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">All Grades</content>
                                    <content styleCode="bold">
                                       <br/>(%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Grade 3 or Higher (%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">All Grades</content>
                                    <content styleCode="bold">
                                       <br/>(%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Grade 3 or Higher (%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Gastrointestinal disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Diarrhea</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">42</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">17</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Nausea</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">22</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">39</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Constipation</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">16</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">16</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Stomatitis*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">14</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Vomiting</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">13</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">20</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Abdominal pain</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">13</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Dyspepsia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Musculoskeletal and connective tissue disorders </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Musculoskeletal pain*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">36</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">20</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Arthralgia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">16</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">7</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Muscle spasms</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">5</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">General disorders and administration site conditions </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Fatigue</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">30</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">38</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">5</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Peripheral edema</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">19</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">9</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Pyrexia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">17</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">14</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Respiratory, thoracic and mediastinal disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Cough</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">22</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">15</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Dyspnea</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Skin and subcutaneous tissue disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Rash*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">21</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Bruising*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">19</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">7</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Eye disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Dry eye</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">17</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">5</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Lacrimation increased</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">13</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">6</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Vision blurred</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">13</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">8</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Visual acuity reduced</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Infections and infestations</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Upper respiratory tract infection</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">17</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">17</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Skin infection*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">15 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Pneumonia*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">14</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">8</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">7</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Urinary tract infections</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">8</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Vascular disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Hypertension*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">14  </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Nervous system disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Headache </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Dizziness</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Investigations</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Weight decreased</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Subjects with multiple events for a given ADR term are counted once only for each ADR term. </paragraph>
                        <paragraph>The body system and individual ADR terms are sorted in descending frequency order in the IMBRUVICA arm.</paragraph>
                        <paragraph>* Includes multiple ADR terms. </paragraph>
                        <table ID="Table10new">
                           <caption>Table 10:  Treatment-Emergent Hematologic Laboratory Abnormalities in Patients with CLL/SLL in RESONATE-2</caption>
                           <col width="169"/>
                           <col width="117"/>
                           <col width="117"/>
                           <col width="117"/>
                           <col width="117"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">
                                    <content styleCode="bold">IMBRUVICA</content>
                                    <content styleCode="bold">
                                       <br/>(N=135)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">
                                    <content styleCode="bold">Chlorambucil</content>
                                    <content styleCode="bold">
                                       <br/>(N=132)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">All Grades</content>
                                    <content styleCode="bold">
                                       <br/>(%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Grade 3 or 4</content>
                                    <content styleCode="bold">
                                       <br/>(%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">All Grades</content>
                                    <content styleCode="bold">
                                       <br/>(%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Grade 3 or 4</content>
                                    <content styleCode="bold">
                                       <br/>(%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Neutrophils Decreased</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">55</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">28</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">67</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">31</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Platelets Decreased</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">47</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">7</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">58</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">14</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Hemoglobin Decreased</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">36</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">39</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Treatment-emergent Grade 4 thrombocytopenia (1% in the IMBRUVICA arm vs 3% in the chlorambucil arm) and neutropenia (11% in the IMBRUVICA arm vs 12% in the chlorambucil arm) occurred in patients.</paragraph>
                        <paragraph>
                           <content styleCode="italics">HELIOS</content>
                        </paragraph>
                        <paragraph>Adverse reactions described below in Table <linkHtml href="#Table11new">11</linkHtml> reflect exposure to IMBRUVICA + BR with a median duration of 14.7 months and exposure to placebo + BR with a median of 12.8 months in HELIOS in patients with previously treated CLL/SLL.</paragraph>
                        <table ID="Table11new">
                           <caption>Table 11:  Adverse Reactions Reported in ≥ 10% of Patients and ≥ 2% Greater in the IMBRUVICA Arm in Patients with CLL/SLL in HELIOS</caption>
                           <col width="202"/>
                           <col width="96"/>
                           <col width="90"/>
                           <col width="92"/>
                           <col width="80"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">Body System</content>
                                    <br/>
                                    <content styleCode="bold">Adverse Reaction</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" valign="bottom" align="center">
                                    <content styleCode="bold">IMBRUVICA + BR</content>
                                    <br/>
                                    <content styleCode="bold">(N=287)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" valign="bottom" align="center">
                                    <content styleCode="bold">Placebo + BR</content>
                                    <br/>
                                    <content styleCode="bold">(N=287)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">All Grades</content>
                                    <content styleCode="bold">
                                       <br/>(%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">Grade 3 or Higher (%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">All Grades</content>
                                    <content styleCode="bold">
                                       <br/>(%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">Grade 3 or Higher (%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Blood and lymphatic system disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Neutropenia*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">66</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">61</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">60</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">56<sup>†</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Thrombocytopenia*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">34</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">16</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">26</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">16</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Gastrointestinal disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">Diarrhea</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">36</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">23</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="center">Abdominal pain</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">8</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&lt;1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Skin and subcutaneous tissue disorders</content>
                                    <content styleCode="bold"> </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Rash*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">32</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">25</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Bruising<sup> </sup>*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">20</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&lt;1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">8</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&lt;1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Musculoskeletal and connective tissue disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Musculoskeletal pain*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">29</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">20</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Muscle spasms</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">&lt;1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">5</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">General disorders and administration site conditions</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Pyrexia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">25</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">22</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Vascular disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Hemorrhage*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">19</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2<sup>†</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">9</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Hypertension*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">5</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">5</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Infections and infestations</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Bronchitis</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">13</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Skin infection* </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">6</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Metabolism and nutrition disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Hyperuricemia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">6</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The body system and individual ADR terms are sorted in descending frequency order in the IMBRUVICA arm.</paragraph>
                        <paragraph>* Includes multiple ADR terms.</paragraph>
                        <paragraph>&lt;1 used for frequency above 0 and below 0.5%.</paragraph>
                        <paragraph>† Includes 2 events of hemorrhage with fatal outcome in the IMBRUVICA arm and 1 event of neutropenia with a fatal outcome in the placebo + BR arm. </paragraph>
                        <paragraph>Atrial fibrillation of any grade occurred in 7% of patients treated with IMBRUVICA + BR and 2% of patients treated with placebo + BR. The frequency of Grade 3 and 4 atrial fibrillation was 3% in patients treated with IMBRUVICA + BR and 1% in patients treated with placebo + BR.</paragraph>
                        <paragraph>
                           <content styleCode="italics">iLLUMINATE</content>
                        </paragraph>
                        <paragraph>Adverse reactions described below in Table <linkHtml href="#Table12new">12</linkHtml> reflect exposure to IMBRUVICA + obinutuzumab with a median duration of 29.3 months and exposure to chlorambucil + obinutuzumab with a median of 5.1 months in iLLUMINATE in patients with previously untreated CLL/SLL.</paragraph>
                        <table ID="Table12new">
                           <caption>Table 12:  Adverse Reactions Reported in ≥ 10% of Patients in the IMBRUVICA Arm in Patients with CLL/SLL in iLLUMINATE</caption>
                           <col width="214"/>
                           <col width="101"/>
                           <col width="106"/>
                           <col width="105"/>
                           <col width="105"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">Body System</content>
                                    <br/>
                                    <content styleCode="bold">Adverse Reaction</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" valign="bottom" align="center">
                                    <content styleCode="bold">IMBRUVICA + </content>
                                    <br/>
                                    <content styleCode="bold">Obinutuzumab</content>
                                    <br/>
                                    <content styleCode="bold">(N=113)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" valign="bottom" align="center">
                                    <content styleCode="bold">Chlorambucil +</content>
                                    <br/>
                                    <content styleCode="bold">Obinutuzumab</content>
                                    <br/>
                                    <content styleCode="bold">(N=115)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">All Grades</content>
                                    <content styleCode="bold">
                                       <br/>(%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">Grade 3 or Higher (%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">All Grades</content>
                                    <content styleCode="bold">
                                       <br/>(%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">Grade 3 or Higher (%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Blood and lymphatic system disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Neutropenia*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">48</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">39</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">64</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">48</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Thrombocytopenia*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">36</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">19</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">28</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Anemia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">17</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">25</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">8</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Skin and subcutaneous tissue disorders</content>
                                    <content styleCode="bold"> </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Rash*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">36</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Bruising*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">32</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Gastrointestinal disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Diarrhea</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">34</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Constipation</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">16</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Nausea</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">30</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Musculoskeletal and connective tissue disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Musculoskeletal pain*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">33</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">23</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Arthralgia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">22</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Muscle spasms</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">13</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">6</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Respiratory, thoracic and mediastinal disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Cough</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">27</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Injury, poisoning and procedural complications</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Infusion related reaction</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">25</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">58</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">8</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Vascular disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Hemorrhage*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">25</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">9</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Hypertension*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">17</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">General disorders and administration site conditions</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Pyrexia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">19</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">26</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Fatigue</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">18</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">17</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Peripheral edema</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">7</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Infections and infestations</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Pneumonia*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">16</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">9</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">9</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4<sup>†</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Upper respiratory tract <br/>      infection</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">14</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">6</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Skin infection*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">13</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Urinary tract infection</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">7</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Nasopharyngitis</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Conjunctivitis</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Metabolism and nutrition disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Hyperuricemia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">13</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Cardiac disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Atrial fibrillation</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">5</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Psychiatric disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Insomnia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The body system and individual ADR terms are sorted in descending frequency order in the IMBRUVICA arm.</paragraph>
                        <paragraph>* Includes multiple ADR terms.</paragraph>
                        <paragraph>† Includes one event with a fatal outcome. </paragraph>
                        <paragraph>
                           <content styleCode="italics">E1912</content>
                        </paragraph>
                        <paragraph>Adverse reactions described below in Table <linkHtml href="#Table13new">13</linkHtml> reflect exposure to IMBRUVICA + rituximab with a median duration of 34.3 months and exposure to FCR with a median of 4.7 months in E1912 in patients with previously untreated CLL/SLL who were 70 years or younger. </paragraph>
                        <table ID="Table13new">
                           <caption>Table 13:  Adverse Reactions Reported in ≥ 15% of Patients in the IMBRUVICA Arm in Patients with CLL/SLL in E1912</caption>
                           <col width="188"/>
                           <col width="109"/>
                           <col width="116"/>
                           <col width="109"/>
                           <col width="116"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">Body System</content>
                                    <br/>
                                    <content styleCode="bold">Adverse Reaction</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" valign="bottom" align="center">
                                    <content styleCode="bold">IMBRUVICA + Rituximab</content>
                                    <br/>
                                    <br/>
                                    <content styleCode="bold">(N=352)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" valign="bottom" align="center">
                                    <content styleCode="bold">Fludarabine + </content>
                                    <br/>
                                    <content styleCode="bold">Cyclophosphamide + </content>
                                    <content styleCode="bold">
                                       <br/>Rituximab</content>
                                    <br/>
                                    <content styleCode="bold">(N=158)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">All Grades</content>
                                    <content styleCode="bold">
                                       <br/>(%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">Grade 3 or </content>
                                    <br/>
                                    <content styleCode="bold">Higher (%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">All Grades</content>
                                    <content styleCode="bold">
                                       <br/>(%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">Grade 3 or </content>
                                    <br/>
                                    <content styleCode="bold">Higher (%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">General disorders and administration site conditions</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Fatigue</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">80</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">78</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Peripheral edema</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">28</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">17</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Pyrexia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">27</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">27</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Pain</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">23</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">8</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Musculoskeletal and connective tissue disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Musculoskeletal pain*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">61</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">5</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">35</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Arthralgia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">41</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">5</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Gastrointestinal disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Diarrhea</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">53</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">27</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Nausea</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">40</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">64</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Stomatitis*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">22</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">8</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Abdominal pain*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">19</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">     Vomiting</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">18</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">28</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Constipation</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">17</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">32</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Skin and subcutaneous tissue disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Rash*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">49</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">29</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">5</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Bruising*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">36</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Vascular disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Hypertension*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">42</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">19</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">22</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Hemorrhage*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">31</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">8</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Nervous system disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Headache</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">40</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">27</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Dizziness</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">21</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">13</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Peripheral neuropathy*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">19</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">13</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Respiratory, thoracic and mediastinal disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Cough</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">32</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">25</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Dyspnea</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">22</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">21</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Infections and infestations</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Upper respiratory tract </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">29</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">19</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule ">      infection</td>
                                 <td styleCode="Lrule Rrule " align="center"/>
                                 <td styleCode="Lrule Rrule " align="center"/>
                                 <td styleCode="Lrule Rrule " align="center"/>
                                 <td styleCode="Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Skin infection*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">16</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Metabolism and nutrition disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Hyperuricemia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">19</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Decreased appetite</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">15</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">20</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Psychiatric disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Insomnia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">16</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">19</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The body system and individual ADR terms are sorted in descending frequency order in the IMBRUVICA arm.</paragraph>
                        <paragraph>* Includes multiple ADR terms.</paragraph>
                        <table>
                           <caption>Table 14:  Select Laboratory Abnormalities (≥ 15% Any Grade), New or Worsening from Baseline in Patients Receiving IMBRUVICA (E1912)</caption>
                           <col width="215"/>
                           <col width="105"/>
                           <col width="105"/>
                           <col width="111"/>
                           <col width="105"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">
                                    <content styleCode="bold">IMBRUVICA + Rituximab</content>
                                    <br/>
                                    <br/>
                                    <content styleCode="bold">(N=352)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">
                                    <content styleCode="bold">Fludarabine + </content>
                                    <br/>
                                    <content styleCode="bold">Cyclophosphamide + </content>
                                    <br/>
                                    <content styleCode="bold">Rituximab</content>
                                    <br/>
                                    <content styleCode="bold">(N=158)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">All Grades</content>
                                    <content styleCode="bold">
                                       <br/>(%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Grade 3 or 4</content>
                                    <content styleCode="bold">
                                       <br/>(%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">All Grades</content>
                                    <content styleCode="bold">
                                       <br/>(%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Grade 3 or 4</content>
                                    <content styleCode="bold">
                                       <br/>(%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Hematology abnormalities</content>
                                    <br/>     Neutrophils decreased<br/>     Platelets decreased<br/>     Hemoglobin decreased</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">53<br/>43<br/>26</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">30<br/>7<br/>0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">70<br/>69<br/>51</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">44<br/>25<br/>2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Chemistry abnormalities</content>
                                    <br/>     Creatinine increased<br/>     Bilirubin increased<br/>     AST increased</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">38<br/>30<br/>25</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1<br/>2<br/>3</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">17<br/>15<br/>23</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1<br/>0<br/>&lt;1</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Based on laboratory measurements per IWCLL criteria.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Waldenström’s Macroglobulinemia</content>
                        </paragraph>
                        <paragraph>The data described below reflect exposure to IMBRUVICA in two single-arm  clinical trials (Study 1118 and the INNOVATE monotherapy arm) and one randomized controlled trial (INNOVATE), including a total of 169 patients with WM exposed to IMBRUVICA. Study 1118 included 63 patients with previously treated WM who received single agent IMBRUVICA. INNOVATE included 150 patients with treatment naïve or previously treated WM who received IMBRUVICA or placebo in combination with rituximab. The INNOVATE monotherapy arm included 31 patients with previously treated WM who received IMBRUVICA after failure of prior rituximab-containing therapy.</paragraph>
                        <paragraph>The most common adverse reactions in Studies 1118 and INNOVATE (≥ 20%) were neutropenia, diarrhea, bruising, thrombocytopenia, hemorrhage, musculoskeletal pain, rash, and nausea.</paragraph>
                        <paragraph>Five percent of patients receiving IMBRUVICA across Studies 1118 and INNOVATE discontinued treatment due to adverse reactions. The most common adverse reaction leading to discontinuation was atrial fibrillation. Adverse reactions leading to dose reduction occurred in 14% of patients.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Study 1118 and INNOVATE Monotherapy Arm</content>
                        </paragraph>
                        <paragraph>Adverse reactions and laboratory abnormalities described below in Table <linkHtml href="#Table15new">15</linkHtml> and Table <linkHtml href="#Table16new">16</linkHtml> reflect exposure to IMBRUVICA with a median duration of 11.7 months in Study 1118 and 33 months in the INNOVATE Monotherapy Arm.</paragraph>
                        <table ID="Table15new">
                           <caption>Table 15:  Non-Hematologic Adverse Reactions in ≥ 10% in Patients with WM in Study 1118 and the INNOVATE Monotherapy Arm (N=94)</caption>
                           <col width="205"/>
                           <col width="225"/>
                           <col width="102"/>
                           <col width="101"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">Body System</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">Adverse Reaction</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">All Grades (%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Grade 3 or</content>
                                    <content styleCode="bold"> </content>
                                    <content styleCode="bold">Higher (%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">
                                    <content styleCode="bold">Gastrointestinal disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="left">Diarrhea<br/>Nausea<br/>Stomatitis*<br/>Constipation<br/>Gastroesophageal reflux disease</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">38<br/>21<br/>15<br/>12<br/>12</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2<br/>0<br/>0<br/>1<br/>0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">
                                    <content styleCode="bold">Skin and subcutaneous tissue disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="left">Bruising*<br/>Rash*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">28<br/>21</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1<br/>1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">
                                    <content styleCode="bold">Vascular disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="left">Hemorrhage*<br/>Hypertension*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">28<br/>14</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0<br/>4</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">
                                    <content styleCode="bold">General disorders and administrative site conditions</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="left">Fatigue<br/>Pyrexia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">18<br/>12</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2<br/>2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">
                                    <content styleCode="bold">Musculoskeletal and connective tissue disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="left">Musculoskeletal pain*<br/>Muscle spasms</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">21<br/>19</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0<br/>0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">
                                    <content styleCode="bold">Infections and infestations</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="left">Upper respiratory tract infection<br/>Skin infection*<br/>Sinusitis*<br/>Pneumonia*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">19<br/>18<br/>16<br/>13</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0<br/>3<br/>0<br/>5</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">
                                    <content styleCode="bold">Nervous system disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="left">Headache<br/>Dizziness</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">14<br/>13</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0<br/>0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">
                                    <content styleCode="bold">Respiratory, thoracic and mediastinal disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="left">Cough</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">13</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The body system and individual ADR preferred terms are sorted in descending frequency order.</paragraph>
                        <paragraph>* Includes multiple ADR terms.</paragraph>
                        <table ID="Table16new">
                           <caption>Table 16:  Treatment-Emergent Hematologic Laboratory Abnormalities in Patients with WM in Study 1118 and the INNOVATE Monotherapy Arm (N=94)</caption>
                           <col width="208"/>
                           <col width="208"/>
                           <col width="207"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">
                                    <content styleCode="bold">Percent of Patients (N=94)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">All Grades (%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Grade 3 or 4 (%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Platelets Decreased</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">38</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">11</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Neutrophils Decreased</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">43</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">16</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Hemoglobin Decreased</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">21</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">6</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Treatment-emergent Grade 4 thrombocytopenia (4%) and neutropenia (7%) occurred in patients.<content styleCode="bold italics"> </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">INNOVATE</content>
                        </paragraph>
                        <paragraph>Adverse reactions described below in Table <linkHtml href="#Table17new">17</linkHtml> reflect exposure to IMBRUVICA + R with a median duration of 25.8 months and exposure to placebo + R with a median duration of 15.5 months in patients with treatment naïve or previously treated WM in INNOVATE. </paragraph>
                        <table ID="Table17new">
                           <caption>Table 17:  Adverse Reactions Reported in ≥ 10% of Patients and ≥ 2% Greater in the IMBRUVICA Arm in Patients with WM in INNOVATE</caption>
                           <col width="211"/>
                           <col width="96"/>
                           <col width="107"/>
                           <col width="85"/>
                           <col width="96"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">Body System</content>
                                    <br/>
                                    <content styleCode="bold">Adverse Reaction</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" valign="bottom" align="center">
                                    <content styleCode="bold">IMBRUVICA + R</content>
                                    <br/>
                                    <content styleCode="bold">(N=75)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" valign="bottom" align="center">
                                    <content styleCode="bold">Placebo + R</content>
                                    <br/>
                                    <content styleCode="bold">(N=75)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">All Grades</content>
                                    <content styleCode="bold">
                                       <br/>(%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">Grade 3 or Higher</content>
                                    <content styleCode="bold">
                                       <br/>(%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">All Grades</content>
                                    <content styleCode="bold">
                                       <br/>(%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">Grade 3 or Higher</content>
                                    <content styleCode="bold">
                                       <br/>(%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Skin and subcutaneous tissue disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">     Bruising*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">37</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">5</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">     Rash*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">24</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Musculoskeletal and connective tissue disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">     Musculoskeletal pain*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">35</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">21</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">     Arthralgia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">24</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">     Muscle spasms</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">17</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Vascular disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">     Hemorrhage*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">32</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">17</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4<sup>†</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">     Hypertension*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">20</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">13</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">5</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Gastrointestinal disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">     Diarrhea</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">28</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">15</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">     Nausea</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">21</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">     Dyspepsia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">16</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">     Constipation</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">13</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Infections and infestations</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">     Pneumonia*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">19</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">13</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">5</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">     Skin infection*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">17</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">     Urinary tract infection</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">13</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">     Bronchitis</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">7</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">     Influenza</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">7</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">     Viral upper respiratory tract infection</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">7</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">General disorders and administration site conditions</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">     Peripheral edema</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">17</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Respiratory, thoracic, and mediastinal disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">     Cough</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">17</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Blood and lymphatic system disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">     Neutropenia*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">16</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Cardiac disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">     Atrial fibrillation</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">15</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Nervous system disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">     Dizziness</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">7</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Psychiatric disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">     Insomnia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Metabolism and nutrition disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">     Hypokalemia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The body system and individual ADR preferred terms are sorted in descending frequency order.</paragraph>
                        <paragraph>* Includes multiple ADR terms.</paragraph>
                        <paragraph>† Includes one event with a fatal outcome. </paragraph>
                        <paragraph>Grade 3 or 4 infusion related reactions were observed in 1% of patients treated with IR.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Chronic Graft versus Host Disease</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Study 1129</content>
                        </paragraph>
                        <paragraph>The data described below reflect exposure to IMBRUVICA in an open-label clinical trial (Study 1129) that included 42 patients with cGVHD after failure of first line corticosteroid therapy and required additional therapy <content styleCode="italics">[see Clinical </content>
                           <content styleCode="italics">Studies </content>
                           <content styleCode="italics">(</content>
                           <content styleCode="italics">
                              <linkHtml href="#Hyperlink143">14.3</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                        <paragraph>The most common adverse reactions in Study 1129 (≥ 20%) were fatigue, bruising, diarrhea, thrombocytopenia, stomatitis, muscle spasms, nausea, hemorrhage, anemia, and pneumonia.  Atrial fibrillation occurred in one patient (2%) which was Grade 3.</paragraph>
                        <paragraph>Twenty-four percent of patients receiving IMBRUVICA in Study 1129 discontinued treatment due to adverse reactions.  The most common adverse reactions leading to discontinuation were fatigue and pneumonia.  Adverse reactions leading to dose reduction occurred in 26% of patients.</paragraph>
                        <paragraph>Adverse reactions and laboratory abnormalities described below in Table <linkHtml href="#Table18new">18</linkHtml> and Table <linkHtml href="#Table19new">19</linkHtml> reflect exposure to IMBRUVICA with a median duration of 4.4 months in Study 1129.</paragraph>
                        <table ID="Table18new">
                           <caption>Table 18:  Non-Hematologic Adverse Reactions in ≥ 10% of Adult Patients with cGVHD in Study 1129 (N=42)</caption>
                           <col width="205"/>
                           <col width="231"/>
                           <col width="96"/>
                           <col width="102"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">Body System</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">Adverse Reaction</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">All Grades (%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Grade 3 or Higher </content>
                                    <br/>
                                    <content styleCode="bold">(%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">
                                    <content styleCode="bold">General disorders and administration site conditions</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="left">Fatigue<br/>Pyrexia<br/>Edema peripheral</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">57<br/>17<br/>12</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12<br/>5<br/>0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">
                                    <content styleCode="bold">Skin and subcutaneous tissue disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="left">Bruising*<br/>Rash*</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">40<br/>12</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0<br/>0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">
                                    <content styleCode="bold">Gastrointestinal disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="left">Diarrhea<br/>Stomatitis*<br/>Nausea<br/>Constipation</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">36<br/>29<br/>26<br/>12</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10<br/>2<br/>0<br/>0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">
                                    <content styleCode="bold">Musculoskeletal and connective tissue disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="left">Muscle spasms<br/>Musculoskeletal pain*</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">29<br/>14</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2<br/>5</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">
                                    <content styleCode="bold">Vascular disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="left">Hemorrhage*</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">26</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">
                                    <content styleCode="bold">Infections and infestations</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="left">Pneumonia*<br/>Upper respiratory tract infection<br/>Sepsis*</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">21<br/>19<br/>10</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">14<sup>†</sup>
                                    <br/>0<br/>10</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">
                                    <content styleCode="bold">Nervous system disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="left">Headache</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">17</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">5</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">
                                    <content styleCode="bold">Injury, poisoning and procedural complications</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="left">Fall</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">17</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">
                                    <content styleCode="bold">Respiratory, thoracic and mediastinal disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="left">Cough<br/>Dyspnea</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">14<br/>12</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0<br/>2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">
                                    <content styleCode="bold">Metabolism and nutrition disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="left">Hypokalemia<br/>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12<br/>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">7<br/>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The system organ class and individual ADR preferred terms are sorted in descending frequency order.</paragraph>
                        <paragraph>* Includes multiple ADR terms.</paragraph>
                        <paragraph>† Includes 2 events with a fatal outcome. </paragraph>
                        <table ID="Table19new">
                           <caption>Table 19:  Treatment-Emergent Hematologic Laboratory Abnormalities in Adult Patients with cGVHD in Study 1129 (N=42)</caption>
                           <col width="208"/>
                           <col width="208"/>
                           <col width="207"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">
                                    <content styleCode="bold">Percent of Patients (N=42)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">All Grades (%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Grade 3 or 4 (%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Platelets decreased</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">33</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Neutrophils decreased</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">10</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">10</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Hemoglobin decreased</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">24</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">2</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Treatment-emergent Grade 4 neutropenia occurred in 2% of patients.</paragraph>
                        <paragraph>
                           <content styleCode="italics">iMAGINE</content>
                        </paragraph>
                        <paragraph>The safety of IMBRUVICA was evaluated in the iMAGINE study, which included 47 pediatric and young adult patients 1 year to less than 22 years of age with cGVHD after failure of one or more lines of systemic therapy. Patients age 12 years and older were treated with IMBRUVICA 420 mg orally once daily, and patients age 1 year to less than 12 years were treated with IMBRUVICA 240 mg/m<sup>2</sup> orally once daily <content styleCode="italics">[see Clinical Studies (</content>
                           <content styleCode="italics">
                              <linkHtml href="#Hyperlink143">14.3</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. The median duration of exposure to IMBRUVICA was 7.1 months (range, 0.2 to 25.9 months).</paragraph>
                        <paragraph>Serious adverse reactions occurred in 64% of patients who received IMBRUVICA. Serious adverse reactions in more than two patients included pneumonia, pyrexia, sepsis, and stomatitis.  Fatal adverse reactions occurred in two patients who received IMBRUVICA, including sepsis and acute respiratory distress syndrome (ARDS). </paragraph>
                        <paragraph>Permanent discontinuation of IMBRUVICA due to an adverse reaction occurred in 23% of patients. Adverse reactions which resulted in permanent discontinuation in at least two patients included hemorrhage. Dose reductions of IMBRUVICA due to an adverse reaction occurred in 19% of patients. Adverse reactions which required dose reduction in at least two patients included stomatitis.</paragraph>
                        <paragraph>The most common (≥ 20%) adverse reactions, including laboratory abnormalities, were anemia, musculoskeletal pain, pyrexia, diarrhea, pneumonia, abdominal pain, stomatitis, thrombocytopenia, and headache. </paragraph>
                        <paragraph>
                           <linkHtml href="#Table20new">Table 20</linkHtml> summarizes the adverse reactions in iMAGINE.</paragraph>
                        <table ID="Table20new">
                           <caption>Table 20:  Adverse Reactions (≥ 10%) in Patients with Previously Treated cGVHD Who Received IMBRUVICA in iMAGINE </caption>
                           <col width="314"/>
                           <col width="163"/>
                           <col width="153"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">
                                    <content styleCode="bold"> IMBRUVICA</content>
                                    <br/>
                                    <content styleCode="bold">(N=47)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">Body System</content>
                                    <br/>
                                    <content styleCode="bold">Adverse Reaction</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">All Grades</content>
                                    <br/>
                                    <content styleCode="bold">(%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Grade 3 or 4 </content>
                                    <br/>
                                    <content styleCode="bold">(%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">
                                    <content styleCode="bold">General disorders and administration site conditions</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">   Pyrexia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">30</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">
                                    <content styleCode="bold">Musculoskeletal and connective tissue disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">   Musculoskeletal pain*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">30</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">   Osteonecrosis</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">9</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Gastrointestinal disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">   Diarrhea</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">28</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">   Abdominal pain*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">23</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">   Stomatitis*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">23</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">9</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">   Vomiting</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">19</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">   Nausea</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">19</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">
                                    <content styleCode="bold">Infections and infestations</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">   Pneumonia*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">23</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">13</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">   Skin infection*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">17</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">   Sepsis* </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">9<sup>†</sup>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">
                                    <content styleCode="bold">Nervous system disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">   Headache</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">21</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">
                                    <content styleCode="bold">Skin and subcutaneous tissue disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">   Rash*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">19</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">   Pruritus</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">13</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">   Petechiae</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">13</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">
                                    <content styleCode="bold">Respiratory, thoracic and mediastinal disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">   Cough</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">19</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">
                                    <content styleCode="bold">Vascular disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">   Hemorrhage*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">17</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">   Hypertension*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">
                                    <content styleCode="bold">Blood and lymphatic system disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">   Hypokalemia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">15</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">   Hypogammaglobulinemia*</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">
                                    <content styleCode="bold">Cardiac Disorders</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">   Sinus tachycardia</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">
                                    <content styleCode="bold">Investigations</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " align="left">   Alanine aminotransferase increased</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The system organ class and individual ADR preferred terms are sorted in descending frequency order.</paragraph>
                        <paragraph>* Includes multiple ADR terms.</paragraph>
                        <paragraph>† Includes 1 fatal outcome. </paragraph>
                        <paragraph>
                           <linkHtml href="#Table21new">Table 21</linkHtml> summarizes the laboratory abnormalities in iMAGINE.</paragraph>
                        <table ID="Table21new">
                           <caption>Table 21:  Select Hematologic Laboratory Abnormalities (≥ 10%) That Worsened from Baseline in Patients with Previously Treated cGVHD Who Received IMBRUVICA in iMAGINE</caption>
                           <col width="180"/>
                           <col width="240"/>
                           <col width="204"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">
                                    <content styleCode="bold"> IMBRUVICA</content>
                                    <br/>
                                    <content styleCode="bold">(N=47)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">All Grades </content>
                                    <br/>
                                    <content styleCode="bold">(%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Grade 3 or 4 </content>
                                    <br/>
                                    <content styleCode="bold">(%)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Hemoglobin decreased </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">49</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">13</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Platelets decreased</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">21</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">4</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Neutrophils decreased </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">13 </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">6</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>Treatment-emergent Grade 4 neutropenia occurred in 3% of patients.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Additional Important Adverse Reactions</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiovascular Events</content>
                        </paragraph>
                        <paragraph>Data on cardiovascular events are based on randomized controlled trials with IMBRUVICA (n=2,115; median treatment duration of 19.1 months for 1,157 patients treated with IMBRUVICA and 5.3 months for 958 patients in the control arm). The incidence of ventricular tachyarrhythmias (ventricular extrasystoles, ventricular arrhythmias, ventricular fibrillation, ventricular flutter, and ventricular tachycardia) of any grade was 1.0% versus 0.4% and of Grade 3 or greater was 0.3% versus 0% in patients treated with IMBRUVICA compared to patients in the control arm.  The incidence of atrial fibrillation and atrial flutter of any grade was 8.4% versus 1.6% and for Grade 3 or greater was 4.0% versus 0.5% in patients treated with IMBRUVICA compared to patients in the control arm. In addition, the incidence of cardiac failure of any grade was 1.7% versus 0.5% and for Grade 3 or greater was 1.2% versus 0.3% in patients treated with IMBRUVICA compared to patients in the control arm.</paragraph>
                        <paragraph>The incidence of ischemic cerebrovascular events (cerebrovascular accidents, ischemic stroke, cerebral ischemia, and transient ischemic attack) of any grade was 1% versus 0.4% and Grade 3 or greater was 0.5% versus 0.2% in patients treated with IMBRUVICA compared to patients in the control arm, respectively. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Diarrhea</content>
                        </paragraph>
                        <paragraph>In randomized controlled trials (n=2,115; median treatment duration of 19.1 months for 1,157 patients treated with IMBRUVICA and 5.3 months for 958 patients in the control arm), diarrhea of any grade occurred at a rate of 43% of patients treated with IMBRUVICA compared to 19% of patients in the control arm. Grade 3 diarrhea occurred in 3% versus 1% of IMBRUVICA-treated patients compared to the control arm, respectively. Less than 1% (0.3%) of subjects discontinued IMBRUVICA due to diarrhea compared with 0% in the control arm.</paragraph>
                        <paragraph>Based on data from 1,605 of these patients, the median time to first onset was 21 days (range, 0 to 708) versus 46 days (range, 0 to 492) for any grade diarrhea and 117 days (range, 3 to 414) versus 194 days (range, 11 to 325) for Grade 3 diarrhea in IMBRUVICA-treated patients compared to the control arm, respectively. Of the patients who reported diarrhea, 85% versus 89% had complete resolution, and 15% versus 11% had not reported resolution at time of analysis in IMBRUVICA-treated patients compared to the control arm, respectively. The median time from onset to resolution in IMBRUVICA-treated subjects was 7 days (range, 1 to 655) versus 4 days (range, 1 to 367) for any grade diarrhea and 7 days (range, 1 to 78) versus 19 days (range, 1 to 56) for Grade 3 diarrhea in IMBRUVICA-treated subjects compared to the control arm, respectively. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Visual Disturbance</content>
                        </paragraph>
                        <paragraph>In randomized controlled trials (n=2,115; median treatment duration of 19.1 months for 1,157 patients treated with IMBRUVICA and 5.3 months for 958 patients in the control arm), blurred vision and decreased visual acuity of any grade occurred in 11% of patients treated with IMBRUVICA (9% Grade 1, 2% Grade 2, no Grade 3 or higher) compared to 6% in the control arm (5% Grade 1 and &lt; 1% Grade 2 and 3). </paragraph>
                        <paragraph>Based on data from 1,605 of these patients, the median time to first onset was 91 days (range, 0 to 617) versus 100 days (range, 2 to 477) in IMBRUVICA-treated patients compared to the control arm, respectively. Of the patients who reported visual disturbances, 60% versus 71% had complete resolution and 40% versus 29% had not reported resolution at the time of analysis in IMBRUVICA-treated patients compared to the control arm, respectively.  The median time from onset to resolution was 37 days (range, 1 to 457) versus 26 days (range, 1 to 721) in IMBRUVICA-treated subjects compared to the control arm, respectively. </paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="_6_2_Postmarketing_Experience">
                     <id root="3c62c1ae-c4db-4b91-92e8-c49b03957f9f"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="90375-7" displayName="POSTMARKETING EXPERIENCE SECTION"/>
                     <title>
                        <content styleCode="bold">6.2</content>
                        <content styleCode="bold">
		     
	Postmarketing Experience</content>
                     </title>
                     <text>
                        <paragraph>The following adverse reactions have been identified during postapproval use of IMBRUVICA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Hepatobiliary disorders: hepatic failure including acute and/or fatal events, hepatic cirrhosis, drug-induced liver injury<br/>
                           </item>
                           <item>Respiratory disorders: interstitial lung disease<br/>
                           </item>
                           <item>Metabolic and nutrition disorders: tumor lysis syndrome <br/>
                           </item>
                           <item>Immune system disorders: anaphylactic shock, angioedema, urticaria<br/>
                           </item>
                           <item>Skin and subcutaneous tissue disorders: Stevens-Johnson Syndrome (SJS), onychoclasis, panniculitis, neutrophilic dermatoses, cutaneous vasculitis<br/>
                           </item>
                           <item>Infections: hepatitis B reactivation<br/>
                           </item>
                           <item>Nervous system disorders: peripheral neuropathy</item>
                        </list>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_7_DRUG_INTERACTIONS">
               <id root="f8875753-d041-4982-bee4-4cf6030dfc65"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34073-7" displayName="DRUG INTERACTIONS SECTION"/>
               <title>
                  <content styleCode="bold">7</content>
		     
	<content styleCode="bold">DRUG INTERACTIONS</content>
               </title>
               <effectiveTime value="20241220"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>CYP3A Inhibitors: Modify IMBRUVICA dose as described (<linkHtml href="#_2_3_Dosage_Modifications">2.3</linkHtml>, <linkHtml href="#_7_1_Effect_of">7.1</linkHtml>).<br/>
                           </item>
                           <item>CYP3A Inducers: Avoid coadministration with strong CYP3A inducers (<linkHtml href="#_7_2_Effect_of">7.2</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_7_1_Effect_of">
                     <id root="feae9a8e-ddb7-461b-ab92-f69ff1633b34"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.1</content>
                        <content styleCode="bold">
		     
	Effect of CYP3A Inhibitors on Ibrutinib</content>
                     </title>
                     <text>
                        <paragraph>The coadministration of IMBRUVICA with a strong or moderate CYP3A inhibitor may increase ibrutinib plasma concentrations <content styleCode="italics">[see Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_12_3_Pharmacokinetics">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. Increased ibrutinib concentrations may increase the risk of drug-related toxicity. </paragraph>
                        <paragraph>Dose modifications of IMBRUVICA are recommended when used concomitantly with posaconazole, voriconazole and moderate CYP3A inhibitors <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_3_Dosage_Modifications">2.3</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content> </paragraph>
                        <paragraph>Avoid concomitant use of other strong CYP3A inhibitors. Interrupt IMBRUVICA if these inhibitors will be used short-term (such as anti-infectives for seven days or less) <content styleCode="italics">[see Dosage and </content>
                           <content styleCode="italics">Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_3_Dosage_Modifications">2.3</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>
                           <content styleCode="italics">]</content>.</paragraph>
                        <paragraph>Avoid grapefruit and Seville oranges during IMBRUVICA treatment, as these contain strong or moderate inhibitors of CYP3A.</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="_7_2_Effect_of">
                     <id root="46ae001b-2879-4ea5-8f2d-51f28ba0af4d"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">7.2</content>
                        <content styleCode="bold">
		     
	Effect of CYP3A Inducers on Ibrutinib</content>
                     </title>
                     <text>
                        <paragraph>The coadministration of IMBRUVICA with strong CYP3A inducers may decrease ibrutinib concentrations. Avoid coadministration with strong CYP3A inducers <content styleCode="italics">[see Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_12_3_Pharmacokinetics">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>
                           <content styleCode="italics">]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="1e135ea3-d4e5-47d5-82ea-47a5ccafe440"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43684-0" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>
                  <content styleCode="bold">8</content>
		     
	<content styleCode="bold">USE IN SPECIFIC POPULATIONS</content>
               </title>
               <effectiveTime value="20241220"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="underline">Lactation</content>: Advise not to breastfeed (<linkHtml href="#_8_2_Lactation">8.2</linkHtml>).<br/>
                           </item>
                           <item>
                              <content styleCode="underline">Hepatic Impairment</content>: Avoid use of IMBRUVICA in patients with severe hepatic impairment. In patients with mild or moderate impairment, reduce IMBRUVICA dose (<linkHtml href="#_2_4_Dosage_Modifications">2.4</linkHtml>, <linkHtml href="#_8_6_Hepatic_Impairment">8.6</linkHtml>).  </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="_8_1_Pregnancy">
                     <id root="010a0679-6c06-43db-a4b1-b3b77f2aa98e"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42228-7" displayName="PREGNANCY SECTION"/>
                     <title>
                        <content styleCode="bold">8.1</content>
                        <content styleCode="bold">
		     
	Pregnancy</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>IMBRUVICA can cause fetal harm based on findings from animal studies. There are no available data on IMBRUVICA use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. In animal reproduction studies, administration of ibrutinib to pregnant rats and rabbits during the period of organogenesis at exposures up to 3-20 times the clinical dose of 420 mg daily produced embryofetal toxicity including structural abnormalities <content styleCode="italics">(see Data)</content>. Advise pregnant women of the potential risk to a fetus.</paragraph>
                        <paragraph>All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Ibrutinib was administered orally to pregnant rats during the period of organogenesis at doses of 10, 40 and 80 mg/kg/day. Ibrutinib at a dose of 80 mg/kg/day was associated with visceral malformations (heart and major vessels) and increased resorptions and post-implantation loss. The dose of 80 mg/kg/day in rats is approximately 20 times the exposure in patients with CLL/SLL or WM administered a dose of  420 mg daily. Ibrutinib at doses of 40 mg/kg/day or greater was associated with decreased fetal weights. The dose of 40 mg/kg/day in rats is approximately 8 times the exposure (AUC) in patients administered a dose of 420 mg daily.</paragraph>
                        <paragraph>Ibrutinib was also administered orally to pregnant rabbits during the period of organogenesis at doses of 5, 15, and 45 mg/kg/day. Ibrutinib at a dose of 15 mg/kg/day or greater was associated with skeletal variations (fused sternebrae) and ibrutinib at a dose of 45 mg/kg/day was associated with increased resorptions and post-implantation loss.  The dose of 15 mg/kg/day in rabbits is approximately 2.8 times the exposure in patients with CLL/SLL or WM administered a dose of  420 mg daily.</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="_8_2_Lactation">
                     <id root="a5fad511-262f-4470-a2a7-1a1685fc662c"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="77290-5" displayName="LACTATION SECTION"/>
                     <title>
                        <content styleCode="bold">8.2</content>
                        <content styleCode="bold">
		     
	Lactation</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There is no information regarding the presence of ibrutinib or its metabolites in human milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment with IMBRUVICA and for 1 week after the last dose.</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="_8_3_Females_and">
                     <id root="b56a9db8-3b34-40e4-af72-d07e89389755"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="77291-3" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>
                        <content styleCode="bold">8.3</content>
                        <content styleCode="bold">
		     
	Females and Males of Reproductive Potential</content>
                     </title>
                     <text>
                        <paragraph>IMBRUVICA can cause fetal harm when administered to pregnant women <content styleCode="italics">[see Use in Specific Populations (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_8_1_Pregnancy">8.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Testing</content>
                        </paragraph>
                        <paragraph>Verify pregnancy status in females of reproductive potential prior to initiating IMBRUVICA.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Contraception</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Females</content>
                        </paragraph>
                        <paragraph>Advise females of reproductive potential to use effective contraception during treatment with IMBRUVICA and for 1 month after the last dose.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Males</content>
                        </paragraph>
                        <paragraph>Advise males with female partners of reproductive potential to use effective contraception during treatment with IMBRUVICA and for 1 month following the last dose.</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="1a1cdf85-89b5-46fe-9edb-80bb1bce8001"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34081-0" displayName="PEDIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.4</content>
                        <content styleCode="bold">
		     
	Pediatric Use</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Chronic GVHD</content>
                        </paragraph>
                        <paragraph>The safety and effectiveness of IMBRUVICA have been established for treatment of cGVHD after failure of one or more lines of systemic therapy in pediatric patients 1 year of age and older. </paragraph>
                        <paragraph>Use of IMBRUVICA for this indication is supported by evidence from iMAGINE, a study which included pediatric patients age 1 year and older with previously treated cGVHD, including patients in the following age groups: one patient 1 year to less than 2 years of age, 20 patients 2 years to less than 12 years of age, and 19 patients 12 years to less than 17 years of age. Additional supportive efficacy data was provided from Study 1129 in adults <content styleCode="italics">[see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_6_1_Clinical_Trials">6.1</linkHtml>
                           </content>
                           <content styleCode="italics">), Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_12_3_Pharmacokinetics">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">), and Clinical Studies (</content>
                           <content styleCode="italics">
                              <linkHtml href="#Hyperlink143">14.3</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. </paragraph>
                        <paragraph>The recommended dosage of IMBRUVICA in patients age 12 years and older is the same as that in adults, and the recommended dosage in patients age 1 year to less than 12 years old is based on body-surface area (BSA) <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_1_Recommended_Dosage">2.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. </paragraph>
                        <paragraph>The safety and effectiveness of IMBRUVICA have not been established for this indication in  pediatric patients less than 1 year of age.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Mature B-cell Non-Hodgkin Lymphoma</content>
                        </paragraph>
                        <paragraph>The safety and effectiveness of IMBRUVICA in combination with chemoimmunotherapy were assessed but have not been established based on an open-label, randomized study (NCT02703272) in 35 patients, which included 26 pediatric patients age 5 to less than 17 years, with previously treated mature B-cell non-Hodgkin lymphoma. The study was stopped for futility. In the randomized population, major hemorrhage and discontinuation of chemoimmunotherapy due to adverse reactions occurred more frequently in the ibrutinib plus chemoimmunotherapy arm compared to the chemoimmunotherapy alone arm. </paragraph>
                        <paragraph>
                           <content styleCode="underline">CLL/SLL, CLL/SLL with 17p deletion, WM</content>
                        </paragraph>
                        <paragraph>The safety and effectiveness of IMBRUVICA in pediatric patients have not been established in CLL/SLL, CLL/SLL with 17p deletion, or WM.</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="738a0a46-41f0-48ea-8230-b01d5ccda88c"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34082-8" displayName="GERIATRIC USE SECTION"/>
                     <title>
                        <content styleCode="bold">8.5</content>
                        <content styleCode="bold">
		     
	Geriatric Use</content>
                     </title>
                     <text>
                        <paragraph>Of 992 patients in clinical studies of IMBRUVICA for B-cell malignancies or cGVHD, 62% were ≥ 65 years of age, while 22% were ≥ 75 years of age <content styleCode="italics">[see Clinical Studies (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_14_1_Chronic_Lymphocytic">14.1</linkHtml>
                           </content>
                           <content styleCode="italics">, </content>
                           <content styleCode="italics">
                              <linkHtml href="#_14_2_Waldenström_s_Macroglobulinemi">14.2</linkHtml>
                           </content>
                           <content styleCode="italics">, </content>
                           <content styleCode="italics">
                              <linkHtml href="#Hyperlink143">14.3</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>. No overall differences in effectiveness were observed between younger and older patients. Anemia (all grades), pneumonia (Grade 3 or higher), thrombocytopenia, hypertension, and atrial fibrillation occurred more frequently among older patients treated with IMBRUVICA <content styleCode="italics">[see Adverse Reactions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_6_1_Clinical_Trials">6.1</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="_8_6_Hepatic_Impairment">
                     <id root="71e15779-4836-46be-8f27-d2a537279f14"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="88829-7" displayName="HEPATIC IMPAIRMENT SUBSECTION"/>
                     <title>
                        <content styleCode="bold">8.6</content>
                        <content styleCode="bold">
		     
	Hepatic Impairment</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Adult Patients with B-cell Malignancies</content>
                        </paragraph>
                        <paragraph>Avoid use of IMBRUVICA in patients with severe hepatic impairment (Child-Pugh class C). The safety of IMBRUVICA has not been evaluated in patients with mild to severe hepatic impairment by Child-Pugh criteria.</paragraph>
                        <paragraph>Reduce the recommended dose when administering IMBRUVICA to patients with mild or moderate hepatic impairment (Child-Pugh class A and B). Monitor patients more frequently for adverse reactions of IMBRUVICA <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_4_Dosage_Modifications">2.4</linkHtml>
                           </content>
                           <content styleCode="italics">), Clinical Pharmacology (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_12_3_Pharmacokinetics">12.3</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">Patients with cGVHD</content>
                        </paragraph>
                        <paragraph>Avoid use of IMBRUVICA in patients with total bilirubin level &gt; 3 x ULN (unless of non-hepatic origin or due to Gilbert’s syndrome). Reduce recommended dose when administering IMBRUVICA to patients with total bilirubin level &gt; 1.5 to 3 x ULN (unless of non-hepatic origin or due to Gilbert’s syndrome) <content styleCode="italics">[see Dosage and Administration (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_2_4_Dosage_Modifications">2.4</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="486536e4-da63-47a4-836d-e102bfece322"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">8.7</content>
                        <content styleCode="bold">
		     
	Plasmapheresis</content>
                     </title>
                     <text>
                        <paragraph>Management of hyperviscosity in WM patients may include plasmapheresis before and during treatment with IMBRUVICA.  Modifications to IMBRUVICA dosing are not required.</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="f16975b6-188e-4b3e-ac6c-b24ca5d21eb4"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34088-5" displayName="OVERDOSAGE SECTION"/>
               <title>
                  <content styleCode="bold">10</content>
		     
	<content styleCode="bold">OVERDOSAGE</content>
               </title>
               <text>
                  <paragraph>There is no specific experience in the management of ibrutinib overdose in patients.  One healthy subject experienced reversible Grade 4 hepatic enzyme increases (AST and ALT) after a dose of 1680 mg. Closely monitor patients who ingest more than the recommended dosage and provide appropriate supportive treatment.</paragraph>
               </text>
               <effectiveTime value="20241220"/>
            </section>
         </component>
         <component>
            <section>
               <id root="9386733a-4ca3-4c80-ac71-ee74d3068cc8"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34089-3" displayName="DESCRIPTION SECTION"/>
               <title>
                  <content styleCode="bold">11</content>
		     
	<content styleCode="bold">DESCRIPTION</content>
               </title>
               <text>
                  <paragraph>Ibrutinib is a kinase inhibitor. It is a white to off-white solid with the empirical formula C<sub>25</sub>H<sub>24</sub>N<sub>6</sub>O<sub>2</sub> and a molecular weight 440.50. Ibrutinib is freely soluble in dimethyl sulfoxide, soluble in methanol and practically insoluble in water. The chemical name for ibrutinib is 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one and has the following structure:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM03000001"/>
                  </paragraph>
                  <paragraph>IMBRUVICA (ibrutinib) is available as immediate-release oral capsules, immediate-release oral tablets, and immediate-release oral suspension.</paragraph>
                  <paragraph>IMBRUVICA (ibrutinib) capsules for oral use are available in the following dosage strengths: 70 mg and 140 mg. Each capsule contains ibrutinib (active ingredient) and the following inactive ingredients: croscarmellose sodium, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate. The capsule shell contains gelatin, titanium dioxide, yellow iron oxide (70 mg capsule only), and black ink.</paragraph>
                  <paragraph>IMBRUVICA (ibrutinib) tablets for oral use are available in the following dosage strengths: 140 mg, 280 mg, and 420 mg. Each tablet contains ibrutinib (active ingredient) and the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, and sodium lauryl sulfate. The film coating for each tablet contains ferrosoferric oxide (140 mg, 280 mg, and 420 mg tablets), polyvinyl alcohol, polyethylene glycol, red iron oxide (280 mg tablets), talc, titanium dioxide, and yellow iron oxide (140 mg and 420 mg tablets).</paragraph>
                  <paragraph>IMBRUVICA (ibrutinib) oral suspension contains 70 mg/mL ibrutinib (active ingredient) and the following inactive ingredients: benzyl alcohol, citric acid monohydrate, disodium hydrogen phosphate, hypromellose, microcrystalline cellulose and carboxymethylcellulose sodium, purified water and sucralose.</paragraph>
               </text>
               <effectiveTime value="20241220"/>
               <component>
                  <observationMedia ID="MM03000001">
                     <text>The following structure for Ibrutinib is kinase inhibitor. It is a white to off-white solid with the empirical formula C25H24N6O2 and a molecular weight 440.50. Ibrutinib is freely soluble in dimethyl sulfoxide, soluble in methanol and practically insoluble in water. The chemical name for ibrutinib is 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4 d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one and has </text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="imbruvica-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="21b0c8cd-2283-409b-bbf7-e36b641eae38"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34090-1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">12</content>
		     
	<content styleCode="bold">CLINICAL PHARMACOLOGY</content>
               </title>
               <effectiveTime value="20241220"/>
               <component>
                  <section>
                     <id root="8e048051-337e-433d-830c-5a7df540236a"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43679-0" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>
                        <content styleCode="bold">12.1</content>
                        <content styleCode="bold">
		     
	Mechanism of Action</content>
                     </title>
                     <text>
                        <paragraph>Ibrutinib is a small-molecule inhibitor of Bruton’s tyrosine kinase (BTK). Ibrutinib forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK enzymatic activity. BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways. BTK’s role in signaling through the B-cell surface receptors results in activation of pathways necessary for B-cell trafficking, chemotaxis, and adhesion. Nonclinical studies show that ibrutinib inhibits malignant B-cell proliferation and survival <content styleCode="italics">in vivo</content> as well as cell migration and substrate adhesion <content styleCode="italics">in vitro</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section>
                     <id root="2d17e2cb-dc1d-4405-bccb-c1a2116d038e"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43681-6" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>
                        <content styleCode="bold">12.2</content>
                        <content styleCode="bold">
		     
	Pharmacodynamics</content>
                     </title>
                     <text>
                        <paragraph>In patients with recurrent B-cell lymphoma &gt; 90% occupancy of the BTK active site in peripheral blood mononuclear cells was observed up to 24 hours after ibrutinib doses of ≥ 2.5 mg/kg/day (≥ 175 mg/day for average weight of 70 kg).</paragraph>
                        <paragraph>In adult patients with cGVHD, 93% occupancy of the BTK active site in peripheral blood mononuclear cells was observed at the ibrutinib recommended dose. The mean BTK occupancy in pediatric patients ranged from 95.1% to 99.6%.</paragraph>
                        <paragraph>
                           <content styleCode="underline">In vitro Platelet Aggregation</content>
                        </paragraph>
                        <paragraph>Ibrutinib demonstrated inhibition of collagen-induced platelet aggregation, with IC50 values at 4.6 µM (2026 ng/mL), 0.8 µM (352 ng/mL), and 3 µM (1321 ng/mL) in blood samples from healthy donors, donors taking warfarin, and donors with severe renal dysfunction, respectively. Ibrutinib did not show meaningful inhibition of platelet aggregation for ADP, arachidonic acid, ristocetin, and TRAP-6.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Cardiac Electrophysiology</content>
                        </paragraph>
                        <paragraph>At a single dose 4 times the maximum recommended dose (1680 mg), IMBRUVICA did not prolong the QT interval to any clinically relevant extent. </paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="_12_3_Pharmacokinetics">
                     <id root="79784d68-b117-4359-9315-a249483d1759"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="43682-4" displayName="PHARMACOKINETICS SECTION"/>
                     <title>
                        <content styleCode="bold">12.3</content>
                        <content styleCode="bold">
		     
	Pharmacokinetics</content>
                     </title>
                     <text>
                        <paragraph>Ibrutinib exposure increases with doses up to 840 mg (2 times the maximum approved recommended dosage) in patients with B-cell malignancies. The mean steady-state AUC (% coefficient of variation) observed in patients at  420 mg with CLL/SLL is 708 (71%) ng×h/mL, with WM is 707 (72%) ng×h/mL, and in adult patients with previously treated cGVHD is 1159 (50%) ng×h/mL. Steady-state concentrations of ibrutinib without CYP3A inhibitors were achieved with an accumulation ratio of 1 to 1.6 after 1 week of multiple daily doses of 420 mg.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>Absolute bioavailability of ibrutinib in fasted condition was 2.9% (90% CI: 2.1, 3.9) in healthy subjects. Ibrutinib is absorbed after oral administration with a median T<sub>max</sub>
                           <sub> </sub>of 1 hour to 2 hours.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Food</content>
                        </paragraph>
                        <paragraph>The administration of IMBRUVICA with a high-fat and high-calorie meal (800 calories to 1,000 calories with approximately 50% of total caloric content of the meal from fat) increased ibrutinib C<sub>max</sub> by 2- to 4-fold and AUC by approximately 2-fold, compared with administration of ibrutinib after overnight fasting. </paragraph>
                        <paragraph>In vitro studies suggest that ibrutinib is not a substrate of p-glycoprotein (P-gp) or breast cancer resistance protein (BCRP).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Reversible binding of ibrutinib to human plasma protein <content styleCode="italics">in vitro</content> was 97.3% with no concentration dependence in the range of 50 ng/mL to 1000 ng/mL. The volume of distribution (V<sub>d</sub>) was 683 L, and the apparent volume of distribution at steady state (V<sub>d,ss</sub>/F) was approximately 10,000 L.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>Intravenous clearance was 62 L/h in fasted conditions and 76 L/h in fed conditions. In line with the high first-pass effect, the apparent oral clearance is 2000 L/h in fasted conditions and 1000 L/h in fed conditions. The half-life of ibrutinib is 4 hours to 6 hours.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism</content>
                        </paragraph>
                        <paragraph>Metabolism is the main route of elimination for ibrutinib. It is metabolized to several metabolites primarily by cytochrome P450 (CYP) 3A and to a minor extent by CYP2D6. The active metabolite, PCI-45227, is a dihydrodiol metabolite with inhibitory activity towards BTK approximately 15 times lower than that of ibrutinib. The range of the mean metabolite to parent ratio for PCI-45227 at steady-state is 1 to 2.8.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion</content>
                        </paragraph>
                        <paragraph>Ibrutinib, mainly in the form of metabolites, is eliminated primarily via feces. After a single oral administration of radiolabeled ibrutinib, 90% of radioactivity was excreted within 168 hours, with 80% excreted in the feces and less than 10% eliminated in urine. Unchanged ibrutinib accounted for 1% of the radiolabeled excreted dose in feces and none in urine, with the remainder of the excreted dose being metabolites.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Age and Sex</content>
                        </paragraph>
                        <paragraph>Age and sex have no clinically meaningful effect on ibrutinib pharmacokinetics.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Renal Impairment</content>
                        </paragraph>
                        <paragraph>Mild and moderate renal impairment (creatinine clearance [CLcr] &gt; 25 mL/min as estimated by Cockcroft-Gault equation) had no influence on the exposure of ibrutinib. No data is available in patients with severe renal impairment (CLcr &lt; 25 mL/min) or in patients on dialysis.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Hepatic Impairment</content>
                        </paragraph>
                        <paragraph>The AUC of ibrutinib increased 2.7-fold in subjects with mild hepatic impairment (Child-Pugh class A), 8.2-fold in subjects with moderate hepatic impairment (Child-Pugh class B) and 9.8-fold in subjects with severe hepatic impairment (Child-Pugh class C) relative to subjects with normal liver function. The C<sub>max</sub> of ibrutinib increased 5.2-fold in mild hepatic impairment, 8.8-fold in moderate hepatic impairment and 7-fold in severe hepatic impairment relative to subjects with normal liver function <content styleCode="italics">[see Use in Specific Populations (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_8_6_Hepatic_Impairment">8.6</linkHtml>
                           </content>
                           <content styleCode="italics">)].</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatric Patients</content>
                        </paragraph>
                        <paragraph>In pediatric patients with cGVHD treated with ibrutinib at 240 mg/m<sup>2</sup> once daily (patients age ≥ 1 to &lt; 12 years) or 420 mg once daily (patients age ≥ 12 years), the geometric mean (%CV) steady state AUC and C<sub>max</sub> in patients age ≥ 1 to &lt; 12 years is 467 (102%) ng×h/mL and 65.7 (96%) ng/mL, respectively, and in patients age ≥ 12 to &lt; 17 years is 966 (78%) ng×h/mL and 149 (79%) ng/mL, respectively.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Clinical Studies and Model-Informed Approaches</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of CYP3A Inhibitors on Ibrutinib: </content>The coadministration of multiple doses of ketoconazole (strong CYP3A inhibitor) increased the C<sub>max</sub> of ibrutinib by 29-fold and AUC by 24-fold. The coadministration of multiple doses of voriconazole (strong CYP3A inhibitor) increased steady state C<sub>max</sub> of ibrutinib by 6.7-fold and AUC by 5.7-fold. Simulations under fed conditions suggest that posaconazole (strong CYP3A inhibitor) may increase the AUC of ibrutinib 3-fold to 10-fold.</paragraph>
                        <paragraph>The coadministration of multiple doses of erythromycin (moderate CYP3A inhibitor) increased steady state C<sub>max</sub> of ibrutinib by 3.4-fold and AUC by 3-fold.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of CYP3A Inducers on Ibrutinib: </content>The coadministration of rifampin (strong CYP3A inducer) decreased the C<sub>max</sub> of ibrutinib by more than 13-fold and AUC by more than 10-fold. Simulations suggest that efavirenz (moderate CYP3A inducer) may decrease the AUC of ibrutinib by 3-fold.</paragraph>
                        <paragraph>
                           <content styleCode="italics">In Vitro Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Ibrutinib on CYP Substrates: </content>In vitro studies suggest that ibrutinib and PCI-45227 are unlikely to inhibit CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 or 3A at clinical doses. Both ibrutinib and PCI-45227 are unlikely to induce CYP1A2, CYP2B6 or CYP3A at clinical doses.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Ibrutinib on Substrates of Transporters: </content>In vitro studies suggest that ibrutinib may inhibit BCRP and P-gp transport at clinical doses. The coadministration of oral P-gp or BCRP substrates  (e.g., digoxin, methotrexate) with IMBRUVICA may increase their concentrations.</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="c8c41572-0ac2-4160-a2f6-0c5fe51c28ed"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="43680-8" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>
                  <content styleCode="bold">13</content>
		     
	<content styleCode="bold">NONCLINICAL TOXICOLOGY</content>
               </title>
               <effectiveTime value="20241220"/>
               <component>
                  <section ID="_13_1_Carcinogenesis__Mutagenesis_">
                     <id root="342fc70a-a894-4ce7-bd8c-368673bb86a7"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="34083-6" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>
                        <content styleCode="bold">13.1</content>
                        <content styleCode="bold">
		     
	Carcinogenesis, Mutagenesis, Impairment of Fertility</content>
                     </title>
                     <text>
                        <paragraph>Ibrutinib was not carcinogenic in a 6-month rasH2 mouse study at oral doses up to 2000 mg/kg/day resulting in exposures approximately 32 (males) to 52 (females) times higher than the exposure in humans at a dose of 420 mg daily <content styleCode="italics">[see Warnings and Precautions (</content>
                           <content styleCode="italics">
                              <linkHtml href="#_5_6_Second_Primary">5.6</linkHtml>
                           </content>
                           <content styleCode="italics">)]</content>.</paragraph>
                        <paragraph>Ibrutinib was not mutagenic in a bacterial mutagenicity (Ames) assay, was not clastogenic in a chromosome aberration assay in mammalian (CHO) cells, nor was it clastogenic in an <content styleCode="italics">in vivo</content> bone marrow micronucleus assay in mice at doses up to 2000 mg/kg.</paragraph>
                        <paragraph>Rats were administered oral daily doses of ibrutinib for 4 weeks prior to pairing and during pairing in males and 2 weeks prior to pairing and during pairing in females.  Treatment of female rats continued following pregnancy up to gestation day (GD) 7, and treatment of male rats continued until end of study.  No effects on fertility or reproductive capacities were observed in male or female rats up to the maximum dose tested, 100 mg/kg/day (Human Equivalent Dose [HED] 16 mg/kg).</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="_14_CLINICAL_STUDIES">
               <id root="33044d92-efba-409e-ae45-81aa1ce19c9b"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34092-7" displayName="CLINICAL STUDIES SECTION"/>
               <title>
                  <content styleCode="bold">14</content>
		     
	<content styleCode="bold">CLINICAL STUDIES</content>
               </title>
               <effectiveTime value="20241220"/>
               <component>
                  <observationMedia ID="MM03000002">
                     <text>Figure 1:  Kaplan-Meier Curve of Progression Free Survival (ITT Population) in Patients with CLL/SLL in RESONATE</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="imbruvica-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000003">
                     <text>Figure 2:  Kaplan-Meier Curve of Overall Survival (ITT Population) in Patients with CLL/SLL in RESONATE</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="imbruvica-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000004">
                     <text>Figure 3:  Kaplan-Meier Curve of Progression-Free Survival (ITT Population) in Patients with CLL/SLL in RESONATE-2</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="imbruvica-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000005">
                     <text>Figure 4:  Kaplan-Meier Curve of Progression-Free Survival (ITT Population) in Patients with CLL/SLL in HELIOS</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="imbruvica-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000006">
                     <text>Figure 5: Kaplan-Meier Curve of Progression-Free Survival (ITT Population) in Patients with CLL/SLL in iLLUMINATE</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="imbruvica-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000007">
                     <text>Figure 6: Kaplan-Meier Curve of Progression-Free Survival (ITT Population) in Patients with CLL/SLL in E1912</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="imbruvica-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM02000008">
                     <text>Figure 7:  Kaplan-Meier Curve of Progression-Free Survival (ITT Population) in Patients with WM in INNOVATE</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="imbruvica-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <section ID="_14_1_Chronic_Lymphocytic">
                     <id root="b219e8c5-6901-42e1-a0d1-d7afd47753c2"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">14.1</content>
		     
	<content styleCode="bold">Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma</content>
                     </title>
                     <text>
                        <paragraph>The safety and efficacy of IMBRUVICA in patients with CLL/SLL were demonstrated in one uncontrolled trial and five randomized, controlled trials.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Study 1102</content>
                        </paragraph>
                        <paragraph>Study 1102 (NCT01105247), an open-label, multi-center trial, was conducted in 48 previously treated CLL patients. IMBRUVICA was administered orally at 420 mg once daily until disease progression or unacceptable toxicity. The ORR and DOR were assessed using a modified version of the International Workshop on CLL Criteria by an Independent Review Committee. </paragraph>
                        <paragraph>The median age was 67 years (range, 37 to 82 years), 71% were male, and 94% were White. All patients had a baseline ECOG performance status of 0 or 1. The median time since diagnosis was 80 months and the median number of prior treatments was 4 (range, 1 to 12 treatments). At baseline, 46% of subjects had at least one tumor ≥ 5 cm.</paragraph>
                        <paragraph>The ORR was 58.3% (95% CI: 43.2%, 72.4%), all partial responses. None of the patients achieved a complete response. The DOR ranged from 5.6 to 24.2+ months. The median DOR was not reached.</paragraph>
                        <paragraph>
                           <content styleCode="underline">RESONATE</content>
                        </paragraph>
                        <paragraph>The RESONATE study, a randomized, multicenter, open-label, phase 3 study of IMBRUVICA versus ofatumumab (NCT01578707), was conducted in patients with previously treated CLL or SLL. Patients (n=391) were randomized 1:1 to receive either IMBRUVICA 420 mg daily until disease progression, or unacceptable toxicity or ofatumumab at an initial dose of 300 mg, followed one week later by a dose of 2000 mg weekly for 7 doses and then every 4 weeks for 4 additional doses. Fifty-seven patients randomized to ofatumumab crossed over following progression to receive IMBRUVICA. </paragraph>
                        <paragraph>The median age was 67 years (range, 30 to 88 years), 68% were male, and 90% were White. All patients had a baseline ECOG performance status of 0 or 1. The trial enrolled 373 patients with CLL and 18 patients with SLL.  The median time since diagnosis was 91 months and the median number of prior treatments was 2 (range, 1 to 13 treatments). At baseline, 58% of patients had at least one tumor ≥ 5 cm. Thirty-two percent of patients had 17p deletion.</paragraph>
                        <paragraph>Efficacy results for RESONATE are shown in Table <linkHtml href="#Table22new">22</linkHtml> and the Kaplan-Meier curves for PFS, assessed by an IRC according to IWCLL criteria, and OS are shown in Figure <linkHtml href="#Figure1">1</linkHtml> and Figure <linkHtml href="#Figure2">2</linkHtml>, respectively. </paragraph>
                        <table ID="Table22new">
                           <caption>Table 22:  Efficacy Results in Patients with CLL/SLL in RESONATE</caption>
                           <col width="213"/>
                           <col width="213"/>
                           <col width="213"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">Endpoint</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">IMBRUVICA</content>
                                    <content styleCode="bold">
                                       <br/>N=195</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Ofatumumab</content>
                                    <content styleCode="bold">
                                       <br/>N=196</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Progression</content>
                                    <content styleCode="bold">-</content>
                                    <content styleCode="bold">Free Survival</content>
                                    <content styleCode="bold">
                                       <sup>b</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Number of events (%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">35 (17.9)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">111 (56.6) </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   Disease progression</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">26</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">93</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   Death events</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">9</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">18</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   Median (95% CI), months</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">NE</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">8.1 (7.2, 8.3)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   HR (95% CI)</td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">0.22 (0.15, 0.32)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Overall Survival</content>
                                    <content styleCode="bold">
                                       <sup>a</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   Number of deaths (%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">16 (8.2)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">33 (16.8)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   HR (95% CI)</td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">0.43 (0.24, 0.79)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Overall Response Rate</content>
                                    <content styleCode="bold">
                                       <sup>b</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">42.6%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4.1%</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>a</sup>
		     
	Median OS not evaluable for either arm.</paragraph>
                        <paragraph>
                           <sup>b</sup>
		     
	IRC evaluated.<sup> </sup>All partial responses achieved; none of the patients achieved a complete response.</paragraph>
                        <paragraph>CI = confidence interval; HR = hazard ratio; NE = not evaluable.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 1:  Kaplan-Meier Curve of Progression</content>
                           <content styleCode="bold">-</content>
                           <content styleCode="bold">Free Survival (ITT Population) in Patients with CLL/SLL in RESONATE</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia ID="Figure1" referencedObject="MM03000002"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 2:  Kaplan-Meier Curve of Overall Survival (ITT Population) in Patients with CLL/SLL in RESONATE</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia ID="Figure2" referencedObject="MM03000003"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">63-Month Follow-Up</content>
                        </paragraph>
                        <paragraph>With an overall follow-up of 63 months, the median investigator-assessed PFS per IWCLL criteria was 44.1 months [95% CI (38.5, 56.9)] in the IMBRUVICA arm and 8.1 months [95% CI (7.8, 8.3)] in the ofatumumab arm. Overall response rate as assessed by investigators was 87.2% in the IMBRUVICA arm versus 22.4% in the ofatumumab arm. </paragraph>
                        <paragraph>
                           <content styleCode="underline">CLL/SLL with 17p deletion (del 17p CLL/SLL) in RESONATE</content>
                        </paragraph>
                        <paragraph>RESONATE included 127 patients with<content styleCode="bold"> </content>del 17p CLL/SLL. The median age was 67 years (range, 30 to 84 years), 62% were male, and 88% were White. All patients had a baseline ECOG performance status of 0 or 1. PFS and ORR were assessed by an IRC. Efficacy results for del 17p CLL/SLL are shown in Table <linkHtml href="#Table23new">23</linkHtml>.</paragraph>
                        <table ID="Table23new">
                           <caption>Table 23:  Efficacy Results in Patients with del 17p CLL/SLL in RESONATE</caption>
                           <col width="213"/>
                           <col width="213"/>
                           <col width="213"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">Endpoint</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">IMBRUVICA</content>
                                    <content styleCode="bold">
                                       <br/>N=63</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Ofatumumab</content>
                                    <content styleCode="bold">
                                       <br/>N=64</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3">
                                    <content styleCode="bold">Progression</content>
                                    <content styleCode="bold">-</content>
                                    <content styleCode="bold">Free Survival</content>
                                    <content styleCode="bold">
                                       <sup>a</sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Number of events (%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">16 (25.4)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">38 (59.4)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   Disease progression</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">31 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   Death events </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">7 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   Median (95% CI), months</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">NE</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">5.8 (5.3, 7.9)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   HR (95% CI)</td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">0.25 (0.14, 0.45)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Overall Response Rate</content>
                                    <content styleCode="bold">
                                       <sup>a</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">47.6%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4.7%</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>a </sup>
		     
	IRC evaluated. All partial responses achieved; none of the patients achieved a complete response.</paragraph>
                        <paragraph>CI = confidence interval; HR = hazard ratio; NE = not evaluable.</paragraph>
                        <paragraph>
                           <content styleCode="italics">63-Month Follow-Up</content>
                        </paragraph>
                        <paragraph>With an overall follow-up of 63 months, the median investigator-assessed PFS in patients with del 17p per IWCLL criteria was 40.6 months [95% CI (25.4, 44.6)] in the IMBRUVICA arm and 6.2 months [95% CI (4.6, 8.1)] in the ofatumumab arm. Overall response rate as assessed by investigators in patients with del 17p was 88.9% in the IMBRUVICA arm versus 18.8% in the ofatumumab arm. </paragraph>
                        <paragraph>
                           <content styleCode="underline">RESONATE-2</content>
                        </paragraph>
                        <paragraph>The RESONATE-2 study, a randomized, multicenter, open-label, phase 3 study of IMBRUVICA versus chlorambucil (NCT01722487), was conducted in patients with treatment naïve CLL or SLL who were 65 years of age or older. Patients (n = 269) were randomized 1:1 to receive either IMBRUVICA 420 mg daily until disease progression or unacceptable toxicity, or chlorambucil at a starting dose of 0.5 mg/kg on Days 1 and 15 of each 28-day cycle for a maximum of 12 cycles, with an allowance for intrapatient dose increases up to 0.8 mg/kg based on tolerability.</paragraph>
                        <paragraph>The median age was 73 years (range, 65 to 90 years), 63% were male, and 91% were White. Ninety one percent of patients had a baseline ECOG performance status of 0 or 1 and 9% had an ECOG performance status of 2. The trial enrolled 249 patients with CLL and 20 patients with SLL. At baseline, 20% of patients had 11q deletion. The most common reasons for initiating CLL therapy include: progressive marrow failure demonstrated by anemia and/or thrombocytopenia (38%), progressive or symptomatic lymphadenopathy (37%), progressive or symptomatic splenomegaly (30%), fatigue (27%) and night sweats (25%).</paragraph>
                        <paragraph>With a median follow-up of 28.1 months, there were 32 observed death events [11 (8.1%) and 21 (15.8%) in IMBRUVICA and chlorambucil treatment arms, respectively].  With 41% of patients switching from chlorambucil to IMBRUVICA, the overall survival analysis in the ITT patient population resulted in a statistically significant HR of 0.44 [95% CI (0.21, 0.92)] and 2-year survival rate estimates of 94.7% [95% CI (89.1, 97.4)] and 84.3% [95% CI (76.7, 89.6)] in the IMBRUVICA and chlorambucil arms, respectively.</paragraph>
                        <paragraph>Efficacy results for RESONATE-2 are shown in Table <linkHtml href="#Table24new">24</linkHtml> and the Kaplan-Meier curve for PFS, assessed by an IRC according to IWCLL criteria is shown in Figure <linkHtml href="#Figure3">3</linkHtml>. </paragraph>
                        <table ID="Table24new">
                           <caption>Table 24:  Efficacy Results in Patients with CLL/SLL in RESONATE-2</caption>
                           <col width="235"/>
                           <col width="190"/>
                           <col width="213"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">Endpoint</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">IMBRUVICA</content>
                                    <content styleCode="bold">
                                       <br/>N=136</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Chlorambucil</content>
                                    <content styleCode="bold">
                                       <br/>N=133</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3">
                                    <content styleCode="bold">Progression</content>
                                    <content styleCode="bold">-</content>
                                    <content styleCode="bold">Free Survival</content>
                                    <content styleCode="bold">
                                       <sup>a</sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">Number of events (%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">15 (11.0)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">64 (48.1)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   Disease progression</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">12 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">57 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   Death events </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">3 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">7 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">        Median (95% CI), months</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">NE</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">18.9 (14.1, 22.0)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">        HR<content styleCode="bold">
                                       <sup>b</sup>
                                    </content> (95% CI)</td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">0.16 (0.09, 0.28)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Overall Response Rate</content>
                                    <content styleCode="bold">
                                       <sup>a</sup>
                                    </content> <content styleCode="bold">(CR + PR)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">82.4%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">35.3%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">        P-value</td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">&lt;0.0001</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>a </sup>
		     
	IRC evaluated; five subjects (3.7%) in the IMBRUVICA arm and two subjects (1.5%) in the Chlorambucil arm achieved complete response.</paragraph>
                        <paragraph>
                           <sup>b </sup>
		     
	HR = hazard ratio; NE = not evaluable.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 3:  Kaplan-Meier Curve of Progression-Free Survival (ITT Population) in Patients with CLL/SLL in RESONATE-2</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia ID="Figure3" referencedObject="MM03000004"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">55-Month Follow-Up</content>
                        </paragraph>
                        <paragraph>With an overall follow-up of 55 months, the median PFS was not reached in the IMBRUVICA arm. </paragraph>
                        <paragraph>
                           <content styleCode="underline">HELIOS</content>
                        </paragraph>
                        <paragraph>The HELIOS study, a randomized, double-blind, placebo-controlled phase 3 study of IMBRUVICA in combination with bendamustine and rituximab (BR) (NCT01611090), was conducted in patients with previously treated CLL or SLL. Patients (n = 578) were randomized 1:1 to receive either IMBRUVICA 420 mg daily or placebo in combination with BR until disease progression, or unacceptable toxicity. All patients received BR for a maximum of six 28-day cycles. Bendamustine was dosed at 70 mg/m<sup>2</sup> infused IV over 30 minutes on Cycle 1, Days 2 and 3, and on Cycles 2-6, Days 1 and 2 for up to 6 cycles, and all patients had a CLcr ≥ 40 mL/min at baseline. Rituximab was administered at a dose of 375 mg/m<sup>2</sup> in the first cycle, Day 1, and 500 mg/m<sup>2</sup> Cycles 2 through 6, Day 1.</paragraph>
                        <paragraph>The median age was 64 years (range, 31 to 86 years), 66% were male, and 91% were White. All patients had a baseline ECOG performance status of 0 or 1. The median time since diagnosis was 5.9 years and the median number of prior treatments was 2 (range, 1 to 11 treatments). At baseline, 56% of patients had at least one tumor <content styleCode="underline">&gt;</content> 5 cm and 26% presented with del11q.</paragraph>
                        <paragraph>Efficacy results for HELIOS are shown in Table <linkHtml href="#Table25new">25</linkHtml> and the Kaplan-Meier curves for PFS are shown in Figure <linkHtml href="#Figure4">4</linkHtml>.</paragraph>
                        <table ID="Table25new">
                           <caption>Table 25:  Efficacy Results in Patients with CLL/SLL in HELIOS</caption>
                           <col width="213"/>
                           <col width="213"/>
                           <col width="213"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">Endpoint</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">IMBRUVICA + BR</content>
                                    <content styleCode="bold">
                                       <br/>N=289</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Placebo + BR</content>
                                    <content styleCode="bold">
                                       <br/>N=289</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3">
                                    <content styleCode="bold">Progression</content>
                                    <content styleCode="bold">-</content>
                                    <content styleCode="bold">Free Survival</content>
                                    <content styleCode="bold">
                                       <sup>a</sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   Number of events (%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">56 (19.4)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">183 (63.3)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   Median (95% CI), months</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">NE</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">13.3 (11.3, 13.9)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   HR (95% CI)</td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">0.20 (0.15, 0.28)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Overall Response Rate</content>
                                    <content styleCode="bold">
                                       <sup>a</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">82.7%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">67.8%</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>a </sup>
		     
	IRC evaluated; twenty-four subjects (8.3%) in the IMBRUVICA + BR arm and six subjects (2.1%) in the placebo + BR arm achieved complete response.</paragraph>
                        <paragraph>BR = bendamustine and rituximab; CI = confidence interval; HR = hazard ratio; NE = not evaluable.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 4:  Kaplan-Meier Curve of Progression-Free Survival (ITT Population) in Patients with CLL/SLL in HELIOS</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia ID="Figure4" referencedObject="MM03000005"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="underline">iLLUMINATE</content>
                        </paragraph>
                        <paragraph>The iLLUMINATE study, a randomized, multi-center, phase 3 study of IMBRUVICA in combination with obinutuzumab versus chlorambucil in combination with obinutuzumab (NCT02264574), was conducted in patients with treatment naïve CLL or SLL. Patients were 65 years of age or older or &lt; 65 years of age with coexisting medical conditions, reduced renal function as measured by creatinine clearance &lt; 70 mL/min, or presence of del 17p/TP53 mutation.  Patients (n = 229) were randomized 1:1 to receive either IMBRUVICA 420 mg daily until disease progression or unacceptable toxicity or chlorambucil at a dose of 0.5 mg/kg on Days 1 and 15 of each 28-day cycle for 6 cycles.  In both arms, patients received 1,000 mg of obinutuzumab on Days 1, 8, and 15 of the first cycle, followed by treatment on the first day of 5 subsequent cycles (total of 6 cycles, 28 days each). The first dose of obinutuzumab was divided between Day 1 (100 mg) and Day 2 (900 mg). </paragraph>
                        <paragraph>The median age was 71 years (range, 40 to 87 years), 64% were male, and 96% were White. All patients had a baseline ECOG performance status of 0 (48%) or 1-2 (52%). The trial enrolled 214 patients with CLL and 15 patients with SLL. At baseline, 65% of patients presented with CLL/SLL with high risk factors (del 17p/TP53 mutation [18%], del 11q [15%], or unmutated immunoglobulin heavy-chain variable region (unmutated IGHV) [54%]). The most common reasons for initiating CLL therapy included: lymphadenopathy (38%), night sweats (34%), progressive marrow failure (31%), fatigue (29%), splenomegaly (25%), and progressive lymphocytosis (21%).</paragraph>
                        <paragraph>With a median follow-up time on study of 31 months, efficacy results for iLLUMINATE assessed by an IRC according to IWCLL criteria are shown in Table <linkHtml href="#Tbale26new">26</linkHtml>, and the Kaplan-Meier curve for PFS is shown in Figure <linkHtml href="#Figure5">5</linkHtml>.</paragraph>
                        <table ID="Tbale26new">
                           <caption>Table 26:  Efficacy Results in Patients with CLL/SLL in iLLUMINATE</caption>
                           <col width="261"/>
                           <col width="186"/>
                           <col width="186"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">Endpoint</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">IMBRUVICA + Obinutuzumab</content>
                                    <content styleCode="bold">
                                       <br/>N=113</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Chlorambucil + Obinutuzumab</content>
                                    <content styleCode="bold">
                                       <br/>N=116</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3">
                                    <content styleCode="bold">Progression</content>
                                    <content styleCode="bold">-</content>
                                    <content styleCode="bold">Free Survival</content>
                                    <content styleCode="bold">
                                       <sup>a</sup>
                                    </content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">  Number of events (%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">24 (21)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">74 (64)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Disease progression</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">11</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">64</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Death events </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">13</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">10</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Median (95% CI), months</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">NE</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">19.0 (15.1, 22.1)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    HR (95% CI)</td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">0.23 (0.15, 0.37)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    P-value<sup>b</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">&lt;0.0001</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Overall Response Rate (%)</content>
                                    <content styleCode="bold">
                                       <sup>a</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">88.5</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">73.3</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">       CR<sup>c</sup> (%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">19.5</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">7.8</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">       PR<sup>d</sup> (%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">69.0</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">65.5</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>a </sup>IRC-evaluated.</paragraph>
                        <paragraph>
                           <sup>b</sup> P-value is from unstratified log-rank test.</paragraph>
                        <paragraph>
                           <sup>c</sup> Includes 1 patient in the IMBRUVICA + obinutuzumab arm with a complete response with incomplete marrow recovery (CRi)</paragraph>
                        <paragraph>
                           <sup>d </sup>PR = nPR +PR.</paragraph>
                        <paragraph>HR = hazard ratio; NE = not evaluable.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 5: Kaplan-Meier Curve of Progression-Free Survival (ITT Population) in Patients with CLL/SLL in iLLUMINATE</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia ID="Figure5" referencedObject="MM03000006"/> </paragraph>
                        <paragraph>In the high risk CLL/SLL population (del 17p/TP53 mutation, del 11q, or unmutated IGHV), the PFS HR was 0.15 [95% CI (0.09, 0.27)]. </paragraph>
                        <paragraph>
                           <content styleCode="underline">E1912</content>
                        </paragraph>
                        <paragraph>The E1912 study, a randomized, multi-center, phase 3 study of IMBRUVICA in combination with rituximab versus standard fludarabine, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy (NCT02048813), was conducted in adult patients who were 70 years or younger with previously untreated CLL or SLL requiring systemic therapy. All patients had a CLcr &gt; 40 mL/min at baseline. Patients with 17p deletion were excluded. Patients (n =529) were randomized 2:1 to receive either IMBRUVICA plus rituximab or FCR.  IMBRUVICA was administered at 420 mg daily until disease progression or unacceptable toxicity. Fludarabine was administered at a dose of 25 mg/m<sup>2</sup>, and cyclophosphamide was administered at a dose of 250 mg/m<sup>2</sup>, both on Days 1, 2, and 3 of Cycles 1-6. Rituximab was initiated in Cycle 2 for the IMBRUVICA plus rituximab arm and in Cycle 1 for the FCR arm and was administered at 50 mg/m<sup>2</sup> on Day 1 of the first cycle, 325 mg/m<sup>2</sup> on Day 2 of the first cycle, and 500 mg/m<sup>2</sup> on Day 1 of 5 subsequent cycles, for a total of 6 cycles. Each cycle was 28 days.</paragraph>
                        <paragraph>The median age was 58 years (range, 28 to 70 years), 67% were male, 90% were White and 98% had a ECOG performance status of 0-1.  At baseline, 43% of patients were Rai stage 3 or 4 and 59% of patients presented with high risk factors (TP53 mutation [6%], del11q [22%], or unmutated IGHV [53%]).</paragraph>
                        <paragraph>With a median follow-up time on study of 37 months, efficacy results for E1912 are shown in Table <linkHtml href="#Table27new">27</linkHtml>. The Kaplan-Meier curves for PFS, assessed according to IWCLL criteria is shown in Figure <linkHtml href="#Figure6">6</linkHtml>.</paragraph>
                        <table ID="Table27new">
                           <caption>Table 27:  Efficacy Results in Patients with CLL/SLL in E1912</caption>
                           <col width="234"/>
                           <col width="200"/>
                           <col width="200"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">Endpoint</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">IMBRUVICA + R</content> <content styleCode="bold">
                                       <br/>N=354</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">FCR</content>
                                    <content styleCode="bold">
                                       <br/>N=175</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " colspan="3">
                                    <content styleCode="bold">Progression</content>
                                    <content styleCode="bold">-</content>
                                    <content styleCode="bold">Free Survival</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   Number of events (%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">41 (12)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">44 (25)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Disease progression</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">39</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">38</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">      Death events </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">2</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">6</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   Median (95% CI), months</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">NE (49.4, NE)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">NE (47.1, NE)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   HR (95% CI)</td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">0.34 (0.22, 0.52)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   P-value<sup>a</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">&lt;0.0001</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <sup>a</sup> P-value is from unstratified log-rank test.</paragraph>
                        <paragraph>FCR = fludarabine, cyclophosphamide, and rituximab; HR = hazard ratio; R = rituximab; NE = not evaluable.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 6: Kaplan-Meier Curve of Progression-Free Survival (ITT Population) in Patients with CLL/SLL in E1912</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia ID="Figure6" referencedObject="MM03000007"/>
                        </paragraph>
                        <paragraph>With a median follow-up time on study of 49 months, median overall survival was not reached with a total of 23 deaths: 11 (3%) in the IMBRUVICA plus rituximab and 12 (7%) in the FCR treatment arms. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Lymphocytosis</content>
                        </paragraph>
                        <paragraph>Upon initiation of single-agent IMBRUVICA, an increase in lymphocyte counts (i.e., ≥ 50% increase from baseline and above absolute lymphocyte count of 5,000/mcL) occurred in 66% of patients in the CLL studies. The onset of isolated lymphocytosis occurs during the first month of IMBRUVICA therapy and resolves by a median of 14 weeks (range, 0.1 to 104 weeks). When IMBRUVICA was administered in combination, lymphocytosis was 7% with IMBRUVICA + BR versus 6% with placebo + BR and 7% with IMBRUVICA + obinutuzumab versus 1% with chlorambucil + obinutuzumab.</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="_14_2_Waldenström_s_Macroglobulinemi">
                     <id root="159d0a4e-8e32-4030-aa33-dbcc8183b6f1"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">14.</content>
                        <content styleCode="bold">2</content>
                        <content styleCode="bold">
		     
	Waldenström’s Macroglobulinemia</content>
                     </title>
                     <text>
                        <paragraph>The safety and efficacy of IMBRUVICA in patients with WM were demonstrated in two single-arm trials and one randomized, controlled trial.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Study 1118 and INNOVATE Monotherapy Arm</content>
                        </paragraph>
                        <paragraph>Study 1118 (NCT01614821), an open-label, multi-center, single-arm trial was conducted in 63 previously treated patients with WM. IMBRUVICA was administered orally at 420 mg once daily until disease progression or unacceptable toxicity. The responses were assessed by investigators and an IRC using criteria adopted from the International Workshop of Waldenström’s Macroglobulinemia.  </paragraph>
                        <paragraph>The median age was 63 years (range, 44 to 86 years), 76% were male, and 95% were White. All patients had a baseline ECOG performance status of 0 or 1. The median time since diagnosis was 74 months, and the median number of prior treatments was 2 (range, 1 to 11 treatments). At baseline, the median serum IgM value was 3.5 g/dL (range, 0.7 to 8.4 g/dL).</paragraph>
                        <paragraph>Responses, defined as partial response or better, per IRC are shown in Table <linkHtml href="#Table28new">28</linkHtml>.</paragraph>
                        <table ID="Table28new">
                           <caption>Table 28: Response Rate and Duration of Response (DOR) Based on IRC Assessment in Patients with WM in Study 1118</caption>
                           <col width="294"/>
                           <col width="294"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Total (N=63)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Response rate (CR+VGPR+PR), (%)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">61.9</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    95% CI (%)</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">(48.8, 73.9)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Complete Response (CR)</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">0</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Very Good Partial Response (VGPR), (%)</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">11.1</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Partial Response (PR), (%)</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">50.8</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Median duration of response, months (range) </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">NE (2.8+, 18.8+)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule " colspan="2">CI = confidence interval; NE = not evaluable.</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The median time to response was 1.2 months (range, 0.7-13.4 months).</paragraph>
                        <paragraph>The INNOVATE monotherapy arm included 31 patients with previously treated WM who failed prior rituximab-containing therapy and received single-agent IMBRUVICA. The median age was 67 years (range, 47 to 90 years). Eighty-one percent of patients had a baseline ECOG performance status of 0 or 1, and 19% had a baseline ECOG performance status of 2. The median number of prior treatments was 4 (range, 1 to 7 treatments). With an overall follow-up of 61 months, the response rate observed in the INNOVATE monotherapy arm per IRC assessment was 77% (0% CR, 29% VGPR, 48% PR). The median duration of response was 33 months (range, 2.4 to 60.2+ months). </paragraph>
                        <paragraph>
                           <content styleCode="underline">INNOVATE</content>
                        </paragraph>
                        <paragraph>The INNOVATE study, a randomized, double-blind, placebo-controlled, phase 3 study of IMBRUVICA or placebo in combination with rituximab (NCT02165397), was conducted in treatment naïve or previously treated patients with WM. Patients (n = 150) were randomized 1:1 to receive either IMBRUVICA 420 mg daily or placebo in combination with rituximab until disease progression or unacceptable toxicity. Rituximab was administered weekly at a dose of 375 mg/m<sup>2</sup> for 4 consecutive weeks (weeks 1-4) followed by a second course of weekly rituximab for 4 consecutive weeks (weeks 17-20). The major efficacy outcome measure is progression-free survival (PFS) assessed by an IRC with additional efficacy measure of response rate. </paragraph>
                        <paragraph>The median age was 69 years (range, 36 to 89 years), 66% were male, and 79% were White. Ninety-three percent of patients had a baseline ECOG performance status of 0 or 1, and 7% of patients had a baseline ECOG performance status of 2. Forty-five percent of patients were treatment naïve, and 55% of patients were previously treated. Among previously treated patients, the median number of prior treatments was 2 (range, 1 to 6 treatments). At baseline, the median serum IgM value was 3.2 g/dL (range, 0.6 to 8.3 g/dL), and MYD88 L265P mutations were present in 77% of patients, absent in 13% of patients, and 9% of patients were not evaluable for mutation status.</paragraph>
                        <paragraph>An exploratory analysis demonstrated a sustained hemoglobin improvement (defined as increase of ≥ 2 g/dL over baseline for at least 8 weeks without blood transfusions or growth factor support) in 65% of patients in the IMBRUVICA + R group and 39% of patients in the placebo + R group.</paragraph>
                        <paragraph>With an overall follow-up of 63 months, efficacy results as assessed by an IRC at the time of the final analysis for INNOVATE are shown in Table <linkHtml href="#Table29new">29</linkHtml>, and the Kaplan-Meier curves for PFS are shown in Figure <linkHtml href="#Figure7">7</linkHtml>.</paragraph>
                        <table ID="Table29new">
                           <caption>Table 29: Efficacy Results in Patients with WM by IRC in INNOVATE (Final Analysis)</caption>
                           <col width="271"/>
                           <col width="184"/>
                           <col width="184"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">
                                    <content styleCode="bold">Endpoint</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">IMBRUVICA + R</content>
                                    <content styleCode="bold">
                                       <br/>N=75</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Placebo + R</content>
                                    <content styleCode="bold">
                                       <br/>N=75</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Progression</content>
                                    <content styleCode="bold">-</content>
                                    <content styleCode="bold">Free Survival</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                                 <td styleCode="Toprule Lrule Rrule " align="center"/>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   Number of events (%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">22 (29)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">50 (67)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   Median (95% CI), months</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">NE (57.7, NE)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">20.3 (13.0, 27.6)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   HR (95% CI)</td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">0.25 (0.15, 0.42)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   P-value<sup>a</sup>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " colspan="2" align="center">&lt;0.0001</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Response Rate (CR+VGPR+PR)</content>
                                    <content styleCode="bold">
                                       <sup>b</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">76%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">31%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   95% CI (%)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">(65, 85)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">(21, 42)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   Complete Response (CR)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">1%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   Very Good Partial Response (VGPR)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">29%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">4%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   Partial Response (PR)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">45%</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">25%</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Median duration of response, months (range)</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">NE (1.9+, 58.9+)</td>
                                 <td styleCode="Toprule Lrule Rrule " align="center">NE (4.6+, 49.7+)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>CI = confidence interval; HR = hazard ratio; NE = not evaluable; R = rituximab.</paragraph>
                        <paragraph>
                           <sup>a</sup> P-value is from the stratified log-rank test.</paragraph>
                        <paragraph>
                           <sup>b</sup>  P-value associated with response rate was &lt;0.0001.</paragraph>
                        <paragraph>
                           <content styleCode="bold">Figure 7:  Kaplan-Meier Curve of Progression-Free Survival (ITT Population) in Patients with WM in INNOVATE</content>
                        </paragraph>
                        <paragraph>
                           <renderMultiMedia ID="Figure7" referencedObject="MM02000008"/>
                        </paragraph>
                        <paragraph>Median overall survival was not reached for either treatment arm. With an overall follow-up of 63 months, 9 (12%) patients on IMBRUVICA + R and 10 (13.3%) patients on placebo + R had died. Forty-seven percent of patients randomized to the placebo + R arm crossed over to receive IMBRUVICA.</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
               <component>
                  <section ID="Hyperlink143">
                     <id root="5366c48b-45ab-46bf-aa32-d4ff840ab24a"/>
                     <code codeSystem="2.16.840.1.113883.6.1" code="42229-5" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>
                        <content styleCode="bold">14.</content>
                        <content styleCode="bold">3</content>
		     
	<content styleCode="bold">Chronic Graft versus Host Disease</content>
                     </title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Study 1129</content>
                        </paragraph>
                        <paragraph>The safety and efficacy of IMBRUVICA in cGVHD were evaluated in Study 1129 (NCT02195869), an open-label, multi-center, single-arm trial of 42 patients with cGVHD after failure of first line corticosteroid therapy and requiring additional therapy. IMBRUVICA was administered orally at 420 mg once daily. The responses were assessed by investigators using the 2005 National Institute of Health (NIH) Consensus Panel Response Criteria with two modifications to align with the updated 2014 NIH Consensus Panel Response Criteria.</paragraph>
                        <paragraph>The median age was 56 years (range, 19 to 74 years), 52% were male, and 93% were White. The most common underlying malignancies leading to transplantation were acute lymphocytic leukemia, acute myeloid leukemia, and CLL. The median time since cGVHD diagnosis was 14 months, the median number of prior cGVHD treatments was 2 (range, 1 to 3 treatments), and 60% of patients had a Karnofsky performance score of ≤ 80. The majority of patients (88 %) had at least 2 organs involved at baseline, with the most commonly involved organs being mouth (86%), skin (81%), and gastrointestinal tract (33%). The median daily corticosteroid dose (prednisone or prednisone equivalent) at baseline was 0.3 mg/kg/day, and 52% of patients were receiving ongoing immunosuppressants in addition to systemic corticosteroids at baseline. Prophylaxis for infections were managed per institutional guidelines with 79% of patients receiving combinations of sulfonamides and trimethoprim and 64% receiving triazole derivatives.</paragraph>
                        <paragraph>Efficacy results are shown in Table <linkHtml href="#Table30new">30</linkHtml>.</paragraph>
                        <table ID="Table30new">
                           <caption>Table 30:  Best Overall Response Rate (ORR) and Sustained Response Rate Based on Investigator Assessment<sup>a</sup> in Patients with cGVHD in Study 1129</caption>
                           <col width="294"/>
                           <col width="294"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Total (N=42)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">ORR</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">28 (67%) </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    95% CI </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">(51%, 80%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Complete Response (CR) </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">9 (21%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">    Partial Response (PR) </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">19 (45%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Sustained response rate</content>
                                    <content styleCode="bold">
                                       <sup>b</sup>
                                    </content>
                                    <content styleCode="bold"> </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">20 (48%) </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule " colspan="2">CI = confidence interval.<br/>
                                    <sup>a</sup>  Investigator assessment based on the 2005 NIH Response Criteria with two modifications (added “not evaluable” for organs with non-cGVHD abnormalities, and organ score change from 0 to 1 was not considered disease progression.) <br/>
                                    <sup>b</sup> Sustained response rate is defined as the proportion of patients who achieved a CR or PR that was sustained for at least 20 weeks.</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>The median time to response coinciding with the first scheduled response assessment was 12.3 weeks (range, 4.1 to 42.1 weeks). Responses were seen across all organs involved for cGVHD (skin, mouth, gastrointestinal tract, and liver).</paragraph>
                        <paragraph>ORR results were supported by exploratory analyses of patient-reported symptom bother which showed at least a 7-point decrease in Lee Symptom Scale overall summary score in 24% (10/42) of patients on at least 2 consecutive visits.</paragraph>
                        <paragraph>
                           <content styleCode="underline">iMAGINE</content>
                        </paragraph>
                        <paragraph>The safety and efficacy of IMBRUVICA were evaluated in iMAGINE (NCT03790332), an open-label, multi-center, single-arm trial of IMBRUVICA for the treatment of pediatric and young adult patients age 1 year to less than 22 years with moderate or severe cGVHD as defined by NIH Consensus Criteria. The study included 47 patients who required additional therapy after failure of one or more prior lines of systemic therapy. All patients had platelets ≥ 30 x 10<sup>9</sup>/L; absolute neutrophil count ≥ 1.0 x 10<sup>9</sup>/L; AST or ALT ≤ 3 x ULN; total bilirubin of ≤ 1.5 x ULN; and estimated creatinine clearance ≥ 30 mL/min. Patients were excluded if single organ genitourinary involvement was the only manifestation of cGVHD.</paragraph>
                        <paragraph>Patients age 12 years and older were treated with IMBRUVICA 420 mg orally once daily, and patients age 1 year to less than 12 years were treated with IMBRUVICA 240 mg/m<sup>2</sup> orally once daily. Concomitant treatment with supportive care therapies for cGVHD was permitted. Initiation of new systemic cGVHD therapy while on study was not permitted.</paragraph>
                        <paragraph>The median age was 13 years (range, 1 to 19 years). Of the 47 patients, 70% of patients were male, and 36% were White, 9% were Black or African American, 55% were other or unreported. The median time since cGVHD diagnosis was 16.1 months, the median number of prior cGVHD treatments was 2 (range, 1 to 12). The majority of patients (87%) had at least 2 organs involved at baseline, with lung involvement at baseline in 49% of patients; 26% of patients had a Karnofsky/Lansky performance score of &lt;80. The median daily corticosteroid dose (prednisone or prednisone equivalent) at baseline was 0.47 mg/kg/day, and 61% (19 of 31) patients were receiving ongoing immunosuppressants in addition to systemic corticosteroids at baseline.  Prophylaxis for infections was managed per institutional guidelines, with 72% of patients receiving combinations of sulfonamides and trimethoprim and 70% receiving systemic antifungal agents. </paragraph>
                        <paragraph>The efficacy of IMBRUVICA was established based on overall response rate (ORR) through Week 25, where overall response included complete response or partial response according to the 2014 National Institutes of Health (NIH) Consensus Development Project Response Criteria. The efficacy results are shown in Table <linkHtml href="#Table31new">31</linkHtml>. </paragraph>
                        <table ID="Table31new">
                           <caption>Table 31:  Efficacy Results in Patients with Previously Treated cGVHD<sup>a</sup> in iMAGINE  </caption>
                           <col width="348"/>
                           <col width="259"/>
                           <tbody>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule "/>
                                 <td styleCode="Toprule Lrule Rrule " align="center">
                                    <content styleCode="bold">Total (N=47)</content>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">ORR by Week 25</content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">28 (60%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   95% CI (%)</td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">(44, 74)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   Complete Response (CR) </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">2 (4%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">   Partial Response (PR) </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">26 (55%)</td>
                              </tr>
                              <tr>
                                 <td styleCode="Toprule Lrule Rrule ">
                                    <content styleCode="bold">Median </content>
                                    <content styleCode="bold">d</content>
                                    <content styleCode="bold">uration of </content>
                                    <content styleCode="bold">r</content>
                                    <content styleCode="bold">esponse, months (95% CI)</content>
                                    <content styleCode="bold">
                                       <sup>b</sup>
                                    </content>
                                 </td>
                                 <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">5.3 (2.8, 8.8)</td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>CI = confidence interval; ORR = overall response rate.</paragraph>
                        <paragraph>
                           <sup>a </sup>Assessment based on 2014 NIH Consensus Development Project Response Criteria.</paragraph>
                        <paragraph>
                           <sup>b </sup>Based on all responders in the study, calculated from first response to progression, death, or new systemic therapies for cGVHD.<sup> </sup>
                        </paragraph>
                        <paragraph>The median time to first response was 0.9 month (range, 0.9 to 6.1 months). The median time from first response to death or new systemic therapies for cGVHD was 14.8 months (95% CI: 4.6, not evaluable).</paragraph>
                        <paragraph>ORR results were supported by exploratory analyses of patient-reported symptom bother which showed at least a 7-point decrease in Lee Symptom Scale overall summary score through Week 25 in 50% (13/26) of patients age 12 years and older.</paragraph>
                     </text>
                     <effectiveTime value="20241220"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="114846dc-2d96-46b4-9f37-f413bcd64a00"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34069-5" displayName="HOW SUPPLIED SECTION"/>
               <title>
                  <content styleCode="bold">16</content>
		     
	<content styleCode="bold">HOW SUPPLIED/STORAGE AND HANDLING</content>
               </title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Capsules</content>
                  </paragraph>
                  <paragraph>The 70 mg capsules are supplied as yellow opaque capsules, marked with “ibr 70 mg” in black ink, in white HDPE bottles with a child-resistant closure:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>28 capsules per bottle: NDC 57962-070-28</item>
                  </list>
                  <paragraph>The 140 mg capsules are supplied as white opaque capsules, marked with “ibr 140 mg” in black ink, in white HDPE bottles with a child-resistant closure:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>90 capsules per bottle:  NDC 57962-140-09<br/>
                     </item>
                     <item>120 capsules per bottle:  NDC 57962-140-12</item>
                  </list>
                  <paragraph>Store bottles at room temperature 20°C to 25°C (68°F to 77°F). Brief exposure to 15°C to 30°C (59°F to 86°F) permitted (see USP Controlled Room Temperature). Retain in original package until dispensing.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Tablets</content>
                  </paragraph>
                  <paragraph>The IMBRUVICA (ibrutinib) tablets are supplied in 3 strengths in the following packaging configurations: </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>140 mg tablets: Yellow green to green round tablets debossed with “ibr” on one side and “140” on the other side. Carton of one folded blister card containing two 14-count blister strips for a total of 28 tablets: NDC 57962-014-28<br/>
                     </item>
                     <item>280 mg tablets: Purple oblong tablets debossed with “ibr” on one side and “280” on the other side. Carton of one folded blister card containing two 14-count blister strips for a total of 28 tablets: NDC 57962-280-28 <br/>
                     </item>
                     <item>420 mg tablets: Yellow green to green oblong tablets debossed with “ibr” on one side and “420” on the other side. Carton of one folded blister card containing two 14-count blister strips for a total of 28 tablets: NDC 57962-420-28</item>
                  </list>
                  <paragraph>Store tablets in original packaging at room temperature 20°C to 25°C (68°F to 77°F). Brief exposure to 15°C to 30°C (59°F to 86°F) permitted (see USP Controlled Room Temperature).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Oral Suspension</content>
                  </paragraph>
                  <paragraph>The IMBRUVICA (ibrutinib) oral suspension is a white to off-white suspension supplied as 108 mL in a 150 mL amber glass bottle with a pre-inserted bottle adapter and a child-resistant closure. Each mL contains 70 mg of ibrutinib. The oral suspension bottle is provided in a carton with two 3 mL reusable oral dosing syringes: NDC 57962-007-12.</paragraph>
                  <paragraph>Store the oral suspension bottle at 2°C to 25°C (36°F to 77°F). Do not freeze. Dispense in original sealed container. Do not use if the carton seal is broken or missing.</paragraph>
                  <paragraph>Discard any unused IMBRUVICA oral suspension remaining 60 days after first opening the bottle.</paragraph>
               </text>
               <effectiveTime value="20241220"/>
            </section>
         </component>
         <component>
            <section>
               <id root="fc85539a-1219-4f7e-8f1d-e4cfaba00c8c"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34076-0" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>
                  <content styleCode="bold">17</content>
		     
	<content styleCode="bold">PATIENT COUNSELING INFORMATION</content>
               </title>
               <text>
                  <paragraph>Advise the patients and caregivers to read the FDA-approved patient labeling (<linkHtml href="#PATIENTINFORMATION">Patient Information</linkHtml> and <linkHtml href="#INSTRUCTIONSFORUSE">Instructions for Use</linkHtml>).</paragraph>
                  <paragraph>
                     <content styleCode="underline">Hemorrhage:</content>
                     <br/>Inform patients of the possibility of bleeding, and to report any signs or symptoms (severe headache, blood in stools or urine, prolonged or uncontrolled bleeding). Inform the patient that IMBRUVICA may need to be interrupted for medical or dental procedures <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_5_1_Hemorrhage">5.1</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Infections:</content>
                     <br/>Inform patients of the possibility of serious infection, and to report any signs or symptoms (fever, chills, weakness, confusion) suggestive of infection <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_5_2_Infections">5.2</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Cardiac arrhythmias</content>
                     <content styleCode="underline">,</content>
                     <content styleCode="underline"> cardiac failure</content>
                     <content styleCode="underline">, and sudden death</content>
                     <content styleCode="underline">:</content>
                  </paragraph>
                  <paragraph>Inform patients of the possibility of irregular heart rhythm, heart failure and sudden death.<br/>Counsel patients to report any signs of palpitations, lightheadedness, dizziness, fainting, shortness of breath, chest discomfort, or edema <content styleCode="italics">[see Warning</content>
                     <content styleCode="italics">s and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_5_3_Cardiac_Arrhythmias_">5.3</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>
                     <content styleCode="italics">.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Hypertension</content>
                     <content styleCode="underline">:</content>
                     <br/>Inform patients that high blood pressure has occurred in patients taking IMBRUVICA, which may require treatment with anti-hypertensive therapy <content styleCode="italics">[see Warnings and Precautions</content> <content styleCode="italics">(</content>
                     <content styleCode="italics">
                        <linkHtml href="#_5_4_Hypertension">5.4</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Second primary malignancies:</content>
                     <br/>Inform patients that other malignancies have occurred in patients who have been treated with IMBRUVICA, including skin cancers and other carcinomas <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_5_6_Second_Primary">5.6</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Hepatotoxicity, including drug-induced liver injury:</content>
                  </paragraph>
                  <paragraph>Inform patients that liver problems, including drug-induced liver injury and abnormalities in liver tests, may develop during IMBRUVICA treatment. Advise patients to contact their healthcare provider immediately if they experience abdominal discomfort, dark urine, or jaundice <content styleCode="italics">[see Warnings and Precautions</content>
                     <content styleCode="italics"> (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_5_7_Hepatotoxicity__Including">5.7</linkHtml>
                     </content>
                     <content styleCode="italics">)]. </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Tumor lysis syndrome:</content>
                     <br/>Inform patients of the potential risk of tumor lysis syndrome and to report any signs and symptoms associated with this event to their healthcare provider for evaluation <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_5_7_Tumor_Lysis">5.8</linkHtml>
                     </content>
                     <content styleCode="italics">)].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Embryo-fetal toxicity:</content>
                     <br/>Advise women of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy <content styleCode="italics">[see Warnings and Precautions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_5_8_Embryo_Fetal_Toxicity">5.9</linkHtml>
                     </content>
                     <content styleCode="italics">), Use in Specific Populations (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_8_1_Pregnancy">8.1</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.<br/>Advise females of reproductive potential to use effective contraception during treatment with IMBRUVICA and for 1 month after the last dose <content styleCode="italics">[see </content>
                     <content styleCode="italics">Use in Specific Populations (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_8_3_Females_and">8.3</linkHtml>
                     </content>
                     <content styleCode="italics">)</content>
                     <content styleCode="italics">]</content>.<br/>Advise males with female partners of reproductive potential to use effective contraception during treatment with IMBRUVICA and for 1 month after the last dose <content styleCode="italics">[see Use in Specific Populations (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_8_3_Females_and">8.3</linkHtml>
                     </content>
                     <content styleCode="italics">), Nonclinical Toxicology (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_13_1_Carcinogenesis__Mutagenesis_">13.1</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Lactation:</content>
                     <br/>Advise women not to breastfeed during treatment with IMBRUVICA and for 1 week after the last dose <content styleCode="italics">[see Use in Specific Populations (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_8_2_Lactation">8.2</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Other Important Information:</content>
                  </paragraph>
                  <paragraph>Inform patients to take IMBRUVICA orally once daily according to their physician’s instructions and that the oral dosage (capsules or tablets) should be swallowed whole with a glass of water without opening, breaking or chewing the capsules or cutting, crushing or chewing the tablets approximately the same time each day <content styleCode="italics">[see Dosage and Administration (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_2_1_Recommended_Dosage">2.1</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>Advise patients that in the event of a missed daily dose of IMBRUVICA, it should be taken as soon as possible on the same day with a return to the normal schedule the following day. Patients should not take extra doses to make up the missed dose <content styleCode="italics">[see Dosage and Administration (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_2_1_Recommended_Dosage">2.1</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>For IMBRUVICA oral suspension, instruct patients or caregivers to read and follow the Instructions for Use for proper preparation, administration, storage and disposal <content styleCode="italics">[see Dosage and Administration (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_2_1_Recommended_Dosage">2.1</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>. </paragraph>
                  <paragraph>Advise patients of the common side effects associated with IMBRUVICA <content styleCode="italics">[see Adverse Reactions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_6_ADVERSE_REACTIONS">6</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>. Direct the patient to a complete list of adverse drug reactions in PATIENT INFORMATION.</paragraph>
                  <paragraph>Advise patients to inform their health care providers of all concomitant medications, including prescription medicines, over-the-counter drugs, vitamins, and herbal products <content styleCode="italics">[see Drug Interactions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_7_DRUG_INTERACTIONS">7</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>Advise patients that they may experience loose stools or diarrhea and should contact their doctor if their diarrhea persists. Advise patients to maintain adequate hydration <content styleCode="italics">[see Adverse Reactions (</content>
                     <content styleCode="italics">
                        <linkHtml href="#_6_1_Clinical_Trials">6.1</linkHtml>
                     </content>
                     <content styleCode="italics">)]</content>.</paragraph>
                  <paragraph>Distributed and Marketed by:<br/>Pharmacyclics LLC<br/>South San Francisco, CA 94080 USA<br/>and<br/>Marketed by:<br/>Janssen Biotech, Inc.<br/>Horsham, PA 19044 USA</paragraph>
                  <paragraph>Patent <content styleCode="italics">http://www.imbruvica.com</content>
                     <br/>IMBRUVICA<sup>®</sup> is a registered trademark owned by Pharmacyclics LLC</paragraph>
                  <paragraph>© Pharmacyclics LLC 2024<br/>© Janssen Biotech, Inc. 2024</paragraph>
                  <paragraph>20088578</paragraph>
               </text>
               <effectiveTime value="20241220"/>
            </section>
         </component>
         <component>
            <section>
               <id root="e972fd75-7fb5-4bc6-93d0-1a8ee96813e8"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="42230-3" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title/>
               <text>
                  <table ID="PATIENTINFORMATION">
                     <col width="193"/>
                     <col width="120"/>
                     <col width="102"/>
                     <col width="6"/>
                     <col width="217"/>
                     <tbody>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="5" align="center">
                              <content styleCode="bold">PATIENT INFORMATION</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " align="center">
                              <content styleCode="bold">IMBRUVICA (im-BRU-vih-kuh)</content>
                              <br/>(ibrutinib)<br/>capsules</td>
                           <td colspan="3" align="center">
                              <content styleCode="bold">IMBRUVICA (im-BRU-vih-kuh)</content>
                              <br/>(ibrutinib)<br/>tablets</td>
                           <td styleCode="Rrule " align="center">
                              <content styleCode="bold">IMBRUVICA (im-BRU-vih-kuh)</content>
                              <br/>(ibrutinib)<br/>oral suspension</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="5">
                              <content styleCode="bold">What is IMBRUVICA?</content>
                              <br/>IMBRUVICA is a prescription medicine used to treat:<br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Adults with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL).<br/>
                                 </item>
                                 <item>Adults with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion.<br/>
                                 </item>
                                 <item>Adults with Waldenström’s macroglobulinemia (WM).<br/>
                                 </item>
                                 <item>Adults and children 1 year of age and older with chronic graft versus host disease (cGVHD) after failure of 1 or more lines of systemic therapy.</item>
                              </list>It is not known if IMBRUVICA is safe and effective in children under 1 year of age.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="5">
                              <content styleCode="bold">Before taking IMBRUVICA, tell your healthcare provider about all of your medical conditions, including if you:</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have had recent surgery or plan to have surgery. Your healthcare provider may stop IMBRUVICA for any planned medical, surgical, or dental procedure.<br/>
                                 </item>
                                 <item>have bleeding problems or are taking a blood thinner medicine.<br/>
                                 </item>
                                 <item>have an infection.<br/>
                                 </item>
                                 <item>have or had heart rhythm problems, smoke, or have a medical condition that increases your risk of heart disease, such as high blood pressure, high cholesterol, or diabetes.<br/>
                                 </item>
                                 <item>have liver problems.<br/>
                                 </item>
                                 <item>are pregnant or plan to become pregnant. IMBRUVICA can harm your unborn baby. If you are able to become pregnant, your healthcare provider will do a pregnancy test before starting treatment with IMBRUVICA. Tell your healthcare provider if you are pregnant or think you may be pregnant during treatment with IMBRUVICA. <br/>
                                    <content styleCode="bold">○ Females </content>who are able to become pregnant should use effective birth control (contraception) during treatment with IMBRUVICA and for 1 month after the last dose.<br/>
                                    <content styleCode="bold">○ Males </content>with female partners who are able to become pregnant<content styleCode="bold"> </content>should use effective birth control, such as condoms, during treatment with IMBRUVICA and for 1 month after the last dose.<br/>
                                 </item>
                                 <item>are breastfeeding or plan to breastfeed. Do not breastfeed during treatment with IMBRUVICA and for 1 week after the last dose. </item>
                              </list>
                              <content styleCode="bold">Tell your healthcare provider about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking IMBRUVICA with certain other medicines may affect how IMBRUVICA works and can cause side effects.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="5">
                              <content styleCode="bold">How should I take </content>
                              <content styleCode="bold">or give </content>
                              <content styleCode="bold">IMBRUVICA?</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Take or give IMBRUVICA exactly as your healthcare provider tells you to take or give it.<br/>
                                 </item>
                                 <item>Take or give IMBRUVICA 1 time a day at about the same time each day.</item>
                              </list>
                              <content styleCode="bold">IMBRUVICA comes as capsules, tablets, and oral suspension.</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">If your healthcare provider prescribes IMBRUVICA capsules or tablets:</content>
                                    <br/>◦ Swallow IMBRUVICA capsules or tablets whole with a glass of water. <br/>◦ Do not open, break, or chew IMBRUVICA capsules. <br/>◦ Do not cut, crush, or chew IMBRUVICA tablets.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">If your healthcare provider prescribes IMBRUVICA oral suspension:</content>
                                    <br/>◦ See the detailed Instructions for Use that comes with IMBRUVICA oral suspension for information about the correct way to take or give a dose. If you have questions about how to take or give IMBRUVICA oral suspension, talk to your healthcare provider.<br/>◦ Do not use if the carton seal is broken or missing.<br/>
                                 </item>
                                 <item>If you miss a dose of IMBRUVICA, take or give it as soon as you remember on the same day. Take  or give the next dose of IMBRUVICA at the regular time on the next day. Do not take or give extra doses of IMBRUVICA to make up for a missed dose.<br/>
                                 </item>
                                 <item>If you take too much IMBRUVICA, call your healthcare provider, or go to the nearest hospital emergency room right away.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="5">
                              <content styleCode="bold">What should I avoid while taking IMBRUVICA?</content>
                              <br/>You should not drink grapefruit juice, eat grapefruit, or eat Seville oranges (often used in marmalades) during treatment with IMBRUVICA. These products may increase the amount of IMBRUVICA in your blood.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="5">
                              <content styleCode="bold">What are the possible side effects of IMBRUVICA?</content>
                              <br/>
                              <content styleCode="bold">IMBRUVICA may cause serious side effects, including:</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Bleeding problems (hemorrhage) are common</content> during treatment with IMBRUVICA and can also be serious and may lead to death. Your risk of<content styleCode="bold"> </content>bleeding may increase if you are also taking a blood thinner medicine.  Tell your healthcare provider if you have any signs of bleeding, including:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " colspan="2">
                              <list listType="unordered" styleCode="Circle">
                                 <item>blood in your stools or black stools (looks like tar)<br/>
                                 </item>
                                 <item>pink or brown urine<br/>
                                 </item>
                                 <item>unexpected bleeding, or bleeding that is severe or that you cannot control<br/>
                                 </item>
                                 <item>vomit blood or vomit looks like coffee grounds<br/>
                                 </item>
                                 <item>cough up blood or blood clots</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " colspan="3">
                              <list listType="unordered" styleCode="Circle">
                                 <item>increased bruising, or small red or purple spots on the skin<br/>
                                 </item>
                                 <item>dizziness<br/>
                                 </item>
                                 <item>weakness<br/>
                                 </item>
                                 <item>confusion<br/>
                                 </item>
                                 <item>change in your speech<br/>
                                 </item>
                                 <item>headache that lasts a long time or severe headache</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule " colspan="5">
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Infections </content>can happen during treatment with IMBRUVICA. These infections can be serious and may lead to death. Tell your healthcare provider right away if you have fever, chills, weakness, confusion, or other signs or symptoms of an infection during treatment with IMBRUVICA.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Heart problems. </content>Serious heart rhythm problems<content styleCode="bold"> </content>(ventricular arrhythmias, atrial fibrillation, and atrial flutter), heart failure and death have happened in people treated with IMBRUVICA, especially in people who have an infection, an increased risk for heart disease,  or have had heart rhythm problems in the past. Your heart function will be checked before and during treatment with IMBRUVICA. Tell your healthcare provider if you get any symptoms of heart problems, such as:</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule ">
                              <list listType="unordered" styleCode="Circle">
                                 <item>feeling as if your heart is beating fast and irregular<br/>
                                 </item>
                                 <item>lightheadedness<br/>
                                 </item>
                                 <item>dizziness</item>
                              </list>
                           </td>
                           <td styleCode="Lrule Rrule " colspan="2">
                              <list listType="unordered" styleCode="Circle">
                                 <item>shortness of breath<br/>
                                 </item>
                                 <item>swelling of the feet, ankles, or legs</item>
                              </list>
                           </td>
                           <td styleCode="Lrule Rrule " colspan="2">
                              <list listType="unordered" styleCode="Circle">
                                 <item>chest discomfort<br/>
                                 </item>
                                 <item>feeling faint</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule " colspan="5">If you develop any of these symptoms, your healthcare provider may do tests to check your heart and may change your IMBRUVICA dose. <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">High blood pressure (hypertension).</content> New or worsening high blood pressure has happened in people treated with IMBRUVICA. Your healthcare provider may start you on blood pressure medicine or change current medicines to treat your blood pressure.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Decrease in blood cell counts. </content>Decreased blood counts (white blood cells, platelets, and red blood cells) are common with IMBRUVICA, but can also be severe.<content styleCode="bold">  </content>Your healthcare provider should do monthly blood tests to check your blood counts.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Second primary cancers.</content> New cancers have happened during treatment with IMBRUVICA, including cancers of the skin or other organs.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Liver problems.</content> Liver problems, which may be severe or life-threatening, or lead to death, can happen in people treated with IMBRUVICA. Your healthcare provider will do blood tests to check your liver before and during treatment with IMBRUVICA. Tell your healthcare provider or get medical help right away if you have any signs of liver problems, including stomach pain or discomfort, dark-colored urine, or yellow skin and eyes. <br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Tumor lysis syndrome (TLS). </content>TLS is caused by the fast breakdown of cancer cells. TLS can cause kidney failure and the need for dialysis treatment, abnormal heart rhythm, seizure, and sometimes death. Your healthcare provider may do blood tests to check you for TLS.</item>
                              </list>
                              <content styleCode="bold">The most common side effects of IMBRUVICA in adults with B-cell malignancies (CLL/SLL</content>
                              <content styleCode="bold"> and</content>
                              <content styleCode="bold"> WM) include:</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule ">
                              <list listType="unordered" styleCode="Circle">
                                 <item>low platelet count</item>
                              </list>
                           </td>
                           <td colspan="2">
                              <list listType="unordered" styleCode="Circle">
                                 <item>muscle, bone, and joint pain</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " colspan="2">
                              <list listType="unordered" styleCode="Circle">
                                 <item>low red blood cell count (anemia)</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule ">
                              <list listType="unordered" styleCode="Circle">
                                 <item>diarrhea</item>
                              </list>
                           </td>
                           <td colspan="2">
                              <list listType="unordered" styleCode="Circle">
                                 <item>low white blood cell count</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " colspan="2">
                              <list listType="unordered" styleCode="Circle">
                                 <item>bruising</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule ">
                              <list listType="unordered" styleCode="Circle">
                                 <item>tiredness</item>
                              </list>
                           </td>
                           <td colspan="2">
                              <list listType="unordered" styleCode="Circle">
                                 <item>rash</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " colspan="2">
                              <list listType="unordered" styleCode="Circle">
                                 <item>nausea</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule " colspan="5">
                              <content styleCode="bold">The most common side effects of IMBRUVICA in adults or children 1 year of age and older with cGVHD include:</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule ">
                              <list listType="unordered" styleCode="Circle">
                                 <item>tiredness</item>
                              </list>
                           </td>
                           <td colspan="2">
                              <list listType="unordered" styleCode="Circle">
                                 <item>muscle, bone, and joint pain</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " colspan="2">
                              <list listType="unordered" styleCode="Circle">
                                 <item>nausea</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule ">
                              <list listType="unordered" styleCode="Circle">
                                 <item>low red blood cell count (anemia)</item>
                              </list>
                           </td>
                           <td colspan="2">
                              <list listType="unordered" styleCode="Circle">
                                 <item>fever </item>
                              </list>
                           </td>
                           <td styleCode="Rrule " colspan="2">
                              <list listType="unordered" styleCode="Circle">
                                 <item>stomach pain</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule ">
                              <list listType="unordered" styleCode="Circle">
                                 <item>bruising</item>
                              </list>
                           </td>
                           <td colspan="2">
                              <list listType="unordered" styleCode="Circle">
                                 <item>muscle spasms</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " colspan="2">
                              <list listType="unordered" styleCode="Circle">
                                 <item>pneumonia</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule ">
                              <list listType="unordered" styleCode="Circle">
                                 <item>diarrhea</item>
                              </list>
                           </td>
                           <td colspan="2">
                              <list listType="unordered" styleCode="Circle">
                                 <item>mouth sores (stomatitis)</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " colspan="2">
                              <list listType="unordered" styleCode="Circle">
                                 <item>headache</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule ">
                              <list listType="unordered" styleCode="Circle">
                                 <item>low platelet count</item>
                              </list>
                           </td>
                           <td colspan="2">
                              <list listType="unordered" styleCode="Circle">
                                 <item>bleeding</item>
                              </list>
                           </td>
                           <td styleCode="Rrule " colspan="2"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule " colspan="5">
                              <content styleCode="bold">Diarrhea is a common side effect in people who take IMBRUVICA. Drink plenty of fluids during treatment with IMBRUVICA to help reduce your risk of losing too much fluid (dehydration) due to diarrhea. Tell your healthcare provider if you have diarrhea that does not go away.</content>
                              <br/>These are not all the possible side effects of IMBRUVICA.<br/>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="5">
                              <content styleCode="bold">How should I store IMBRUVICA?</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Store IMBRUVICA capsules and tablets</content> at room temperature between 68°F and 77°F (20°C and 25°C).<br/>
                                 </item>
                                 <item>Keep IMBRUVICA capsules in the original container with the lid tightly closed.<br/>
                                 </item>
                                 <item>Keep IMBRUVICA tablets in the original carton.<br/>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Store IMBRUVICA oral suspension</content> bottle between 36°F and 77°F (2°C and 25°C). Do not freeze. <br/>
                                 </item>
                                 <item>Use IMBRUVICA oral suspension within 60 days after first opening the bottle. Throw away (dispose of) any unused portion 60 days after opening.<br/>
                                 </item>
                                 <item>IMBRUVICA capsules and oral suspension come in a bottle with a child-resistant cap.</item>
                              </list>
                              <content styleCode="bold">Keep IMBRUVICA and all medicines out of the reach of children.</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="5">
                              <content styleCode="bold">General information about the safe and effective use of IMBRUVICA.</content>
                              <br/>Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet.  Do not use IMBRUVICA for a condition for which it was not prescribed.  Do not give IMBRUVICA to other people, even if they have the same symptoms that you have. It may harm them.  You can ask your pharmacist or healthcare provider for information about IMBRUVICA that is written for health professionals.</td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="5">
                              <content styleCode="bold">What are the ingredients in IMBRUVICA?</content>
                              <br/>
                              <content styleCode="bold">Active ingredient:</content> ibrutinib<br/>
                              <content styleCode="bold">Inactive ingredients:</content>
                              <br/>
                              <content styleCode="bold">IMBRUVICA capsules</content>: croscarmellose sodium, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate. The 70 mg capsule shell contains gelatin, titanium dioxide, yellow iron oxide, and black ink. The 140 mg capsule shell contains gelatin, titanium dioxide, and black ink.<br/>
                              <content styleCode="bold">IMBRUVICA tablets:</content> colloidal silicon dioxide, croscarmellose sodium, lactose monohydrate, magnesium stearate, microcrystalline cellulose, povidone, and sodium lauryl sulfate. The film coating for each tablet contains ferrosoferric oxide (140 mg, 280 mg, and 420 mg tablets), polyvinyl alcohol, polyethylene glycol, red iron oxide (280 mg tablets), talc, titanium dioxide, and yellow iron oxide (140 mg and 420 mg tablets).<br/>
                              <content styleCode="bold">IMBRUVICA oral suspension: </content>benzyl alcohol, citric acid monohydrate, disodium hydrogen phosphate, hypromellose, microcrystalline cellulose and carboxymethylcellulose sodium, purified water, and sucralose. <br/>Distributed and Marketed by: Pharmacyclics LLC South San Francisco, CA 94080 USA<br/>Marketed by: Janssen Biotech, Inc. Horsham, PA 19044 USA<br/>© Pharmacyclics LLC 2024<br/>© Janssen Biotech, Inc. 2024<br/>20088578<br/>For more information, go to www.imbruvica.com or call 1-877-877-3536.    </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Patient Information has been approved by the U.S. Food and Drug Administration.                                                                          Revised: 5/2024</paragraph>
               </text>
               <effectiveTime value="20241220"/>
            </section>
         </component>
         <component>
            <section ID="INSTRUCTIONSFORUSE">
               <id root="46e54010-cf11-4e97-ae9e-c875b8768de5"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="59845-8" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">INSTRUCTIONS FOR USE</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">IMBRUVICA (im-BRU-vih-kuh)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold"> </content>
                     <content styleCode="bold">(ibrutinib)</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">oral </content>
                     <content styleCode="bold">suspension</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">This Instructions for Use contains information about how to prepare and </content>
                     <content styleCode="bold">take or </content>
                     <content styleCode="bold">give a dose of IMBRUVICA </content>
                     <content styleCode="bold">oral suspension</content>
                     <content styleCode="bold">.</content>
                  </paragraph>
                  <paragraph>Read this Instructions for Use before you take or give IMBRUVICA and each time you get a refill. There may be new information. </paragraph>
                  <paragraph>This Instructions for Use does not take the place of talking to your healthcare provider about your or your child’s medical condition or treatment.</paragraph>
                  <paragraph>Call your healthcare provider or 1-877-877-3536 if you need help or have any questions about how to take or give IMBRUVICA the right way.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Important information you need to know before </content>
                     <content styleCode="bold">taking or </content>
                     <content styleCode="bold">giving IMBRUVICA.</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>
                        <content styleCode="bold">IMBRUVICA is for oral use only.</content>
                        <br/>
                     </item>
                     <item>Take or give IMBRUVICA exactly as your healthcare provider tells you to.<br/>
                     </item>
                     <item>If you miss a dose of IMBRUVICA, it can be taken or given as soon as possible on the same day. Do not take or give<content styleCode="bold"> </content>more than the prescribed dose in 1 day. </item>
                  </list>
                  <table>
                     <col width="45"/>
                     <col width="565"/>
                     <tbody>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM03000009"/>
                           </td>
                           <td>If you or your child take too much IMBRUVICA, call your healthcare provider for help.</td>
                        </tr>
                     </tbody>
                  </table>
                  <list listType="unordered" styleCode="Disc">
                     <item>Keep these instructions for future use.</item>
                  </list>
                  <paragraph>Each IMBRUVICA carton contains (see <content styleCode="bold">Figure A</content>):</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>1 bottle of IMBRUVICA (called ‘bottle’ in this Instructions for Use) with pre-inserted bottle adapter (called ‘adapter’ in this Instructions for Use). <content styleCode="bold">Do not remove the bottle adapt</content>
                        <content styleCode="bold">e</content>
                        <content styleCode="bold">r.</content>
                        <br/>
                     </item>
                     <item>2 reusable 3 mL oral dosing syringes (called ‘syringe’ in this Instructions for Use) measuring in 0.1 mL increments.</item>
                  </list>
                  <table>
                     <col width="45"/>
                     <col width="553"/>
                     <tbody>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM03000009"/>
                           </td>
                           <td>
                              <content styleCode="bold">Only use the syringes that come with</content> <content styleCode="bold">IMBRUVICA</content>. <content styleCode="bold">Do not</content> use the syringes for other patients or with other medicines. </td>
                        </tr>
                        <tr>
                           <td>
                              <renderMultiMedia referencedObject="MM03000009"/>
                           </td>
                           <td>If you cannot read the markings on the syringes, throw them away and call 1-877-877-3536 to get new ones.</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">P</content>
                     <content styleCode="bold">reparing and </content>
                     <content styleCode="bold">taking or </content>
                     <content styleCode="bold">giving a dose </content>
                     <content styleCode="bold">of</content>
                     <content styleCode="bold"> </content>
                     <content styleCode="bold">IMBRUVICA</content>
                  </paragraph>
                  <table>
                     <col width="37"/>
                     <col width="6"/>
                     <col width="338"/>
                     <col width="244"/>
                     <tbody>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">
                              <content styleCode="bold">Step 1: Gather and check supplies</content>
                              <content styleCode="bold">.</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Check  the prescribed dose in milliliters (mLs). Find this mL marking on the syringe.<br/>
                                 </item>
                                 <item>If the dose is more than the marking on the syringe, split the dose between syringes as prescribed.<br/>
                                 </item>
                                 <item>Gather bottle and syringe(s) (see <content styleCode="bold">Figure A</content>
                                    <content styleCode="italics">).</content>
                                    <br/>
                                 </item>
                                 <item>Check the bottle and make sure that the bottle has IMBRUVICA Oral Suspension printed on it and the expiration date (“EXP”) has not passed<content styleCode="italics">.</content>
                                 </item>
                              </list>
                           </td>
                           <td styleCode="Toprule Lrule Rrule " align="center">
                              <renderMultiMedia referencedObject="MM0300000A"/>
                              <br/>
                              <content styleCode="bold">Figure A</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule ">
                              <renderMultiMedia referencedObject="MM03000009"/>
                           </td>
                           <td styleCode="Rrule " colspan="2">
                              <content styleCode="bold">Do not  </content>use IMBRUVICA after the “EXP” date printed on the carton and on the bottle.</td>
                           <td styleCode="Lrule Rrule " align="center"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule ">
                              <renderMultiMedia referencedObject="MM03000009"/>
                           </td>
                           <td styleCode="Rrule " colspan="2">
                              <content styleCode="bold">Do not </content>use if the IMBRUVICA carton seal appears to be tampered with.</td>
                           <td styleCode="Lrule Rrule " align="center"/>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">
                              <content styleCode="bold">Step 2: Record</content>
                              <content styleCode="bold"> or check </content>
                              <content styleCode="bold">the </content>
                              <content styleCode="bold">discard date</content>
                              <content styleCode="bold">.</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>When opening the bottle for the first time, record the date that is 60 days from the day the bottle is opened underneath the words “Discard Date” (see <content styleCode="bold">Figure B</content>). <br/>
                                 </item>
                                 <item>Use IMBRUVICA within 60 days after first opening the bottle. </item>
                              </list>
                           </td>
                           <td styleCode="Toprule Lrule Rrule " align="center">
                              <renderMultiMedia referencedObject="MM0300000B"/>
                              <br/>
                              <content styleCode="bold">Figure B</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule ">
                              <renderMultiMedia referencedObject="MM03000009"/>
                           </td>
                           <td styleCode="Rrule " colspan="2">
                              <content styleCode="bold">Do not </content>use IMBRUVICA past the discard date recorded on the bottle.</td>
                           <td styleCode="Lrule Rrule " align="center"/>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">
                              <content styleCode="bold">Step 3: Shake </content>
                              <content styleCode="bold">the </content>
                              <content styleCode="bold">bottle</content>
                              <content styleCode="bold">.</content>
                              <content styleCode="bold"> </content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Shake the bottle well before each use (see <content styleCode="bold">Figure C</content>
                                    <content styleCode="italics">)</content>.</item>
                              </list>
                           </td>
                           <td styleCode="Toprule Lrule Rrule " align="center">
                              <renderMultiMedia referencedObject="MM0300000C"/>
                              <br/>
                              <content styleCode="bold">Figure C</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">
                              <content styleCode="bold">Step 4: Remove </content>
                              <content styleCode="bold">the </content>
                              <content styleCode="bold">cap from </content>
                              <content styleCode="bold">the </content>
                              <content styleCode="bold">bottle</content>
                              <content styleCode="bold">.</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Press down and twist the cap counterclockwise to remove it from the bottle (see <content styleCode="bold">Figure D</content>).<br/>
                                 </item>
                                 <item>If there is fluid on top of the adapter, you may wipe it with a clean disposable tissue.</item>
                              </list>
                              <content styleCode="bold">Do not remove the bottle adapter.</content>
                           </td>
                           <td styleCode="Toprule Lrule Rrule " align="center">
                              <renderMultiMedia referencedObject="MM0300000D"/>
                              <br/>
                              <content styleCode="bold">Figure D</content>
                              <br/>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">
                              <content styleCode="bold">Step 5: Attach </content>
                              <content styleCode="bold">the </content>
                              <content styleCode="bold">syringe</content>
                              <content styleCode="bold"> </content>
                              <content styleCode="bold">to </content>
                              <content styleCode="bold">the </content>
                              <content styleCode="bold">bottle</content>
                              <content styleCode="bold">.</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Make sure the syringe is clean and dry before use.<br/>
                                 </item>
                                 <item>Push the plunger down all the way. <br/>
                                 </item>
                                 <item>Gently insert tip of the syringe into the adapter.<br/>
                                 </item>
                                 <item>Turn the assembled bottle and syringe upside down (see <content styleCode="bold">Figure E</content>).</item>
                              </list>
                           </td>
                           <td styleCode="Toprule Lrule Rrule " align="center">
                              <renderMultiMedia referencedObject="MM0300000E"/>
                              <br/>
                              <content styleCode="bold">Figure E</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">
                              <content styleCode="bold">Step 6: </content>
                              <content styleCode="bold">Fill </content>
                              <content styleCode="bold">the </content>
                              <content styleCode="bold">syringe</content>
                              <content styleCode="bold">.</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Slowly pull the syringe plunger down, past the number of mLs for your prescribed dose (see <content styleCode="bold">Figure F</content>).   <br/>
                                 </item>
                                 <item>Check for air bubbles and proceed to Step 7 for instructions on how to remove air bubbles.<content styleCode="bold"> </content>
                                 </item>
                              </list>
                           </td>
                           <td styleCode="Toprule Lrule Rrule " align="center">
                              <renderMultiMedia referencedObject="MM0300000F"/>
                              <br/>
                              <content styleCode="bold">Figure F</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">
                              <content styleCode="bold">Step 7: Remove air bubbles and adjust to the prescribed dose (mL)</content>
                              <content styleCode="bold">.</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Hold the syringe and tap the sides to send bubbles to the tip. <br/>
                                 </item>
                                 <item>With the syringe attached to the bottle, push the plunger up to remove the air bubbles from the top (see<content styleCode="italics"> </content>
                                    <content styleCode="bold">Figure G</content>).<br/>
                                 </item>
                                 <item>After the bubbles are removed, push the plunger up until the top of the colored plunger is even with the markings on the syringe for the prescribed dose. </item>
                              </list>
                           </td>
                           <td styleCode="Toprule Lrule Rrule " align="center">
                              <renderMultiMedia referencedObject="MM03000010"/>
                              <br/>
                              <content styleCode="bold">Figure G</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule ">
                              <renderMultiMedia referencedObject="MM03000009"/>
                           </td>
                           <td styleCode="Rrule " colspan="2">Air bubbles must be removed to ensure the correct dose.</td>
                           <td styleCode="Lrule Rrule " align="center"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule " colspan="3">
                              <content styleCode="bold">Note: </content>Repeat steps 6 and 7 if any air bubbles remain.<content styleCode="bold">  </content>
                           </td>
                           <td styleCode="Lrule Rrule " align="center"/>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">
                              <content styleCode="bold">Step 8: Remove </content>
                              <content styleCode="bold">the </content>
                              <content styleCode="bold">syringe</content>
                              <content styleCode="bold"> </content>
                              <content styleCode="bold">from </content>
                              <content styleCode="bold">the </content>
                              <content styleCode="bold">bottle</content>
                              <content styleCode="bold">.</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Turn the assembled bottle upright.<br/>
                                 </item>
                                 <item>Hold the middle of the syringe and carefully remove it from the bottle (see <content styleCode="bold">Figure H</content>).<br/>
                                 </item>
                                 <item>Place the bottle aside.</item>
                              </list>
                           </td>
                           <td styleCode="Toprule Lrule Rrule " align="center">
                              <renderMultiMedia referencedObject="MM03000011"/>
                              <br/>
                              <content styleCode="bold">Figure H</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule ">
                              <renderMultiMedia referencedObject="MM03000009"/>
                           </td>
                           <td styleCode="Rrule " colspan="2">
                              <content styleCode="bold">Do not </content>touch the plunger of the syringe to avoid accidentally spilling the medicine before you are ready to take or give the dose.</td>
                           <td styleCode="Lrule Rrule " align="center"/>
                        </tr>
                        <tr>
                           <td styleCode="Lrule Rrule " colspan="3">
                              <content styleCode="bold">Note:</content> If more than 1 syringe is needed to take or give the full dose, repeat steps 5 to 8 with the second syringe to complete the prescribed dose.</td>
                           <td styleCode="Lrule Rrule " align="center"/>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">
                              <content styleCode="bold">Step 9: </content>
                              <content styleCode="bold">Take or give</content>
                              <content styleCode="bold"> IMBRUVICA</content>
                              <content styleCode="bold">.</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Place the tip of the syringe along the inside of the cheek.<br/>
                                 </item>
                                 <item>Slowly push the plunger all the way in to take or give the entire dose (see <content styleCode="bold">Figure I</content>).<br/>
                                 </item>
                                 <item>Repeat with second syringe if needed to complete the prescribed dose.</item>
                              </list>
                              <content styleCode="bold">Note: </content>IMBRUVICA must be taken or given as soon as possible after being drawn from the bottle.<content styleCode="bold"> </content>
                              <br/>
                              <content styleCode="bold">Note: </content>After swallowing the dose of medicine make sure to drink water. </td>
                           <td styleCode="Toprule Lrule Rrule " align="center">
                              <renderMultiMedia referencedObject="MM03000012"/>
                              <br/>
                              <content styleCode="bold">Figure I</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">
                              <content styleCode="bold">Step 10: Recap </content>
                              <content styleCode="bold">the </content>
                              <content styleCode="bold">bottle</content>
                              <content styleCode="bold">.</content>
                              <br/>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Place the cap back on the IMBRUVICA bottle (see <content styleCode="bold">Figure J</content>
                                    <content styleCode="italics">).</content>
                                    <content styleCode="bold"> </content>
                                    <br/>
                                 </item>
                                 <item>Make sure the bottle is tightly closed between each use.</item>
                              </list>
                           </td>
                           <td styleCode="Toprule Lrule Rrule " align="center">
                              <renderMultiMedia referencedObject="MM03000013"/>
                              <br/>
                              <content styleCode="bold">Figure J</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Toprule Lrule Rrule " colspan="3">
                              <content styleCode="bold">Step 11: Rinse</content>
                              <content styleCode="bold"> the</content>
                              <content styleCode="bold"> </content>
                              <content styleCode="bold">syringe</content>
                              <content styleCode="bold">.</content>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Remove the plunger from the syringe.<br/>
                                 </item>
                                 <item>Rinse the plunger and the syringe only with water and air dry (see <content styleCode="bold">Figure K</content>). <br/>
                                 </item>
                                 <item>Store the syringe in a clean, dry place. </item>
                              </list>
                           </td>
                           <td styleCode="Toprule Lrule Rrule " align="center">
                              <renderMultiMedia referencedObject="MM03000014"/>
                              <br/>
                              <content styleCode="bold">Figure K</content>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode="Lrule " colspan="2">
                              <renderMultiMedia referencedObject="MM03000009"/>
                           </td>
                           <td styleCode="Rrule ">
                              <content styleCode="bold">Do not</content> clean the syringe with soap or in the dishwasher.</td>
                           <td styleCode="Lrule Rrule " align="center"/>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
                     <content styleCode="bold">Turn over for more </content>
                     <content styleCode="bold"> </content> <content styleCode="bold">information </content>
                     <renderMultiMedia referencedObject="MM03000015"/>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">How to </content>
                     <content styleCode="bold">s</content>
                     <content styleCode="bold">tore </content>
                     <content styleCode="bold">IMBRUVICA</content>
                     <content styleCode="bold"> </content>
                     <content styleCode="bold">Oral Suspension</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Store the bottle between 36°F and 77°F (2°C and 25°C).  </item>
                  </list>
                  <table>
                     <col width="45"/>
                     <col width="354"/>
                     <tbody>
                        <tr>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM03000009"/>
                           </td>
                           <td>
                              <content styleCode="bold">Do not</content> freeze.</td>
                        </tr>
                     </tbody>
                  </table>
                  <list listType="unordered" styleCode="Disc">
                     <item>IMBRUVICA oral suspension comes in a bottle with a child-resistant cap.<br/>
                     </item>
                     <item>
                        <content styleCode="bold">Store </content>
                        <content styleCode="bold">IMBRUVICA and all medications </content>
                        <content styleCode="bold">out of</content>
                        <content styleCode="bold"> </content>
                        <content styleCode="bold">the </content>
                        <content styleCode="bold">reach of children.</content>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">How to d</content>
                     <content styleCode="bold">ispose of </content>
                     <content styleCode="bold">IMBRUVICA</content>
                     <content styleCode="bold"> </content>
                  </paragraph>
                  <table>
                     <col width="45"/>
                     <col width="555"/>
                     <tbody>
                        <tr>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM03000009"/>
                           </td>
                           <td>Throw away (dispose of) any unused medicine within 60 days after first opening of the bottle. At the same time, throw away any used or unused syringes.</td>
                        </tr>
                     </tbody>
                  </table>
                  <list listType="unordered" styleCode="Disc">
                     <item>Ask your pharmacist how to properly dispose of the medicine.<br/>
                     </item>
                     <item>For syringe disposal, rinse and place in household trash.  </item>
                  </list>
                  <paragraph>This Instructions for Use has been approved by the U.S. Food and Drug Administration.</paragraph>
                  <paragraph>Distributed and Marketed by:<br/>Pharmacyclics LLC<br/>South San Francisco, CA 94080 USA<br/>and<br/>Marketed by:<br/>Janssen Biotech, Inc.<br/>Horsham, PA 19044 USA</paragraph>
                  <paragraph>Patent http://www.imbruvica.com<br/>IMBRUVICA® is a registered trademark owned by Pharmacyclics LLC </paragraph>
                  <paragraph>© 2024 Pharmacyclics LLC <br/>© 2024 Janssen Biotech, Inc. <br/>20080493<br/>Revised: 2/2024</paragraph>
               </text>
               <effectiveTime value="20241220"/>
               <component>
                  <observationMedia ID="MM03000009">
                     <text>Warning</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="imbruvica-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0300000A">
                     <text>Figure A</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="imbruvica-0a.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0300000B">
                     <text>Figure B</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="imbruvica-0b.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0300000C">
                     <text>Figure C</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="imbruvica-0c.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0300000D">
                     <text>Figure D</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="imbruvica-0d.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0300000E">
                     <text>Diagram

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="imbruvica-0e.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM0300000F">
                     <text>Diagram

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="imbruvica-0f.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000010">
                     <text>Diagram

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="imbruvica-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000011">
                     <text>Figure H</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="imbruvica-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000012">
                     <text>Diagram

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="imbruvica-12.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000013">
                     <text>A picture containing vector graphics

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="imbruvica-13.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000014">
                     <text>Diagram

Description automatically generated</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="imbruvica-14.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM03000015">
                     <text>Arrow</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="imbruvica-15.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="f016524e-2bc9-480b-a57d-e34c2f5cb697"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
                     <content styleCode="bold"> </content>
                     <content styleCode="bold">- 28 Capsule Bottle Carton</content>
                  </paragraph>
                  <paragraph>NDC 57962-070-28</paragraph>
                  <paragraph>
                     <content styleCode="bold">Imbruvica</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content>
                     <content styleCode="bold">
                        <br/>(ibrutinib) capsules</content>
                  </paragraph>
                  <paragraph>70 mg</paragraph>
                  <paragraph>Each capsule contains: ibrutinib 70 mg<br/>Swallow capsules whole with water</paragraph>
                  <paragraph>
                     <content styleCode="bold">28 Capsules</content>
                  </paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>
                     <content styleCode="bold italics">p</content>
                     <content styleCode="bold italics">harmacyclics</content>
                     <content styleCode="bold italics">
                        <sup>®</sup>
                     </content>
                     <content styleCode="bold">
                        <br/>An AbbVie Company</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">j</content>
                     <content styleCode="bold">anssen</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM02000016"/>
                  </paragraph>
               </text>
               <effectiveTime value="20241220"/>
               <component>
                  <observationMedia ID="MM02000016">
                     <text>NDC 57962-070-28
Imbruvica®
(ibrutinib) capsules
70 mg
Each capsule contains: ibrutinib 70 mg
Swallow capsules whole with water
28 Capsules
Rx Only
pharmacyclics®
An AbbVie Company
janssen
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="imbruvica-16.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="ac1831f4-8874-4f2f-8a29-f75043c45a9f"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL - 90 Capsule Bottle Carton</content>
                  </paragraph>
                  <paragraph>NDC 57962-140-09</paragraph>
                  <paragraph>
                     <content styleCode="bold">Imbruvica</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content>
                     <content styleCode="bold">
                        <br/>(ibrutinib) capsules</content>
                  </paragraph>
                  <paragraph>140 mg</paragraph>
                  <paragraph>
                     <content styleCode="bold">Each capsule contains: ibrutinib 140 mg</content>
                     <content styleCode="bold">
                        <br/>Swallow capsules whole with water</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">90 Capsules</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold italics">p</content>
                     <content styleCode="bold italics">harmacyclics</content>
                     <content styleCode="bold italics">
                        <sup>®</sup>
                     </content>
                     <content styleCode="bold">
                        <br/>An AbbVie Company</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">j</content>
                     <content styleCode="bold">anssen</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM02000017"/>
                  </paragraph>
               </text>
               <effectiveTime value="20241220"/>
               <component>
                  <observationMedia ID="MM02000017">
                     <text>NDC 57962-140-09
Imbruvica®
(ibrutinib) capsules
140 mg
Each capsule contains: ibrutinib 140 mg
Swallow capsules whole with water
90 Capsules
Rx Only
pharmacyclics®
An AbbVie Company
janssen
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="imbruvica-17.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="88ea68d2-2045-4adf-920d-86ce71bd1b54"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL - 28 Tablet Blister Carton</content>
                  </paragraph>
                  <paragraph>NDC 57962-014-28</paragraph>
                  <paragraph>
                     <content styleCode="bold">Imbruvica</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content>
                     <content styleCode="bold">
                        <br/>(ibrutinib) tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">140 mg</content>
                     <content styleCode="bold"> </content>per tablet</paragraph>
                  <paragraph>Each tablet contains ibrutinib 140 mg<br/>
                     <content styleCode="bold">Wallet card contains 28 tablets</content>
                  </paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>
                     <content styleCode="bold italics">p</content>
                     <content styleCode="bold italics">harmacyclics</content>
                     <content styleCode="bold italics">
                        <sup>®</sup>
                     </content>
                     <content styleCode="bold">
                        <br/>An AbbVie Company</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">j</content>
                     <content styleCode="bold">anssen</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM02000018"/>
                  </paragraph>
               </text>
               <effectiveTime value="20241220"/>
               <component>
                  <observationMedia ID="MM02000018">
                     <text>NDC 57962-014-28
Imbruvica®
(ibrutinib) tablets
140 mg per tablet
Each tablet contains ibrutinib 140 mg
Wallet card contains 28 tablets
Rx Only
pharmacyclics®
An AbbVie Company
janssen
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="imbruvica-18.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="bbe9e869-1bc0-4239-bb5e-7d8b6ef66bfe"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL - 28 Tablet Blister Carton</content>
                  </paragraph>
                  <paragraph>NDC 57962-280-28</paragraph>
                  <paragraph>
                     <content styleCode="bold">Imbruvica</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content>
                     <content styleCode="bold">
                        <br/>(ibrutinib) tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">280 mg</content>
                     <content styleCode="bold"> </content>per tablet</paragraph>
                  <paragraph>Each tablet contains ibrutinib 280 mg<br/>
                     <content styleCode="bold">Wallet card contains 28 tablets</content>
                  </paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>
                     <content styleCode="bold italics">p</content>
                     <content styleCode="bold italics">harmacyclics</content>
                     <content styleCode="bold italics">
                        <sup>®</sup>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">An AbbVie Company</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">j</content>
                     <content styleCode="bold">anssen</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM02000019"/>
                  </paragraph>
               </text>
               <effectiveTime value="20241220"/>
               <component>
                  <observationMedia ID="MM02000019">
                     <text>NDC 57962-280-28
Imbruvica®
(ibrutinib) tablets
280 mg per tablet
Each tablet contains ibrutinib 280 mg
Wallet card contains 28 tablets
Rx Only
pharmacyclics®
An AbbVie Company
janssen
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="imbruvica-19.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="1b510cbe-ae27-45f8-b73c-777e8cc8606b"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL - 28 Tablet Blister Carton</content>
                  </paragraph>
                  <paragraph>NDC 57962-420-28</paragraph>
                  <paragraph>
                     <content styleCode="bold">Imbruvica</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content>
                     <content styleCode="bold">
                        <br/>(ibrutinib) tablets</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">420 mg</content>
                     <content styleCode="bold"> </content>per tablet</paragraph>
                  <paragraph>Each tablet contains ibrutinib 420 mg<br/>
                     <content styleCode="bold">Wallet card contains 28 tablets</content>
                  </paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>
                     <content styleCode="bold italics">p</content>
                     <content styleCode="bold italics">harmacyclics</content>
                     <content styleCode="bold italics">
                        <sup>®</sup>
                     </content>
                     <content styleCode="bold">
                        <br/>An AbbVie Company</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">j</content>
                     <content styleCode="bold">anssen</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM0200001A"/>
                  </paragraph>
               </text>
               <effectiveTime value="20241220"/>
               <component>
                  <observationMedia ID="MM0200001A">
                     <text>NDC 57962-420-28
Imbruvica®
(ibrutinib) tablets
420 mg per tablet
Each tablet contains ibrutinib 420 mg
Wallet card contains 28 tablets
Rx Only
pharmacyclics®
An AbbVie Company
janssen
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="imbruvica-1a.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section>
               <id root="de29bc11-a83e-4a74-897e-1a77aa66c9af"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="51945-4" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title/>
               <text>
                  <paragraph>
                     <content styleCode="bold">PRINCIPAL DISPLAY PANEL</content>
                  </paragraph>
                  <paragraph>NDC 57962-007-12</paragraph>
                  <paragraph>
                     <content styleCode="bold">Imbruvica</content>
                     <content styleCode="bold">
                        <sup>®</sup>
                     </content>
                     <content styleCode="bold">
                        <br/>(ibrutinib)</content>
                     <content styleCode="bold">
                        <br/>Oral Suspension</content>
                  </paragraph>
                  <paragraph>70 mg/mL</paragraph>
                  <paragraph>
                     <content styleCode="bold">For Oral Use Only</content>
                     <content styleCode="bold">
                        <br/>Shake well before each use</content>
                     <br/>
                     <content styleCode="bold">Discard after 60 Days</content>
                  </paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>108mL per Bottle </paragraph>
                  <paragraph>
                     <content styleCode="bold italics">pharmacyclics</content>
                     <content styleCode="bold italics">
                        <sup>®</sup>
                     </content>
                     <content styleCode="bold">
                        <br/>An AbbVie Company</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">j</content>
                     <content styleCode="bold">anssen</content>
                  </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM0200001B"/>
                  </paragraph>
               </text>
               <effectiveTime value="20241220"/>
               <component>
                  <observationMedia ID="MM0200001B">
                     <text>NDC 57962-007-12
Imbruvica®
(ibrutinib)
Oral Suspension
70 mg/mL
For Oral Use Only
Shake well before each use
Discard after 60 Days

Rx Only
108mL per Bottle 
pharmacyclics®
An AbbVie Company
janssen
</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="imbruvica-1b.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>